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SUMMARY 
Introduction:-The human gut microbiota outnumbers our own human cells by 100-1 and is 
often considered an extension of our genome harboring fundamental functions of which we are 
genetically incapable. However, it can also be a significant liability and has been implicated in 
numerous diseases, particularly; Inflammatory Bowel Disease (IBD). The efforts of this research 
entailed evaluating a specific molecular mechanism of the gut bacterial metagenome; proteolytic 
activity, collectively known as the Degradome due to their putative role as significant virulence 
factors in IBD. In order to access this degradome of the gut microbiota, firstly, novel functional 
metagenomic (FM) tools were developed with an aim of facilitating the isolation of proteases. 
Secondly, a comprehensive cohort study was conducted comparing faecal protease activity, 16S 
rRNA microbial community structure and the potential of the faecal degradome to act as 
virulence factors between a group of IBD patients and a group of healthy volunteers to begin to 
determine the role of microbial proteases in disease aetiology.                                                                      
Results:-The IBD cohort exhibited significantly higher protease activity than the healthy cohort. 
Inhibitor assays also showed that the IBD cohort contained different types of proteases to the 
healthy cohort with significantly higher levels of metalloprotease activity. 16S rRNA gene 
analysis of the microbial community also revealed a dysbiosis of the gut microbiota between the 
IBD cohort and the healthy cohort. Dysbiosis was also observed between the high protease 
producers and the low protease producers and protease activity in the IBD cohort was able to 
decrease trans epithelial resistance in an HT-29 cell line and increase cellular permeability.  
Functional metagenomics tools were also assessed for isolation of proteases from the gut 
microbiota. The ability of a protease deficient strain; Bacillus subtilis WB800N to express 
proteases was compared with E. coli to determine its usefulness as a host for FM screening for 
proteases. B. subtilis WB800N was able to express gelatinase E and neutral protease while E. 
coli was not suggesting B. subtilis WB800N was more suitable as a host. However, when the gut 
microbiota was screened for proteases using this host, none were isolated suggesting 
improvements still needed to be made. Conclusions: - Compositional alterations of the gut 
microbiota appear to be associated with high and low levels of protease activity. The IBD cohort 
had elevated activity and an expanded repertoire of faecal proteases which also appear to have 
the potential to act as a virulence factor by disrupting epithelial cell barrier integrity. Proteases 
remain elusive via FM screening; however this study has highlighted the areas that need 
improvement to optimize future screens for accessing the degradome of the gut microbiota. 
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1.0 INTRODUCTION 
1.1 The Human Gut and it’s Microbiota 
The human gastrointestinal tract is the site where the food we intake undergoes its 
metabolic journey, its catabolised as much as possible, and converted to the essential 
energy, nutrients and other products of metabolism that are necessary for life. The 
human gut has its own nervous system (enteric or intrinsic nervous system) that is 
capable of functioning autonomously, carrying out numerous physiological and 
pathophysiological processes including; modulating exocrine and endocrine functions, 
gastrointestinal blood flow, motility and modulation of enteric immune functions and 
consequently epithelial homeostasis [1]. Clearly, the human gut is a vastly complex 
organ. Aside from these fundamental functions, this nutrient-rich environment is also the 
‘home’ to trillions of microbial inhabitants that exist in numbers exceeding those found 
anywhere else in the human body, and that have co-evolved to form an intrinsic, 
interdependent relationship with us, as their hosts, to a point where the absence of our 
gut colonisers could have significant effects on our health. This intricate and delicate 
relationship has led, unsurprisingly, to the human gut microbiota becoming a major area 
of research in the scientific world with a major focus on determining it’s abundance, 
diversity, function and how we influence them but equally how they influence us.  
 
The gut microbiota is comprised of viruses, eukaryotic microorganisms and Archaea, 
but these are outnumbered both in cell density and phylogenetic diversity by the 
kingdom: Bacteria. This knowledge, and our ever increasing knowledge of the gut 
microbiota has been significantly aided by the advent of culture-free molecular based 
techniques, particularly bacterial community profiling by 16S rRNA gene sequencing 
analysis and shotgun metagenomics. Both such strategies by-pass the need to culture, as 
we are now aware that culture techniques available now are currently only able to 
support the growth of as few as 1% of total microbial diversity (for more information 
please Chapters 3 and 5). The 16S rRNA gene is commonly used to carry out diversity 
analysis of bacteria due to its uniform presence amongst bacteria and the ability to 
identify species based on unique domains.  Metagenomics has become a term used to 
encompass all the genes in their entirety that are isolated from a particular environment. 
While there are sections in this thesis dedicated to the detailed description of 
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metagenomics (section 1.3) in brief, the process is characterised by; the isolation of 
DNA from an environment of interest, random shearing of the DNA using various 
methods and reconstruction of sheared fragments into vectors to create a metagenomic 
library. This library is subsequently sequenced by way of the increasingly high-
throughput DNA sequencing methods. The cloning step can also be side-stepped and 
samples can be subject to next generation sequencing straight away. These include 
technologies such as Roche/454 pyrosequencing, Illumina Genome analyzer and the 
SOLiD™ Sequencer (more details of which will be discussed further on in section 1.3).  
Generated data can be vast (gigabases of nucelotide sequencing data) and must be made 
sense of using advanced bioinformatics using a variety of computational tools. 
 
The characterisation of microbial communities using 16S rRNA gene sequences and 
metagenomics in pinnacle projects that have completely altered the way we view 
microbial ecology conducted  on human faecal samples (as well as other parts of the 
human body) such as those conducted by Eckburg et al.,[2] large scale international 
projects such as the United States National Institute of Health sponsored Human 
Microbiome Project (HMP) [3] , the Metagenomics of the Human Intestinal Tract 
(MetaHIT) project [4, 5] and ELDERMET [6] (http://commonfund.nih.gov/hmp/) have 
helped uncover the magnitude of microbial abundance, diversity and functional 
potential. These data suggest that there are over 1000 different bacterial species can 
inhabit the human gut [7] and a possible 8000 bacterial strains [8] and an individual can 
harbour around 160 different bacterial species at one time [4]With data such as this it 
has been estimated that the human gut microbiota harbours ≥ 100 times more genes than 
the human genome of ~3 billion base pairs [8] (Ley, 2006). Understanding diversity and 
abundance of the gut microbiota has also been key in providing the stepping stones for 
going on to determine what these 300 or so billion base pairs of DNA are genetically 
capable of and the implications for us as their hosts. For example, we now understand 
that we have coevolved a mutually beneficial relationship with our gut microbiota, and 
that their genetic repertoire confers us with necessary metabolic attributes that we are 
not capable of such as the digestion of otherwise indigestible protein and 
polysaccharides of which the metabolites can be utilised by our cells [9] . It has also 
been demonstrated that perturbations in the gut microbiota can contribute to a plethora 
of diseases. It is unsurprising therefore, that there is significant and increasing 
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interesting research occurring in the field of gut microbiology as demonstrated by figure 
1.1 
 
Figure 1.1. Publications per year in the research field of gut microbiology from 
2000 to 2014. Adapted from [10] Figure 1 helps draw attention to just how much 
interest is being gathered in the area of gut microbiology since the increased 
implementation of culture-independent techniques and next generation sequencing 
(NGS) technologies showing the increase in publications since 2000 to present. Values 
for the figure were obtained using the keywords; ‘gut microbiota’ from the ISI Web of 
knowledge database (http://apps.isiknowledge.com/). 
1.1.1 Acquisition and development of the human gut microbiota and the 
Core Adult Microbiome 
Microbial colonisation begins immediately after birth as in the womb, infants are widely 
believed to be born sterile [11] however recent research such as those conducted by 
Jiménez and colleagues [12, 13] have challenged this concept having isolated bacteria 
from umbilical cord blood and amniotic fluid of neonates [13] as well as from the 
meconium of murine neonates [12]. Acquisition of the gut microbiota is incredibly 
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complex and driven by both external and internal factors. Research has shown that it is 
highly dynamic, subject to dramatic change and relatively low in diversity compared to 
bacterial communities of the healthy adult gut that reaches numbers previously 
described. 
 
A pioneering study into the acquisition of the gut microbiota was undertaken by Ley et 
al., comparing gut bacterial community compositions of related mice [9]. They found 
that mothers and offspring shared similar community profiles as did siblings and 
different litters from the same mother, but litters from different mothers had 
significantly different bacterial communities thus suggesting that microbial communities 
are inherited from mothers. The bacterial communities are ‘inherited’ predominantly 
from mothers via vertical transmission i.e. skin-oral transmission and faecal-oral 
transmission [14] and also the external environment upon birth and human genotype 
also indirectly contribute to determining an individual’s gut microbiota by determining 
their immunological phenotype [15]. Culture-dependent and independent analysis have 
deduced that ‘pioneer’ gut bacteria to predominantly include members of the 
Enterobacteria, Bifidobacteria, Eneterococci, Bacteroides spp, Clostridia and 
Ruminococcus spp.[14]. However, there are a number of factors that can also influence 
the first bacterial colonisers of a new-born; research has shown that initial bacterial 
species differs as a result of mode of delivery and mode of feeding [14]. For example, 
vaginal delivery results in a microbiota resembling that of the vaginal microbiome with 
Lactobacilli dominating and lower numbers of the  Enterobacteriaceae family and 
Enterococci phyla compared with Caesarean-section delivery where bacteria that are 
usually found inhabiting skin such, i.e.  Staphyloccous spp. and Propionobacteriums 
spp. are more likely to be the dominant species [16]. Though their poor adaptation to the 
human gut leads to significant decline in following months [17]. Other factors affecting 
this early colonisation have also been studied, such as feeding, prematurity and exposure 
to antibiotics. Exclusively breast-fed infants’ gut bacterial communities differ from 
exclusively formula-fed infants according to research by Penders et al., [18] Significant 
species found colonising the formula-fed infants in significantly higher numbers include 
E. coli, Clostridium difficile, Lactobacilli and Bacteroides fragilis [18]. The use of 
antibiotics and hygiene as well as other lifestyle related factors have also been shown to 
influence the infant gut microbiota [17, 18]. 
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Following this preliminary colonisation of these ‘pioneer’ bacteria [15], the gut 
microbiota develops in complexity and diversity throughout the first year of life, 
although it has been demonstrated that the microbial communities remain distinct [19] 
after such time the gut microbiota begins to converge to resemble that of an adult in that 
species commonly found in infants, but rarely in adults begin to decline and disappear 
and species commonly found in adults begin to dominate. However, immune, genetic 
and other environmental factors also play a role in determining an individuals’ gut 
microbiota (to be discussed later). The adult gut microbiota is also considerably more 
stable in that the community profile of an individual will remain more comparable over 
time than it will to another individual’s gut microbiota.  An adult human has been 
estimated to harbour as many as 100 trillion bacterial cells, encoding at least 100 fold 
more genes than there are on our own genomes [8] and the majority of which are found 
in the gut [2]. Most of the pioneering studies analysing the gut microbiota implementing 
culture-independent techniques (that include temperature gradient gel electrophoresis 
analysis of 16S rRNA genes [20], denaturing gradient electrophoresis analysis of 16S 
rRNA genes [21] and fluorescence in situ hybridisation (FISH) [22] and more recent 
analyses have implemented high throughput culture independent techniques; direct 16S 
rRNA gene sequencing coupled with community profiling and metagenomics [2, 23] on 
samples from healthy adult volunteers. The definative work of Eckburg and colleagues 
[2] analysed mucosal tissue samples from the colon, cecum, ascending colon, transverse 
colon, descending colon, sigmoid colon and rectum by colonoscopy from three healthy 
individuals as well and faecal samples from the three individuals taken 1 month after 
colonoscopy. In total 13,335 16S rRNA gene sequences were analysed and over 395 
bacterial phylotypes were identified and, although 1524 archaeal sequences were 
identified, it was found that they all belonged to just one archaeal phylotype; 
Methanobrevibacter smithii highlighting the difference in diversity between the two 
prokaryotic Kingdoms. The vast majority of bacterial sequences analysed contained 
novel species (62%) and 80% sequences were from species that were yet to be cultivated 
thus highlighting the extent of novelty in the gut. This study also revealed most 
sequences isolated from the gut belonged to the Firmicutes (most of which were from 
the Clostridiales) and the Bacteroidetes phyla and fewer numbers belonged to 
Proteobacteria, Actinobacteria, Fusobacteria and Verrucomicrobia [2].  These data 
were concordant with previous findings that had implemented 16S rRNA gene analysis 
techniques towards characterising the gut microbiota [24, 25] as well as 16S rRNA gene 
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analysis coupled with anaerobic culture methods [26]. These studies have also shown 
that there is distinct variation between individuals, but also intra-sample variations along 
different anatomical sites of the gut [2]. 
 
Fluctuations in the gut microbiota have been shown to have profound impact on host 
health. Understanding the diversity and genetic and functional potential of the gut 
microbiota is fundamental to understanding the role they have in human health and this 
is why recent years have seen increased effort in trying to decipher the gut microbiome 
and firstly elucidating the presence of microorganisms that might be indicative of a 
‘healthy’ state [27]. While studies on the gut microbiota still often report variations 
within and between individuals, it has still been put forward that, if we are to begin to 
understand the precise roles the gut microbiota has on health and disease we need to 
establish whether or not there is a ‘core’ microbiome found within at least a majority of 
individuals regardless of external factors (diet, ethnic origin, lifestyle etc.) that may also 
influence the gut microbiota. To begin to answer this question, Arumugam et al., 
conducted an interesting study to determine if there were microbial commonalities 
between different global populations. They conducted a large cohort based study 
spanning samples from Danish, French, Italian and Spanish individuals and compared 
the sequenced metagenomes of these individuals with existing databases comprising 
Japanese and American samples. One of this study’s key finds was that individuals from 
the entire cohort clustered into 3 distinct clusters which were enriched in certain 
bacterial species. These clusters became known as enterotypes (which could be thought 
of a much less stringent human blood type sort of system of characterising populations) 
which clustered independently of continent or nation.  The three enteroptypes were 
groups that were enriched in; Bacteroides, Prevotella and Ruminococcus and 
additionally functional profiles exhibited a similar clustering suggesting function of a 
particular population could be estimated depending on their enterotype [28]. 
 
Qin et al., [4] conducted a study as part of the MetaHIT consortium to both determine 
core species and core functions of the gut microbiota. In this study, 124 volunteers were 
recruited, including healthy individuals and individuals with obesity and IBD. While 
bacterial communities were found to cluster depending on disease state, they also found 
18 species that spanned the entire cohort at a 1% coverage rate. Core species included 
Faecalibacterium prausnitzii, Roseburia intestinalis and Bacteroides uniformis the 
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beneficial attributes of which will be discussed further (section 1.13.1). The study 
sought to determine functions of the gut microbiota that might be indicative of 
adaptation to life in the gut. They hypothesised core functions should appear in all or at 
least most of the bacterial species present at a frequency higher than that of functions 
found only in a limited number of species. Main function uncovered following 
metagenomic analysis revealed housekeeping functions that are similar for most bacteria 
regardless of habitat and include functions such as amino acid synthesis and 
carbohydrate metabolism. However, putative gut specific functions were also put 
forward and these including functions that appeared to be involved in bacterial adhesion 
to host protein such as collagen and fibrinogen. However over 80% of the putative 
orthologous group uncovered contained genes that are currently of unknown function 
indicating that much work in this area is still to be done if we are to uncover the gut 
function of individuals or populations. Definite functions uncovered included a number 
of genes involved in the degradation of complex sugars and glycans indicating that 
dietary sugars must be a core energy source of the gut microbiota [4]. Similarly, a large 
scale metagenomic study by Gill et al., found the gut microbial metagenome to be 
enriched in genes involved in the degradative pathways of plant polysaccharide, glycan 
and amino acid synthesis [23]. An interesting study conducted by Hehemann and 
colleagues [29] has also demonstrated how gut bacteria have acquired such functional 
genes. In their study, they identified genes encoding porphyranases first characterised 
from a marine Bacteroidetes species; Zobiella galactanivorans in the gut bacterium 
Bacteroides plebius in a Japanese population. Zobiella galactanivorans is an inhabitant 
of the seaweed that makes up a proportion of the Japanese typical diet. These data 
suggest a mechanism for how polysaccharide degrtading enzymes, such as 
porphyranases, were acquired by the gut microbiota and also how the function of the gut 
microbiota may be governed by the host diet [29]. 
 
Larger studies are now needed to determine whether these findings are synchronous, and 
to also begin to investigate how core functions of the gut microbiota may be 
contributing the state of the host (i.e. healthy/ diseased). Lozupone et al., suggest that 
the concept of a core microbiome is becoming more implausible as data sets expand 
globally [30]. While some studies discussed here demonstrate a level of concordance 
between a core microbiome globally, other studies have found contrasting results [31-
33]. The contribution of metagenomics and invaluable use of animal, mainly mouse 
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models have shown that the gut is enriched for functions that significantly contribute to 
host health and gut function. An arsenal of tools are now available and will be 
increasingly progressed in order to unravel the fundamental functions that contribute to 
host health and gut function. 
 
The environment of the gut puts enormous selection pressure on the bacterial 
community [8] for example, the ability to adhere to the mucus lined gut epithelia cell 
lining, a repertoire of degradative enzymes to metabolise the vast array of nutrients 
available and out-compete other microorganisms, the ability to evade or avoid the host 
immune system and the ability to grow fast and adapt should it be required, are all 
obligatory features of which a microorganism must be genetically capable in order to 
establish and maintain a community in the human gut.  Bacterial density and diversity 
fluctuate throughout the length of the gut. Figure 1.2 highlights some of the key intrinsic 
factors that selects the bacterial species present and affects distribution of bacteria 
including the molecular mechanisms that allow them to inhabit in some cases 
particularly harsh environments.  
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Figure 1.2. Intrinsic and extrinsic (in the purple circles) factors that contribute to both 
the shaping of the gut microbiota and also in altering the gut microbiota and how the gut 
microbiota affects health and disease. Intrinsic factors of the host are often different at 
different anatomical sites of the gut and govern the bacteria that can inhabit. Some 
extrinsic factors have an effect on both acquisition and alteration of the gut microbiota 
as shown by the factors in the overlap of the circles. A ‘healthy’ gut  
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 Continued from previous page 
microbiota lives harmoniously with its host conducting essential metabolic and 
protective functions.  It is currently unknown whether the altered gut microbiota 
(dysbiosis) is a cause or effect of certain diseases such as those shown here. Either way, 
dysbiosis of the gut microbiota is associated with a plethora of disorders both specific to 
the gut and elsewhere in the human body. Extrinsic factors may very well be directly 
altering a gut microbiota to favour those capable of contributing to such diseases. 
 
Wang and colleagues compared the bacterial diversity from biopsies of the mucosa of 
the human jejunum, distal ileum, ascending colon and rectum using 16S rRNA gene 
analysis and found that the jejunum was the least diverse and was dominated by species 
belonging to the Streptococcus genus (Firmicutes phyla). Diversity increased in the ileal 
and colonic samples with the Bacteroides phyla and Clostridium clusters XIVa and IV 
(part of the Firmicutes phyla) dominating [34] which was concordant with many 
subsequent analyses previously mentioned [2, 23] which were conducted using 
advanced next generation DNA sequencing technologies.  
 
Bik et al. also used 16S rRNA gene sequencing for community analysis of the human 
stomach, which had been previously concluded to harbour very few bacterial genera; 
Helicobacter [35] and Lactobacillus [36] due to their ability to survive the acidic gastric 
pH as a result of urease production [37] and regulation of a extracellular and 
cytoplasmic pH gradient [38]. 16S rRNA analysis revealed a more abundant and diverse 
bacterial gastric community than previously thought with many species present 
previously undescribed by culture techniques including the genera Caulobacter, 
Actinobacillus, Corynebacterium and Deinococcus [39], thus highlighting both the 
strength on sequencing and the ability of some bacterial genera to withstand such 
extreme environments.  
      
When Bacterial density reaches its peak, they outnumber our own cells by at least 100-1 
and subsequently also outnumber our own genes. As previously alluded, there is 
significant urgency to determine what these 300 or so billion base pairs of DNA are 
genetically capable of and how they impact us, as their hosts. [8]. The collective genes 
of all the microorganisms within the human gut (the microbiome) can be thought of as 
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an extension of our genome conferring genetic attributes that we are not capable of. 
Bacteria have been found to have such a distinctive role within the human gut that now 
many microbiologists may often refer to it as ‘the forgotten organ’.[40]. Is the presence 
of any particular organisms indicative of health? To answer this question it is first 
essential to understand their functional and genetic repertoire. 
 
Aims put forward by many large scale projects (for example, The human microbiome 
project, MetaHIT) are to include a wider data set of individuals from heterogeneous 
backgrounds that have had their gut microbial community sequenced and identified to 
try to help us answer the fundamental question; is there a core microbiome associated 
with a ‘healthy’ gut?   A question that can only be answered with a much expanded data 
set and analysis of the functions the gut microbiota has specifically regarding the effect 
they have on the host.[7]. It is also paramount to understand the external factors that 
contribute to shaping and altering the gut microbiota that are likely having a profound 
effect on gut microbiota function. 
1.1.2 Genetic and Environmental factors shaping the gut micrbiota 
While the human gut microbiota is variable from one individual to the next, studies have 
shown that family members tend to harbour more similar microbial communities [9, 41]. 
Theories emerged that similar lifestyles and similar environmental factors such as diet 
and hygiene (figure 1.2) have a profound impact on the gut microbiota and these will be 
discussed in more detail further on in this section, however  it has been demonstrated 
that host genotype plays a substantial role in shaping the gut microbiota in terms of 
bacterial communities [8] conversely, this has been demonstrated to not be the case for 
viral communities [42].  Studies focused on the ‘heritability’ of the gut microbiota 
through twin studies, mouse lines and quantitative trait loci (QTL) have provided 
valuable insights into how host genotype contributes to the development of the gut 
microbiota. Heritability of the gut microbiota refers to the genetic basis of development 
of the gut microbiota as opposed to non-genetic acquisition of the gut microbiota 
previously discussed. 
 
Benson and colleagues utilised mouse models and QTL analysis to determine whether 
specific bacterial taxa co-segregated as quantitative traits linked with genomic 
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polymorphisms. Using 520 polymorphism markers, 18 host QTL were identified that 
showed significant association with relative abundance of specific bacterial taxa. It was 
also found that QTL had 3 means of affecting microbial abundance by loci either 
controlling one particular species, groups of related species or one loci could influence 
multiple, and distantly related bacterial taxa [43]. However, studies have also revealed 
equally similar gut microbiota in monozygotic twins as well as dizygotic twins strongly 
suggesting a role for environmental and not just genetic factors in shaping the gut 
microbiota [41]. 
 
Host diet is a significant contributory factor and has been comprehensively reviewed 
[44-46]. Changes in diet or differences in diet due to geographical location and lifestyles 
cause a difference in the substrate available within the large intestine as exemplified by 
the previously discussed work of Hehemann for example [29]. Different substrates may 
also initiate changes in the gut environment in terms of pH, oxygen and gut transit time 
also of which can significantly contribute to determining the taxonomy of bacterial 
species present on the gut due to their different genetic composition and metabolic 
capacity [44]. Studies investigating the effect of specific diets characteristic of different 
parts of the world have highlighted how diet causes changes in abundance of microbial 
taxa and also changes in metabolic pathways.  Perhaps some of the more prestigious 
work on diet-induced changes of the gut microbiota includes the work of Turnbaugh and 
colleagues [47] who presented a study where human adult faecal samples were 
transplanted into germ free C57BL/6J mice and implemented metagenomic analysis to 
monitor the heritability of the microbiota. It was found that the mice became colonised 
with a microbiota comparable to the donor. These mice were subject to dietary 
alterations, from a low fat, plant based, polysaccharide rich diet to a high fat, high sugar 
diet typical of the Western world. After only, 1 day, shifts in their microbiota were 
observed in terms of not only diversity, but also metabolic pathways and gene 
expression. It was also found that mice fed on the western diet had a significant increase 
in adiposity and that this trait could be transferred to other mice via faecal transplant 
[45] strongly inferring that the gut microbiota can contribute to an increase in fat 
storage. 
 
Diets high in protein and animal fat had a characteristic association with members of the 
Bacteroides and diets high in carbohydrate were strongly associated with Prevotella 
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[48]. In the second part of their study, 10 volunteers were recruited and subject to a 
controlled feeding study where one group were fed diets high in fat and low in fibre and 
the other group were fed the converse. While dietary changes were shown to alter the 
entire gut microbiome, enterotypes remained stable, thus suggesting that short term 
dietary changes do not alter gut enterotypes, but that these changes are more dependent 
on long term dietary habits [48]. 
 
Clearly, diet can alter specific taxa of the gut microbiota and studies such as those by 
Turnbaugh et al., [47]have shown the metabolic consequences. Thus diet has been 
increasingly implicated in disease related to the gut microbiota, particularly obesity 
which will be discussed in more detail later on. David and colleagues [46] recently set 
about to determine how dietary interventions alter the gut microbiome and found that 
short term animal-based diets increased microorganisms such as Alistipes, Bilophila and 
Bacteroides; these are bile tolerant organisms, and the levels of Firmicutes were found 
to be reduced. Conversely, the diet composed of mainly plant polysaccharides 
constituted an increase in Roseburia, Eubacterium rectale and Ruminococcus bromii, 
organisms that have a demonstrated ability to metabolize plant polysaccharides [46].  
Clearly, microbial metabolic capacity is a key driving force behind changes in the gut 
microbiota in response to dietary changes.  
 
Lifestyle choices other than diet such as sanitation, urbanisation, use of antibiotics and 
vaccinations have also been demonstrated to have various levels of impact on the gut 
microbiota and consequently, alter intestinal metabolism having potential implications 
on human health. The increasing use of broad spectrum antibiotics has received attention 
for numerous factors, one of which is the effect antibiotic usage are having on 
perturbations on the gut microbiota. It is widely accepted that antibiotics have profound 
short term effects on the gut microbiota as demonstrated by studies such as that of 
Pérez-Cobas and colleagues [49] who implemented the use of multiple ‘omic’ based 
strategies to monitor how antibiotics caused disturbances of the gut microbiota. 
Unsurprisingly, a significant drop in diversity was initially observed along with a 
decrease in protein expression determined by metaproteoimcs and an enhanced 
expression of certain proteins involved in glycolysis, pyruvate decarboxylation the 
tricarboxylic acid cycle, glutamate metabolism, iron uptake, GTP hydrolysis and 
translation termination but protein expression alterations reverted back to more normal 
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levels after treatment was completed [49]. Some studies have also sought to determine 
the more long term effects antibiotic usage may be having on the gut microbiota. 
Jernberg et al., [50] studied the effect of a 7-day treatment of clindamycin on the gut 
microbiota, but more specifically, Bacteroides, for a period of 2 years using repetitive 
sequence-based PCR and real-time PCR. It was found that Bacteroides isolates had a 
marked decrease in clonal diversity after antibiotic usage and a rapid enrichment of 
resistant clones was also observed. The overall level of resistance genes after antibiotic 
usage significantly increased and Bacteroides fluctuated throughout the 2 year sampling 
period and did not return to its original composition suggesting long term change in the 
gut microbiota due to antibiotic exposure [50]. 
 
Perhaps related to antibiotic treatment, invasion by ‘new’ species may also have 
consequence on the diversity of the gut microbiota. Previous data have shown that the 
resident microbiota contribute to preventing invasion by potentially harmful bacteria 
[51, 52] and generally forms the basis behind the development of many probiotics. 
Manichanh et al., [53] however challenged this quite well established concept and 
determined that the gut microbiota could be much more easily manipulated than 
previously anticipated [53]. Perhaps the most widely known example of a coupling of 
antibiotic therapy and invasion of a new species in altering the composition of the gut 
microbiota is Clostridium difficile associated diarrhoea. Here, normally a hospitalised 
person who is receiving antibiotics for various reasons, becomes infected with C. 
difficile as a result of a perturbed and reduced gut microbiota. Symptoms include severe 
diarrhoea, abdominal pain and fever. The success of faecal transplantation in 
ameliorating this disease has highlighted the plasticity of the gut microbiota [54]. This 
approach also highlights some of the beneficial attributes a gut microbiota can confer. 
1.1.3 The Gut Microbiota as an Asset 
The relationship between the mucosal surface of the gut epithelia and it’s microbiota is 
one of mutual symbiosis. Here the trillions of microorganisms can conduct a repertoire 
of metabolic, structural and defensive functions that are beneficial to their human host 
and in return, they have a nutrient rich environment in which they can flourish.  
      
 
15 
 
1.1.3.1 Metabolic function 
Gut bacteria are responsible for many metabolic reactions that lead to the subsequent 
availability of valuable nutrients and energy such as amino acids, vitamins including; 
vitamin B, riboflavin, pantoic acid vitamin B12, vitamin K, nicotinic acid, thiamine and 
biotin [55, 56] and are fundamental in the metabolism of certain, otherwise indigestible 
complex carbohydrates, proteins, dietary fibre or plant polysaccharides and fat 
predominantly by Bacteroides and Bifidobacterium species [57, 58] (figure 1.2 
highlights some of the benefits of a gut microbiota). Metabolism of complex 
carbohydrates by the gut microbiota provides the host with a variety of end products, the 
most notable of which relating to gut health is that of short chain fatty acids (SCFAs). 
SCFAs include acetate, butyrate and propionate and are involved in modulating 
inflammation, wound healing and motility in the gut and also act as substrates for 
energy conversion For example; acetate has been shown to increase cholesterol 
synthesis, butyrate acts as main energy source for colonocytes [58, 59] and propionate 
acts as the main energy source for peripheral tissue [60] [59] [61]. Some bacteria that 
have been identified in a majority of healthy individuals from sequencing projects have 
been further studied to determine their metabolic function and the consequence of this 
on host healthy with regards to determining whether putative ‘core’ species are 
beneficial to their hosts. For example, Roseburia intestinalas has been demonstrated as a 
butyrate producing organism [62] as have other species such as Butyricoccus 
pullicaecorum [63]. Numbers of B. pullicaecorum as well as Faecalibacterium 
praznitzii have been demonstrated to often significantly decline in the gut microbiota of 
IBD patients [64] instigating research into their role as mediators of inflammation in the 
gut. Sokol and colleagues [65] assessed the anti-inflammatory properties of F. 
prausnitzii in vitro and in vivo and found that F. prausnitzii supernatant could reduce 
interleukin-8 (IL-8)-a pro-inflammatory cytokine, secretion by a human gut epithelial 
cell line (Caco-2) as well as eliminate nuclear factor-kappa B, a protein that controls 
DNA transcription of genes such as cytokines, chemokines and as adhesion molecules as 
part of the pro-inflammatory response [66]. The F. prausnitzii also attenuated the effect 
of colitis in mouse models of inflammation and increased the secretion of IL-10, an anti-
inflammatory cytokine, and reduced secretion of Tumour necrosis factor alpha (TNF-α) 
and Il-12 which are both pro-inflammatory molecules [65]. Butyrate production, another 
characteristic of F. prausnitzii, as well as other putative beneficial bacteria previously 
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mentioned, can also exert anti-inflammatory effects through inhibition of NF-KB [67]. 
Clearly there is evidence to suggest a beneficial role of the gut microbiota perhaps even 
down to the species level. 
 
The gut microbiota also plays a profound role in the biotransformation of bile acids. Bile 
acids are synthesised from endogenous cholesterol in the liver and consists of a steroid 
core conjugated to glycine or taurine which is secreted into the intestine where they 
carry out their main role of solubilising dietary fat. While this is a fundamental role, the 
detergent –like nature of these molecules means they can be toxic to colonocytes and 
have been linked with the pathogenesis of colon cancer [68]. The ability to metabolise 
bile acids to non-toxic metabolites (and sometimes toxic metabolites such as 
deoxycholic acid which is notably a by-product of microbial metabolism)is an attribute 
found in many commonly isolated species of the gut microbiota including Bacteroides, 
Clostridium and Bifidobactera [69]. The bacterial enzymes responsible are known as 
bile salt hydrolases (BSH) and have been found to be a conserved function within the 
gut microbiota [70] and their activity on bile acids results in free primary bile acid 
(deconjugated) and amino acids. BSH enzymes therefore detoxify bile acids and are 
often a characteristic function of bacteria used in probiotics [71]. However use of BSH 
activity probiotics remains a controversial subject as BSH activity has also been noted to 
exert detrimental effects on the host [71] and because metabolism sometimes yield toxic 
by-products. 
1.1.3.2 Maturation of the Immune system 
Perhaps one of the more defined positive activities of the gut microbiota is it’s role in 
the maturation of both the innate and adaptive immune response. Early exposure to 
commensal bacteria in the gut is involved with immune system adaptation and tolerance 
to such bacteria. Germ-free animals compared with their normally inhabited 
counterparts have demonstrated that animals kept under sterile conditions have reduced 
circulatory levels of specific and non-specific antimicrobial components such as 
Immunoglobin A which are essential for protecting the mucosal barrier [72]. 
 
In addition to their protective role in developing the immune system, pathogens also 
have to compete for survival with these long established commensals making it much 
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harder for them to successfully establish an infection [72]. The occurrence of antibiotic 
associated C. difficile infection as described previously is an example of the protective 
role of the gut microbiota. Some species produce or initiate the secretion of molecules 
that exert antimicrobial effects against invading fungi, viruses and other bacteria [40]. 
For example, research has shown that another commonly isolated gut species, 
Bacteroides thetaiotaomicron induces the secretion of angiogenin; a bactericidial protein 
specific to the gut [73]. Factors such as this demonstrate the integral importance of the 
gut microbiota and that we have a circumstantial dependence on their presence. This 
dependence can be further illustrated in studies of germ free animals whereby the 
absence of gut colonisers results in an overall decrease in health and an increased 
susceptibility to infection [74]. Specifically, germ free or gnotobiotic animals have been 
shown to have reduced digestive enzyme activity, a decrease in mucosal cell turnover, 
decreased cytokine production due to the decreased exposure to indigenous microbiota  
and altered structure and morphology of the epithelial wall such as much thinner 
intestinal wall with thinner and more pointed villi and a reduction in mucosal surface 
area and smaller peyer’s patches resulting in the very little secretoy IgA [75]. After 
exposure to typical enteric gut bacteria, germ-free animals begin to resemble normal 
mucosal structure and function [76]. Germ free animal models have also been shown to 
have an increased intake in calories, eating on average 30% more than conventional 
animals in order to sustain their body weight [75, 77] suggesting there may also be a 
role for the indigenous bacterial gut microbiota in fat deposition [78] especially 
considering gut bacteria are essential for the metabolism of otherwise indigestible 
dietary components.  
1.1.3.3 Allergies 
The importance of the protection and development of immunity that exposure and 
colonisation of commensals gives us has been re-iterated by what is known as ‘the 
hygiene hypothesis’ first proposed by work of Strachan [79] which essentially suggested 
that increased personal cleanliness and reduced exposure to infectious agents was 
correlated with an increase in hay fever. Subsequent research has linked other allergic 
responses and even autoimmune diseases to decreased exposure to bacteria [80]. The 
‘disappearing microbiota’ hypothesis put forward by Blaser and colleagues [81] 
suggests that one of the main factors behind the increase in allergies and metabolic 
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diseases in the western world is a consequence of a loss in our ancestral microbiota as 
opposed to the ‘hygiene hypothesis’. It is believed that we co-evolved to form our 
mutually beneficial relationship with our microbiota with global differences such as diet, 
lifestyle, geography and ecological disturbances as a key driving force leading to out 
‘indigenous’ microbiota. In the ‘disappearing microbiota’ theory it is believed that our 
ancestral microbiota is diminishing as a result of a decrease in the vertical transmission 
of the gut microbiota. Decreases in exposure to certain microbial species via horizontal 
transmission (water, food etc.) mean bacteria that could have been acquired via either 
mode of transmission, are not acquired at all [82]. A key example of this phenomena 
involves the loss of Helicobacter pylori colonisation in inhabitants of the developed 
world [83]. Loss of the species is likely due to decrease in transmission and also 
increased antibiotic usage and in parallel, peptic ulcer disease and gastric cancer rates 
are decreasing [84]. However, incidence rates of oesophageal reflux and 
adenocarcinoma are increasing. The ‘disappearing microbiota’ hypothesis suggests that 
the two trends in disease incidence are intricately linked to the colonisation of H. pylori 
[82].  
1.1.4 The Gut Microbiota and Disease 
Aside from the beneficial functions, the gut microbiota has a dark side and can also be a 
significant liability. Certain microbial pathogens are also able to invade the human gut 
thanks to an arsenal of evolved virulence factors. 
  1.1.4.1 Invasion by pathogens 
Infectious intestinal diseases can be caused by a plethora of microorganisms not only 
belonging to the Bacteria Kingdom and all anatomical parts of the human gut, including 
the oral cavity, can gain an infection. The main bacterial causative agents of 
gastrointestinal infection (gastroenteritis) include; Camplyobacter spp. Clostridium 
difficile, enterotoxigenic E. coli, Salmonella, Shigella and Vibrio cholera. Often, the 
consequence of the infection are diarrhoea, vomiting and abdominal pain. 
Enterotoxigenic bacteria are contracted via external sources, mainly food or 
contaminated water and are well equipped for adherence to and invasion of intestinal 
epithelial cells. 
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Aside from the invasion of specific pathogens, gastrointestinal infectious can also be 
largely attributed to the consequence of an external stimuli such as dietary changes, 
illness, use of antibiotics instigating a change in the composition of the gut microbiota 
[85]. This change is known as microbial dysbiosis and can have serious implications on 
host health (figure 1.2). Many bacteria residing in the gut are opportunistic pathogens, 
that upon suppression of the immune system, including suppression of the protective 
indigenous microbiota, can evade our defences and establish an infective lifecycle 
leading to gut associated diseases such as diarrhoea and colitis. Another theory 
implicating dysbiosis in disease is due to a shift in abundance of ‘aggressive’ 
commensals normally fewer in abundance but for one reason or another, become 
enhanced and indirectly cause an alteration in the genetic pool of the gut microbiota 
with different metabolic functions leading to either a different immune reaction from the 
host, or different metabolic activities of the gut microbiota which may contribute to the 
disease. This is one of the theories that is involved in the pathogenesis of Inflammatory 
Bowel Disease (IBD) and is discussed in much more detail in Chapter 7.0. 
 
Gut microbial dysbiosis has also been linked with a number of other serious illnesses 
including type 2 diabetes, alcoholic liver disease, necrotising enterocolitis [86] and 
metabolic syndrome or obesity [47]. Perhaps one of the most well established incidences 
of an external stimuli altering the gut microbiota and leading to disease is antibiotic-
associated diarrhoea notably caused by overgrowth of Clostridium difficile as discussed 
previously. 
 
One of the main questions that has arisen as a result of these associations is whether or 
not these gut bacteria are directly influencing the pathology of such diseases or whether 
the changes are just ‘collateral damage’ as a consequence of the disease, but before this 
can be determined it is important to first determine the specific phylotypes or genera and 
possibly even species that are altered in the plethora of disease states associated with 
dysbiosis of the gut microbiota and also, the genes and functions accompanied that may 
be implicated in the molecular basis behind the disease.  
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1.1.4.2 Irritable Bowel Syndrome and Inflammotory Bowel Disorders 
Both Irritable Bowel Syndrome (IBS) and Inflammatory bowel disorders (IBD) such as 
Ulcerative colitis and Crohn’s disease are debilitating, chronically recurring disorders of 
the human gastrointestinal tract. There is clinical overlap between the two diseases [87] 
and within IBD itself there are numerous forms of disease of which the two main 
disorders are Crohn’s disease (CD) and Ulcerative colitis (UC) though diagnostically 
different, they share similar disease aetiology which include alterations in the gut 
immune response [88], inflammation and dysbiosis of the gut microbiota with shared 
symptoms characterised by abdominal pain, irregular bowel patterns including bouts of 
diarrhoea and constipation [88]. The cause of such diseases is multifactoral, but can be 
mainly attributed to; the genotype of the sufferer, environmental stimuli and host-
microbe interactions occurring at the gut/epithelial barrier interface. Different substrate 
availability as a result of the sufferers genotype, different conditions in the gut, 
proliferation of pathogens due to impaired immune system, overactive or uncontrolled 
response of the immune system to commensal bacteria are microbial related factors 
involved in the onset of IBD [89].  
The relationship between the gut microbiota and IBD remains complex and is discussed 
in extensive detail in Chapter 7.0.  
1.1.4.3 Cancer 
It is well established that infection by viruses, bacteria or eukaryotic microorganisms are 
involved in the development of malignant tumours in humans, for example the epstein 
barr virus can cause lymphomas and nasopharyngeal cancer [90] the human 
papillomavirus causes cervical cancer [91], and relevant to the human gut; Helicobacter 
pylori is known to cause gastric cancer [92].  Similar to the case of IBD, the relationship 
between bacteria and colon cancer is complex and as yet, far from established.  Colon 
cancer is the fourth most common cancer in the UK and is the second leading cause of 
death due to cancer in developing countries [93]. Like IBD, it is also considered a 
disease  of the developed world [94]. 
 
Colon cancer’s onset is due to a series of somatic mutations [94] and develops after the 
initiation of colonic polyps. However not all polyps develop into malignant tumours 
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suggesting that other stimuli are involved in the development of cancer, one of which is 
potentially the gut microbiota. 
 
However current lab techniques are inadequate to support the culture of most of the gut 
microbiota, and so studying their interaction with the host, and their involvement in 
diseases such as colon cancer, is no trivial challenge. 
 
1.1.4.4 Obesity and related metabolic disorders 
Obesity has become prolific in the westernised world substantially caused by excessive 
caloric intake and is characterised by excess body fat. It is also associated with 
numerous other diseases including heart disease, metabolic endotoxemia and diabetes. 
At present, the disease poses a significant threat to many inhabitants of the developed 
world. While disproportionate caloric intake is obviously the main cause of obesity, 
there is evidence to suggest a genetic predisposition to the disease including altered 
microbial diversity and subsequent metabolic function. 
 
Research by Ley et al., have demonstrated altered gut microbial ecology in obesity in an 
elegant study using genetically obese mice (mutations in the leptin gene [95]) and lean 
littermate comparisons and found significant taxonomic difference between the two 
dominant phyla. Firmicutes were markedly higher in the obese group while the 
Bacteroidetes phylum was diminished. The implications for metabolic function of the 
gut are enrichment in enzymes involved in degradation of indigestible polysaccharides 
and have an increased ability to harvest energy from dietary components [9]. This 
research coupled with other research that has shown enhanced adiposity as a result of 
the transplant of a gut microbiota acquired following a diet high in fat and low in fibre 
[47] in mouse models provide evidence for a causative role of the gut microbiota in the 
disease. Backhed et al.,[96] showed that following inoculation of germ-free mice with 
the gut microbiota of conventional mice, the recently inoculated mice incurred a 60% 
increase in fat accumulation after just 2 weeks despite a reduced diet and an enhanced 
exercise routine [96]. The gut microbiota in obesity in humans has also been studied 
particularly with the use of twin studies and concordant variations in phyla have been 
observed [41]. Type 2 diabetes (T2D) is characterised by hypoergylcemia and insulin 
resistance and appears to be intricately linked with obesity and people that are obese are 
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at considerable risk of developing T2D. Dysbiosis of the gut microbiota has been 
observed in patients with diabetes [97].  Obesity and diabetes can be characterised by 
low-grade gut inflammation. The altered gut microbiota is thought to affect homeostasis 
of glucose and lipids contributing to insulin resistance and hyperglycemia. Metabolic 
endotoxemia is also a contributory factor toward obesity and diabetes progression. 
Metabolic endotoxemia occurs as a result of increased levels of lipopolysaccharide 
(LPS) resulting in a deregulated inflammatory episodes within the gut, enhanced gut 
epithelial permeability and insulin resistance [98] and consequently, it has been 
postulated that the gut microbiota in obesity may alter the pool of luminal LPs, causing 
intestinal inflammation and increased permeability and contributes to insulin resistance 
and the onset of T2D. 
1.1.5 “The Unculturable majority” and culture independent technqiues to 
study the gut microbiota 
Until relatively recently, bacterial culture and microscopic observation were the ultimate 
means of characterising microorganisms and understanding microbial composition of 
environmental habitats. For example, the human gut microbiota was first observed by 
these methods and revealed 113 different bacteria present [99]. While such culture 
dependent techniques still provide an invaluable means of accessing the physiology and 
biochemistry of microorganisms, the advent of culture-independent techniques has 
allowed microbiologists and geneticist to observe the full extent of microbial diversity 
and abundance. It is now firmly understood that the bacteria isolated via culturing an 
environmental sample are rarely the most numerically dominant in situ [100].Those that 
do grow so successfully, often inhibiting the growth of others as well, are commonly 
referred to as ‘weeds’ This culture bias has become known as ‘The great plate count 
anomaly’[101]. Culture-independent techniques have become the more desirable path to 
take to analyse microbial community diversity and function. Profiling of microbial 
communities can be characterised via denaturing gradient gel electrophoresis (DGGE) 
analysis of the 16S rRNA gene and has been implemented to study bacterial 
communities of the gut [102]. Other analyses that have been implemented to study gut 
microbial communities include terminal restriction fragment length polymorphism (T-
RFLP) [103], fluorescence in situ hybridisation (FISH) and DNA microarrays [104]. 
These techniques are relatively high-throughput and cost effective, however, it is the use 
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of next generation sequencing of 16S rRNA amplicons through various culture-
independent techniques that is becoming the ‘gold-standard’ for studying complex 
microbial communities (particularly for studying the gut microbiota) due to their 
extremely high-throughput, decreasing costs and the enormity of data generated from 
the techniques. 
1.2 Metagenomics 
Arguably, the emergence of metagenomics in recent years represents the most 
momentous development in the field of microbial genomics and ecology. Metagenomics 
has become one of the most valuable ‘go-to’ technologies for studying microbial 
communities as they are in their natural environment and has significantly aided the 
progression of culture-independent technology in over-coming “the great plate count 
anomaly”. Metagenomics can be defined as a direct ‘meta’-analysis of the genomes of 
all the micro-organisms isolated from a particular environment, bypassing the need to 
culture [105]. Analysis of genetic information can be conducted in a manner analogous 
to that of studying single genomes isolated from cultured microorgansisms to elucidate 
microbial diversity, abundance and key genetic functions within a microbial community. 
As mentioned previously, it was the implementation of metagenomics and NGS that has 
allowed us to elucidate both the enormity of diversity and abundance within the gut 
microbiota [2, 4, 23, 28]. 
 
The term ‘metagenomics’ was first coined in 1998 and was implemented to study the 
soil microbiome by cloning environmental DNA [106], but the basic principles 
underlying the concept of metagenomics; studying the entire genomes of a mixed 
community of bacteria taken from an environment, had been used before by Norman 
Pace’s lab [107] with the understanding that microorganisms of a particular environment 
are all intricately linked and interact with one another and should therefore be viewed as 
a functioning interrelated system rather than simply individual organisms. 
 
The basic principles and procedures behind metagenomics are depicted in figure 1.3.  
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 from previous page 
Figure 1.3 A schematic diagram of the general methodology encompassing functional 
metagenomics and sequencing metagenomics. Upon identification and validation of a 
positive clone via FM, the insert will be sequenced and subject to extensive 
bioinformatic analysis also. The sequencing analysis pipeline is not included but is 
explained in more detail in the text. 
 
The mains steps in the process consist of isolating DNA from a given environment and 
cloning random fragments into an appropriate vector which is subsequently transformed 
into a surrogate host for construction of the metagenomic library. [108].The library 
represents portions of the genetic repertoire of the microbial community within the 
environment in question and can  be analysed by one, or a combination of two methods: 
sequencing analysis or functional analysis. These techniques will be discussed in more 
detail but in the first instance, both techniques rely on the isolation of environmental 
DNA. 
1.2.1 Sample Preparation and DNA Isolation 
The extraction of total DNA is relevant to both sequencing and functional metagenomics 
and following experimental design, one of the most crucial steps in metagenomics 
studies is the isolation of good quality DNA. As highlighted in a review by Ekkers et al., 
the DNA extraction protocols need to results in genomic DNA of high yield, high DNA 
quality/purity, large fragment size, and give an unbiased representation of the microbial 
community in question which can be difficult as some bacterial taxa, such as Gram 
positive organisms, require harsher lysis methods to recover high yields of DNA so it 
may be more difficult to isolate less abundant bacteria. Often, enhancement of one such 
criteria results in negative effect on one of the other factors [109]. In order to achieve a 
fair representation of the microbial community under scrutiny, DNA can be normalised 
based on G-C content. This normalisation can be achieved by caesium chloride gradient 
centrifugation in the presence of an intercalating agent (normally a dye) which will 
preferentially bind to specific regions of the DNA (for example biz-benzimide is often 
the intercalating agent and this dye preferentially binds to AT regions). In the presence 
of the caesium chloride gradient, the DNA will fractionate allowing separation of the 
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DNA sample based on base content Short et al., (1999)  DNA can also be normalised by 
denaturing DNA fragments. Here, the environmental DNA sample is denatured and left 
to re-anneal to double stranded DNA once more under strict conditions for an extended 
period of time (commonly 68 °C for up to 36 hours). DNA from abundant species will 
anneal faster than the less abundant and upon re-annealing, the DNA is separated 
allowing the less abundant DNA to re-anneal and become enriched [110]. 
 
Genomic DNA can be extracted from any sample type for use in FM analyses. However, 
cell lysis and consequently the DNA extraction of the entire microbial community can 
be carried out either directly from the environmental sample in question, or by indirect 
means where cells are first isolated from the sample (for example, by Nycodenz density 
gradient [111]) and subsequently subject to cell lysis and DNA extraction. Cell lysis 
may be carried out similarly for both direct and indirect methods and can include 
mechanical (e.g., bead beating), enzymatic, or chemical-based cell breakage. Although 
bead beating can yield heavily sheared DNA which can be challenging to generate 
‘sticky ends’ for subsequent ligation, blunt end cloning is usually more successful when 
working with heavily sheared DNA [110]. A number of studies have been conducted to 
determine optimum DNA extraction methods for different environments. Salonen and 
co-workers compared 4 methods for isolating DNA from fecal samples, for 
metagenomic studies of the human gut microbiota. The four different methods entailed; 
differential centrifugation and enzymatic lysis, the Promega Wizard DNA extraction kit 
relying purely on enzymatic lysis, repeated bead beating rounds with SDS, salt and 
EDTA and lastly, the QiaAmp DNA stool mini kit coupled with a preceding bead 
beating step [112]. They found the extraction methods to give highly variable DNA 
yields with as much as 35-fold variations in DNA yields amongst the methods.   
However their results demonstrated that optimal DNA recovery from human faecal 
samples was as a consequence of coupling  mechanical DNA extraction by repeated 
bead beating followed by precipitation [112]. Comprehensive and copious studies have 
been conducted on comparison of DNA extraction methods on different types of soil 
sample since this environment is often a site dedicated to FM screening for antibiotics 
[113] and due to the sheer enormity of the soil metagenome [114]. Purohit and Singh 
assessed ‘soft’ lysis (SDS and enzymatic extraction), ‘harsh’ lysis (bead beating and 
sonicator) and soft and harsh together DNA extraction methods for isolation of DNA 
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from saline soil habitats. They found that coupling of bead beating with the soft lysis 
method provided the purest quality, high molecular weight DNA [23-26]. 
 
Once the extracted DNA has been verified to be of sufficient quantity, the more the 
better but most methodologies specify a DNA concentration range that should be 
expected after correct extraction procedure. The quality of the DNA can be tested to 
verify that no inhibitors have been co-extracted, DNA is typically tested using an 
enzymatic test such as PCR amplification with broad-spectrum primers (e.g. primers 
targeting conserved regions of bacterial ribosomal RNA genes). Extracted DNA is also 
run on a gel to ensure high molecular weight DNA has been extracted. Once verified, 
DNA can be manipulated for further steps of functional metagenomic analysis namely 
ligation into an appropriate vector (size of DNA is also dependent on the type of vector 
being used) and transformed into a surrogate host for subsequent screening.  
1.2.2 Sequencing-based metagenomics 
The process of metagenomic sequencing, coupled with the development of next 
generation sequencing technologies has paved the way for perhaps the most significant 
developments in microbial genomics. It has allowed the deduction of entire microbial 
genomes, microbial diversity, abundance and adaptation to environments and the 
mapping of entire microbial communities [115]. Sequencing metagenomics traditionally 
involves large DNA inserts, size selected by pulse-field gel electrophoresis and  a vector 
that is capable of maintaining  a large DNA insert such as a bacterial artificial 
chromosome (BAC) cosmids or, most commonly, a fosmid which must  be packaged 
into a phage and transfected into a host. This metagenomic library can  be sequenced to 
identify microbial diversity, abundance and gene content as well as achieving an overall 
characterisation of the microbial environment in question. Sequencing strategies 
originated from Sanger sequencing which is still considered a ‘gold standard’ process 
for sequencing due to its low error rate and relatively long read length of over 700 bp 
[116],  but huge developments in next generation sequencing technologies (NGS) such 
as 454 sequencing or Illumina (discussed further in 1.3.3) have enabled the generation of 
extremely large datasets consisting of millions of gene sequences inevitably containing 
novel genetic information. Sequencing technology is a particularly dynamic area of 
research at present. Techniques are constantly progressing at costs that are constantly 
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decreasing making next generation sequencing a possibility for many laboratories 
globally. NGS methodology includes the preparation of genomic or metagenomic DNA 
under scrutiny, a library is prepared small synthetic oligonucleotide adapters are ligated 
to the ends of the fragments. Fragments are amplified by PCR and prepared in a 
particular way specific to the NGS platform being used. DNA libraries are sequenced 
and imaged and subject to extensive data analysis [117]. Some of the most commonly 
used NGS platforms include the Life Technologies Ion Torrent Personal Genome 
Machine (PGM), the Illumiona MiSeq,  Roche’s 454 pyrosequencing, Applied 
biosystems SOLiD system and the PacBio RS II system. Sequencing throughput has 
increased at an unprecedented rate in recent years, and we are currently able to acquire 
gigabases of sequence data in a few days [118]. Following retrieval of such data, it must 
be processed to remove poor quality sequence, raw data as a result of the sequencing 
technology used (such as barcode or ligated adaptor sequence), vector screening using 
programs such as cross_match (www.phrao.org) VecScreen 
(http://www.ncbi.nlm.nih.gov/VecScreen/UniVec.html) and LUCY [119]. Contaminant 
removal is also necessary but no trivial task, namely for E. coli contamination (as E. coli 
is routinely the cloning host) [105] or screening for human (host) contamination. 
Sequences are  assembled into contigs (contiguous stretches of DNA) via de novo 
sequence assembly or alignment using the increasing variety of bioinformatics software 
[120] [118]. Bioinformatic gene prediction and annotation follow a lengthy assembly 
process. Genes can be predicted by homology based searches using the BLAST 
algorithm [121] or by an ‘ab initio’ process to identify genes that do not necessarily 
have homologs via identification (prediction) of coding regions of DNA. There are a 
number of programs that assist with this kind of gene prediction such as GeneMark 
[122], MetaGene [123] Orpheus [124] and GLIMMER [125]. After gene prediction, 
genes are functionally annotated and predicated by similarity searches to already 
annotated genes and again, this is usually preformed using function prediction software 
such as the PFAM database [126], RPS-BLAST [127] and the assignment of clusters of 
orthologous groups (COGs) [128]. 
 
From here, entire genomes or structures of genome communities can be put together and 
microbial diversity deduced [129] as well as functions of communities [115].  
One of the first milestone, large scale metagenomics projects implemented the original 
DNA sequencing technology of Sanger sequencing to characterise the Sargasso sea 
      
 
29 
 
microbiota. In this project, > 1 billion bp of DNA were sequenced and over 1.2 million 
novel genes were identified including over 782 rhodopsin-like photoreceptor genes 
cementing a recent suggestion of a level of phototrophic function within marine 
environments [130], a function previously believed to be exclusive to halophilic archaea 
[131] .   
 
Metagenomics is becoming a baseline technology for understanding the diversity of 
microbial ecosystems, and from here, further hypotheses can be developed and with an 
ever decreasing cost of sequencing technologies due to such a significant amount of 
competition, sequencing metagenomics is becoming possible for many laboratories 
worldwide [100] and so is becoming a nascent technology for many microbial genetics 
research.  However, there are also some important limitations associated with this 
sequence-based approach that must not be overlooked. Firstly, sequencing 
metagenomics relies entirely on identification of sequence similarity with already 
known sequences which have been uploaded to public databases, and sequences that are 
not already known are left unidentified meaning that the entire ‘picture’ cannot be 
interpreted and entirely novel genes will rarely be identified. Also, many of the 
reference databases are currently extremely bias, dominated by just 3 phyla; 
Proteobacteria, Firmicutes and Actinobacteria [105]. Secondly, entire gene sequences 
are rarely revealed using this approach meaning there is always an aspect of ambiguity 
surrounding deduced gene products preventing a comprehensive biochemical and 
functional analysis; you can never be positive about the actual function of the gene 
sequence, additionally, small genes are often missed out completely. At present, it is 
probably fair to say that the resources and tools available to aid in the functional 
annotation process are insufficient to keep up with the demands of the huge amount of 
metagenomic data being produced [132].  Therefore some form of phenotypic analysis is 
the only alternative to find novel genes and to be able to understand and characterise 
their function. 
1.2.3 Functional metagenomics 
Functional metagenomics (FM) is a strategy to identify novel functional genes. FM 
relies on screening clones in these metagenomic libraries for a particular desired 
function that is exemplified by heterologous gene expression of the randomly inserted 
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DNA. Expression of a function can be indicated by various means, namely a measurable 
phenotype. These screening techniques can include observable phenotypic 
morphological or physiological changes such as alterations in colony pigmentation, size, 
shape or growth (inhibition). The use of indicator dyes is also indicative of the 
expression of particular genes via enzymatic reaction. To date, the majority of 
successful FM projects identify hydrolytic enzymes such as lipases, esterase and 
glycoside hydrolases (see table 1.2) and this is likely due to the relative ease of 
screening methodology. The incorporation of BCIP (5-Bromo-4-chloro-3-indolyl 
phosphate) in the growth media is a commonly used methods that allows for the 
colorimetric detection of alkaline phosphatase activity as alkaline phosphatases will 
hydrolyse BCIP to 5-Bromo-4-chloro-3-indole which is subsequently oxidised to form a 
dark blue dye. Dark blue colonies are thus indicative of a heterologously expressed 
alkaline phosphatase which may very well be novel.  
 
Other screening means involve the insertion of, and heterologous expression of a novel 
gene that allows growth of the host organism, and a screening means known as 
heterologous complementation. For example Culligan et al., isolated novel salt tolerance 
inferring genes after selection for E. coli clones that were able to grow at elevated salt 
concentration, concentrations at which the host could not grow [133]. Similarly, Simon 
and colleagues identified novel DNA polymerase genes by utilising a strain of E. coli 
harbouring a mutation in the 5’-3’ exonuclease domain of DNA polymerase. Following 
growth of the metagenomic library at 18 °C clones harbouring an insert encoding 
functional DNA polymerase would grow only [134]. 
 
The progression of high-throughput screening technologies has markedly improved the 
efficiency with which a metagenomic library can be screened for a particular function. 
Jones et al., for example, aimed for a library of over 250,000 clones [70] and Culligan et 
al., screened over 20,000 [133] and this is not abnormal as numbers such as this are 
needed to generate appropriate levels of genetic coverage for the environment in 
question . Automating the process of screening by way of microplate readers and in 
particular, colony picking robot such as the Pickolo™ and the RapidPick™ have 
enormously aided the ability to screen such large numbers of clones in a timely, 
repeatable and logical manner. Sophisticated, high-throughput screening methodologies 
are becoming developed too. Such methods have incorporated the use of high 
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performance liquid chromatography (HPLC) and the production of chromogenic or 
fluorescent or bioluminescent substrate. For example Rabausch and colleagues 
developed the META system (metagenome extract thin-layer chromatography analysis 
system) for detection of glycosyltransferases [135]. SIGEX (substrate-induced gene 
expression) and PIGEX (product-induced gene expression) systems have also been 
developed [136, 137]. Here (SIGEX), a green fluorescent protein (GFP) vector is used to 
construct the metagenomic library. The library is subject to a gene of interest induction 
and if the gene of interest if present and can be expressed by the FM host, the 
downstream GFP will also be expressed and thus the inserted gene can be identified via 
fluorescence-activated cell sorting (FACS). PIGEX is similar except the GFP reporter 
gene is located on a product of enzymatic (gene of interest) activity [137]. Other novel 
screening methodologies recently developed include the METREX system [138]. 
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Table 1.1 Recent successful functional metagenomic projects, the hosts that were used for heterologous expression, the vector, the assay 
type and the number of clones screened compared to the number of positive hits. 
Environment Target gene Host(s) 
Vector / 
Average 
Insert size 
# positives / 
#screened clones 
Assay type Ref 
Human gut Dietary fiber 
catabolic enzymes 
E. coli Fosmid (30- 
40kbb)  
310/704,000 Agar plate assay supplemented 
with polysaccharides 
[139] 
Soil (deciduous 
forest, creek bed 
and cold desert) 
Antimicrobial Agrobacterium tumefaciens 
Burkholderia graminis Caulobacter 
vibrioides 
E. coli 
Pseudomonas putida Ralstonia 
metallidurans. 
Cosmid 
(n/a
a
) 
170,000 (forest) 
450,000(creek) 
130,000( desert) 
Primary agar plate assay screen 
looking for alterations in 
colony morphology and 
pigmentation,  overlay with B. 
Subtilis to screen for growth 
inhibition 
[140] 
Activated sludge 
from a coke Waste 
treatment plant 
Amidase E. coli harbouring pCmGFPbenR 
(benzoate-responsive sensor plasmid 
Fosmid (33 
kb) 
4/96,000 PIGEX [137] 
Soil 4’-
phosphoantetheinyl 
E. coli Plasmid (2-6 
kb) 
4/3 x 10
6
 Agar plate assay: Blue 
coloration 
[141] 
Glacier ice DNA polymerase E. coli Plasmid (4kb) 
fosmid 
(36kb) 
Plasmid = 230,00 
Fosmid=4000 
Agar plate assay-ability to grow 
at 18°C 
[134] 
Compost soil Cellulase E. coli Cosmid (33 
kb) 
4/100,000 Plate assay [142] 
Forest soil and 
grassland soil 
Lipase E. coli Plasmid& 
Fosmid 
28/2217648 (plasmid) 
9/711794 (fosmid) 
Agar plate assay-agar 
supplemented with 1% 
tributyrin 
[143] 
      
 
33 
 
Soil from an urban 
environment 
Antibiotic 
resistance 
E. coli Plasmid (2 
kb) 
39/n/a Agar plate assay- using 
inhibitory concentrations of 
antibiotics 
[144] 
Soil; agricultural 
field soil and soil in 
vicinity of 
Mammillaria carnea 
Antibiotic 
resistance 
E. coli Plasmid (6.5 -
7 kb) 
11/550,000 Agar plate assay- using 
inhibitory concentrations of 
antibiotics 
[113] 
Human gut Salt tolerance E. coli Fosmid 
(~40 kb) 
 
47
b
/23,040 Agar plate assay-inhibitory 
concentrations of NaCl 
[133] 
[145]
c
 
Marine sponge Antimicrobial E. coli Fosmid 
(~40 kb) 
1/250,000 Agar plate assay; overlay with 
B. cereus 
[146] 
Alaskan soil Antibiotic 
resistance 
E. coli Plasmid  
Fosmid (~40 
kb) 
1/(13,201 Mb DNA) Agar plate assay; inhibitory 
concentrations of antibiotics 
[147] 
Deep-sea sediment Lipase E. coli Fosmid 
(15-33 kb) 
/681,100 Agar plate assay;agar 
supplemented with 1% 
tributyrin 
[148] 
Unvegetated 
Antarctic soil 
Cellulase E. coli BAC 
(5.1 kb) 
11/124,000 Agar plate assay; agar 
supplemented with cellulose 
[149] 
Human Gut (fecal 
and ileum mucosa) 
Hydrolytic 
enzymes-(probiotic 
breakdown) 
E. coli Fosmid 
 
Fecal=11 hits 
Ileum = 49 
Agar plate assay; supplemented 
with carbon source  
[150] 
Activated sludge 
from a paper mill 
Esterase E. coli Plasmid 
(3 kb) 
 
2/40,000 Agar plate assay-agar 
supplemented with 1% 
tributyrin 
[151] 
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Forest soil Protease E. coli Plasmid 
(7-12 kb) 
1 positive clone Agar plate assay: agar 
supplemented with  AZCL-
casein 
[152] 
Human gut Antibiotic 
resistance 
E. coli Fosmid 
(30 kb) 
17/415,000 Agar plate assay- using 
inhibitory concentrations of 
antibiotics 
[153] 
Biomass from  
sequencing fed-
batch reactor  
Lipase 
Esterase protease 
E. coli 
Strepytomycse lividans 
Cosmid 
 
17/2000 (esterase/lipase Agar plate assay-agar 
supplemented with 1% 
Tributyrin or skimmed milk 
[154] 
Desert sand (Death 
valley and Gobi) 
Protease E. coli Plasmid 
(6 kb) 
Fosmid 
(32 kb) 
Plasmid 1/30,000 
Fosmid 4/17,000 
Agar plate assay-agar 
supplemented with skimmed 
milk 
[155] 
Apple Orchid soil Antibiotic 
resistance 
E. coli Fosmid 
(30 kb) 
13/446,000 Agar plate assay- using 
inhibitory concentrations of 
antibiotics 
[156] 
Elephant faeces and 
river sediment 
Flavonoid-
modifying enzymes 
E. coli Fosmid 
(35 kb) 
1/50,000 Extra this layer 
chromatography 
[135] 
Cotton field Tannase E. coli Plasmid 
(3.5 kb) 
1/92,000 Agar plate assay; agar 
supplemented with X-caprylate 
[157] 
35 
 
FM is potentially an extremely useful tool and is the only way that novel genes can be 
found [108]. It has been shown to have the capabilities of identifying many novel genes, 
including those of medical significance such as polyketide antibiotic genes [158] and 
bacterial antibiotic resistance genes [159]. Functional metagenomics has revealed the 
extent and diversity of CAZymes [160], bile salt hydrolases [70] and a number of 
studies have revealed numerous degradative enzymes including esterases, glycoside 
hydrolases and lipases (see Table 1.1). These findings may have useful implications for 
biotechnology; they may have clinical significance and above all give us a specific 
insight into the roles these microbes may be playing in the environments they inhabit, an 
insight that without functional metagenomics, would remain unseen. This process 
therefore shows potential for not only furthering our knowledge of the microbial world, 
but also for effective drug discovery, and unravelling resistance mechanisms and 
potential mechanisms of disease. 
 
However, although FM is a very powerful technique, it is far more labour intensive 
process than that of the sequencing approach and the frequency of positive results, i.e. 
an active clone, remains relatively low. To get enough genetic coverage, clone libraries 
of tens of thousands of clones have to be screened for a positive phenotype.  
For a successful metagenomic screen a gene has to be successfully ligated into a vector, 
transformed into a surrogate host where it must be faithfully transcribed and translated 
into the fully functioning protein or product which must  be secreted from the cell and 
its function demonstrated [108]. The major issues surrounding the success of FM have 
been highlighted by Ekkers et al., [161]. The efficiency and yield of DNA extraction 
from a given environment remains a significant consideration, although this has been 
discussed in-depth previously, and this is also a consideration in sequencing-based 
metagenomics. One of the most hampering processes in FM is that it requires 
heterologous gene expression of foreign DNA in a surrogate, domesticated host. 
Therefore, careful consideration must be given to; the size on the insert DNA, the 
cloning vector and importantly, the surrogate host. While E. coli is normally the 
organism of choice for routine cloning procedures, this cannot be the case with FM 
when the whole point is to clone DNA from potentially unusual, ‘exotic’, uncultured 
microorganisms to rely entirely on E. coli would be counterintuitive [108]. 
Consequently, more recently FM is veering towards alternative hosts for more efficient 
screening, the wider genetic capacity a host system has, the more chance it will be able 
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to dependably express a foreign gene. Problems with gene expression arise for a number 
of reasons for example, incorrect protein folding, enzymatic breakdown of product, the 
product may exert a toxic effect on the host, gene promoter regions may not be 
recognised (cis-acting DNA factors), the formation of inclusion bodies or missing 
initiation factors or the inability to process signal peptides for secretion of the product 
(trans-acting DNA factors) [161]. Clearly there are a profusion of factors to consider, 
broadening host range is an attractive response. However, this does limit the vector 
choice since the chosen vector has to be replicable inside the chosen host and as most 
fosmids, cosmids and Bacterial Artificial Chromosomes (BACs) are designed for E. coli 
replication, in most instances with alternative hosts FM is restricted to smaller (<15kb) 
insert libraries using plasmid vectors. Libraries requiring larger insert sizes (exogenous 
DNA >15 kb) are typically processed using cosmids (15-35 kb), fosmids (25-45 kb) or 
BACs (100-200 kb). Large insert size libraries have their advantage in that greater 
coverage can be achieved with fewer clones and increase the likelihood of contained an 
intact gene or multiple genes involved in specific biochemical pathways. 
 
The implementation of alternative hosts or hosts used in conjunction with E. coli for 
generation of FM libraries can be seen in table 1.1. Multiple host cloning systems 
implementing a minimum of two hosts (often E. coli remains the surrogate of choice for 
library maintenance however) meaning a diversification of genetic arsenal and thus an 
increased chance of expression and secretion of functional product. If a ‘positive hit’ is 
observed and it is certain that the clone is not a contaminant, the clone is isolated, and 
the potential novel insert is sequenced. After the sequence of the insert has been 
determined it is subject to bioinformatic analysis and activity based assays to 
characterise the expressed molecule.  Following sequencing, the sequence is annotated 
using sequence editing software such as the commercially available Lasergene99 core 
suite (DNASTAR, Inc., Madison, Wisconsin, USA) or sequence editor modules within 
the CodonCode Alignment Software (CodonCode Corporation, Dedham, 
Massachusetts) or free software which includes BioEdit [162] or Mega (Molecular 
Evolutionary Genetics Analysis) [163] and predictions of open reading frames, 
structures, promoters and homology searches can be conducted using software such as 
the NCBI Open Reading frame Finder. For specific enzymes, there are numerous 
BLAST algorithm based databases publicly available that specialise in specific classes 
of enzymes for homology searches and structural and biochemical properties 
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predictions. For example, the MEROPS database for proteolytic enzymes 
(http://merops.sanger.ac.uk/index.shtml) can be used for homology searches and to 
determine substrates and inhibitors of proteases [164], the Carbohydrate-Active Enzyme 
Database can be used to analyse Carbohyrdate-Active Enzymes (CAZymes) such as 
glycoside hydrolases (http://www.cazy.org/) [165] and the Lipase Engineering Database 
(http://www.led.uni-stuttgart.de/) [166] can be used for similar analyses on putative 
lipase enzymes. A comprehensive list of enzyme databases are discussed in the work of 
Schomburg and Schomburg  [167]. 
 
As important as the bioinformatic analyses is, the  activity-based characterisation of the 
insert DNA is as important. Often, following bioinformatic analysis, primers can be 
designed to span the specific coding region of DNA of which the product can be sub-
cloned using standard sub-cloning vector systems (such a pBluescript variations or pET 
vector expression systems) and screened for recapitulation of the primary phenotype. It 
clones to recapitulate the particular phenotype it can be fair to assume that a gene 
encoding a functioning protein has been captured via the FM techniques. From here, 
further functions of the protein can be explored to determine biochemical traits such as 
temperature optima, pH optima, the effect of certain inhibitors and substrate specificity. 
 
Thus, this amplifies the notion that FM is currently our only strategy for extracting 
novel biocatalysts and biomolecules and enables their direct characterisation and 
insights into microbial function while with sequencing approach these parameters can 
only be conjectured. 
 
1.3 Microbial Proteases: The Degradome  
 
Proteases are responsible for the hydrolysis of the peptide bond between amino acids in 
proteins and are essential in many biological processes [168] in all organisms. They 
comprise an extremely diverse group of enzymes and are classified into the main types 
according to their catalytic type, or the amino acid that is present at their active site 
giving the groups; aspartic, cysteine-, threonine-, serine-, glutamic- and Metallo-
proteases. Proteases act upon proteases via hydrolysis reaction of the covalent peptide 
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bond in protein and the different proteases are specific in their mechanism of action and 
the peptide bond that they hydrolyse. One of the first proteases to be studied in detail 
was Chymotrypsin, a serine protease secreted by the pancreas in humans and gave great 
insight into the mechanism of action of such enzymes. The clarification of the 3 
dimensional structure of the enzyme helped reveal that the arrangement of amino acids 
in the 3D structure was such that protons and charge could move within the active site of 
the enzyme allowing amino acids to act as proton acceptors and donors, nucleophiles 
and electrophiles. For the different type of proteases, different amino acid residues act as 
the nucleophile to attack the carbonyl group of the peptide bond. For example in 
Chymotrypsin, a serine residue in the active site partakes in the nucleophillic attack 
[169], in cysteine proteases, a nucleophilic cysteine thiol is the nucleophile that initiates 
the proteolytic reaction, for metalloproteases, a metal ion, commonly a zinc ion, is 
needed for catalysis. 
 
All groups contain proteases that have a broad range of substrates, for example the 
serine protease group contains Proteinase K, produced by the fungus Tritirachium 
album, which acts on vast array of substrates including keratin, casein and haemoglobin 
[170]. In contrast, there are many proteases that have a highly specific substrate usually 
involved in processes that need to be tightly regulated for example small ubiquitin-like 
modifier (SUMO) proteases [171, 172]. While proteases can be structurally similar, and 
be members of the same protease type, their difference in substrate specificity is due to 
their recognition of different amino acid residues within a substrate. 
 
Proteases from all organisms are also implicated in a multiplicity of diseases including 
Alzheimer’s [173], cancer [174], the pathogenesis of HIV [175] and a plethora of 
bacterial diseases which will be discussed in more detail later. Though, as previously 
mentioned, proteases are ubiquitous and essential in all living organisms, those 
produced by the microbial world are often our principle interest due to their relative ease 
of genetic manipulation, because of certain physiological and biochemical traits, their 
vast genetic diversity and their roles in virulence [176].  
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1.3.1 Microbial Proteases and their uses 
 
Due to their genetic diversity, broad substrate specificity, the relative ease it takes to 
genetically manipulate them to tailor specific needs, microbial proteases are some of the 
most important and cost effective biocatalysts involved in the production process of a 
huge number of commercially and pharmaceutically important products 
[176, 177]. Perhaps some of the most well-known products of which microbial proteases 
are essential in the production include; laundry detergents, where most notably 
subtilisins, a group of serine proteases isolated from the Bacillus Genus are used to 
degrade substrate found in certain stains [178], bacterial and fungal keratinases and 
elastases are used extensively in the leather making industry for bating and unhairing of 
product [179]. They are extensively used in the food and drink industry; yeast proteases 
are used extensively in bread baking and beer manufacturing, bacterial and fungal 
proteases are important in the development of coffee and cocoa and microbial rennets 
are being increasingly used in the dairy industry [176].  In the pharmaceutical industry, 
Clostridial Collagenase, a metalloproteases isolated from Clostridium histolyticum has 
many clinical applications. It is used in conjunction with antibiotics to promote wound 
healing [180] and in the treatment of peyronie’s disease in men [181]. Aspraginase, a 
protease isolated from two bacteria; E. coli and Erwinia chrysanthemi, is commonly 
used to treat malignant lymphomas by converting circulating asparginine (for which 
leukaemia cells are auxotrophic, but normal cells are not) into aspartic acid [182].  
1.3.2 Proteases as virulence factors 
 In addition to their application in industry, microbial proteases are also clinically 
relevant as proteases are thought to account for up to 5% of the genome of infectious 
organisms and are often associated with the pathology of certain human diseases acting 
as significant virulence factors aiding the onset of infection [183, 184]. Recent research 
has suggested this number may be much higher [168] and with the advance of culture-
independent techniques for studying microbial communities it is fair to theorize that 
there are many proteases, as well many other molecules, that are yet to be discovered 
many in microorganisms that we are currently unable to culture. 
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Bacterial proteases may be implicated as virulence factors for a variety of reasons. A 
virulence factor can be defined as it enables a microorganism to invade, replicate and 
establish themselves in a host and cause disease by subverting the host immune system. 
There are many ways that pathogenic bacteria utilise proteases to enable such processes. 
For example, some bacterial proteases directly act as toxins targeting proteins of whose 
degradation directly leads to disease, the role of many proteases of pathogenic 
organisms is to degrade specific proteins of the immune response thus actively 
inhibiting the immune system, and some proteases may indirectly act as virulence 
factors by utilising a substrate for nutritional purpose but causing damage to the host as 
a consequence. Table 1.2 shows some pathogenic bacteria, proteases they produce, and a 
more detailed description of the mechanism behind how they act as virulence factors. 
 
 
Table 1.2. Some well known pathogens that utilise proteases as virulence factors in the 
onset and protgresion of infection.The mechansims of those proteases in disease are also 
described with the reference that carried out the research to implicate the proteases as 
significant viruelnce factors. 
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Species Protease Target/function Reference 
Staphylococcus aureus Metalloprotease 
aurolysin 
Inhibition of host immune response-Blocks phagocytosis and neutrophil 
activation by cleaving and inactivating complement protein C3 
[185] 
Bacillus anthracis Metalloprotease 
anthrax lethal factor 
Evasion of host imune system , cleaveage and inactivation of mitogen-
activated protein kinase kinases leading to disregulation in many 
cellular processes such as apoptosis 
[186] 
Clostridium botulinium Metalloprotease 
bontoxilysin 
This protease is part of the botulinum toxin that binds and cleaves  
synaptosomal-associated proteins consequently preventing vesicle 
fusion  and release of the excitory neurotransmitter, acetylcholine. 
[187] 
Helicobacter pylori Serine protease HtrA Cleaves the transmembrane glycoprotein e-cadherin leading to 
disruption of epithelial barrier function. E-cadherin is also considered a 
tumour suppressor protein due to it’s role in cell-cell adhesion. Loss of 
funtion of e-cadherin  allows the proliferation of tumour cells. 
[188] 
Pseudomonas aeruginosa Thermolysin-like 
metallo protease; 
Elastase 
Elastase B from P. aeruginosa has a broad spectrum of activity 
contributing to it’s virulence including disprution of epithelial barrier 
function by degradation of tight junctions and degradation of a nu,ber of 
innate and adaptive immunity proteins including TNF-α and IFN-γ, IgA 
and IgG. 
[189] 
Enterococcus faecalis Metalloprotease; 
Gelatinase E (GelE) 
GelE has a broad spectrum of activity which contributes to E. faecalis 
virulence including disruption of epithelial barrier function and evasion 
of the host immune system by degradation of C3 and iC3b 
[190] 
      
 
42 
 
Proteus mirabilis Metalloprotease; 
ZapA/mirabilysin 
ZapA degrades IgA1, IgA2 and IgG 
[191] 
Bacteroides fragilis Metalloprotease; 
Fragilysin 
Hydrlyses the extracellular domain of E-cadherin to disrupt epithelial 
barrier function 
[192] 
Enterotoxigenic/Enterohemorrhagic 
E. coli 
Metalloprotease StcE StcE is sectreted by  the type II secretion system and degrades the high 
molecular weight glycoprotein; mucin lining the epithelaial cells of the 
human gut thus allowing intimate adherence of the E.coli to host cells. 
[193] 
Clostridium spp. Collagenase A Degrade collagen [194] 
Vibrio cholerae Metalloprotease; TagA Carries out the same function as StcE [195] 
Mycobacterium tuberculosis Mycosin-1 subtilisin-
like serine protease 
Mycosin-1 activates the ESX-1 secretion system for transportation of 
other protein and virulence factors into infected macrophages and is 
essential for establishment in initial infection 
 
[196, 197] 
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1.3.3 Protease activity in the human gut 
Given that a large aspect of the human diet is constituted of protein, it is probably 
unsurprising that there is substantial amount of  exogenous (dietary) protein available as 
substrate for the gut microbiota [198, 199]. Macfarlane and colleagues also 
demonstrated that the microbiota harbours large quantities of proteases that may be 
contributing to proteolysis of dietary protein [200].  
 
However, we hypothesise that there may also be a substantial amount of substrate 
available for degradation by the gut microbiota that is endogenous to the host. Examples 
of such protein include the high molecular weight glycoprotein mucin, keratin [201], 
proteins of the immune system including immunoglobulins and antimicrobial peptide 
and protein that make up tight junctions between intestinal epithelial cells and contribute 
to gut barrier function (cadherins, zonulin, claudin).  The ability of bacteria to degrade 
these proteins may have implications on host health since in order to develop and 
maintain themselves in the GI tract, bacteria must compete against both the primary 
defence including physical barriers such as mucin and the innate immune system such as 
non-specific secretary Immunoglobin A- the most abundant immunoglobin in the gut, 
the vast array of other antimicrobial peptides and must outcompete other bacteria for 
nutrients needed for growth. Bacterial degradation of such proteins may have relevance 
in the pathological process of a number of gut related disorders. 
 
It was mentioned previously that while there are many contributing factors to disorders 
such as Crohn’s disease and Ulcerative colitis, one of the key processes is host-
microbial interactions at the gut barrier interface and previous research has shown that 
there is elevated microbial proteolytic activity in the gut of those suffering with 
disorders such as IBS. Increasing evidence for the roles of proteases in disorders of the 
human gut stem from pinnacle studies such as those conducted by Steck et al., whereby 
a matrix metalloprotease, gelE, isolated from Entercoccus faecalis, often a commensal 
of the gut microbiota,  was able to directly contribute to chronic intestinal inflammation 
to animal models of IBD via impairment epithelial barrier function and increased 
extracellular permeability through degradation of the transmembrane glycoprotein, E- 
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cadherin [202]. Prunteanu and colleagues also found that a proteolytic isolate form the 
gut, Clostridium perfringens, was capable of reducing transepithelial resistance in 
Ussing chamber experiments thus suggesting the ability of this isolate to compromise 
epithelial barrier function. Two pinnacle reviews have been published outlining the 
possible mechanisms by which bacterial proteases may be contributing the inflammatory 
disorders of the gut [203, 204]. Recent research as part of the European Union research 
project; Intestinal Proteases: Opportunity for Drug Discover (IPODD) Consortium 
(http://www.ipodd.eu/) has also highlighted that the activity of matrix metalloproteases 
(MMPs) previously believed to be of host origin, may actually be produced by gut 
bacteria and more so, this may mean that bacteria could be a source of protease 
inhibitors for both bacterial and host proteases and could be a source of anti-
inflammatory drugs. 
 
A more comprehensive view of the underlying molecular mechanisms and interactions 
that are occurring here is needed if we are to understand the impact the gut microbiota is 
having on host health. The problems of culture make this difficult however culture-
independent processes may facilitate the analysis of microbial proteases that are 
produced by the vastly uncultivated gut microbiota and may well be implicated in 
disease. 
 
1.3.4 Proteases and functional metagenomics 
Clearly there is much evidence supporting the role of proteases as virulence factors in 
disorders of the gut. However, when applying experimental data to the human gut, it is 
inappropriate to simply analyse pure cultures of isolated microorganisms alone as 
species such as E. faecalis and C. perfringens man not be numerically dominant in IBD. 
Also, little is known about their interaction with other members of the gut microbiota. 
Additionally, as current culture methods do not support the growth of the vast majority 
of the gut microbiota, there remains a lot of ambiguity surrounding the proteolytic 
capacity of the uncultured gut microbiota. Therefore alternative strategies need to be 
implemented if we are to uncover the entire potential and function of the gut microbiota 
degradome. 
 
    
 
46 
 
As previously discussed, one of the most effective ways to isolate novels genes and 
therefore functions, in the case of this research, proteolytic functions, of bacteria from 
environments such as the gut, FM provides the means to access these functions. 
Functional metagenomics has been used to screen for and successfully isolate a number 
of different microbial enzymes that have potential for industrial applications [205] and 
are clinically relevant [206] and provide generous insights into the functional diversity 
of bacteria and how they have adapted to their environment [70]. However, when it 
comes to screening for proteases via functional metagenomics there are a currently a 
number of limitations that have been highlighted previously (section 1.3.3) and the lack 
of success of FM screening for proteases are well documented [207-209]. Solutions to 
these limitations need to be explored if we are to access the entirety of the ‘Degradome’. 
1.3.5 Protease “Degradomics” 
In light of increasing knowledge that proteases are intricately involved, if not in control 
of in many cellular processes as well as pathological processes, increasing efforts have 
been implemented to determine means for identifying and characterising proteases. The 
MEROPS database is a large, comprehensive peptidase database currently including 
sequence and function information for around 3000 proteases and protease inhibitors 
and provides an excellent resource for the study of proteases that have already been 
characterised in one way or another and to study protein that are homologous to those 
already in the database. Data from this site has also helped generate the estimate that 
proteases account for at least 2% of protein in all organisms [164]. Additionally, another 
“–omic” technology has also been coined dedicated to studying the function of 
proteases, their substrate specificity and their inhibitors; Degradomics [210]. 
Degradomics aims to encompass genomic and proteomic methodologies dedicated to the 
identification of proteases (family, type etc), elucidating their function, their endogenous 
inhibitors and their substrate specificity. 
Degradomics will help uncover the biological roles of proteases in the environments 
they exist be it the human body, soil, the ocean and further characterisation will aid 
treatments for diseases of which proteases are central. Degradomic studies coupled with 
improvement of and implementation of other metagenomic analyses will significantly 
advance our knowledge of microbial proteases in the human gut. 
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1.4 AIMS AND OBJECTIVES 
 
Proteolytic degradation of both exogenous and endogenous protein has been 
demonstrated to have implications on host health and the gut microbiota has been shown 
to significantly contribute to proteolysis in the human colon [200]. It has been estimated 
the proteases make up a significant percentage of protein within the genomes of both 
pathogens and commensals [164]. There is also data to suggest contribution of bacterial 
proteases to IBD [202-204]. 
 
Thus far research into proteases and their contribution to gut inflammation have been 
conducted on pure cultures on laboratory isolates. A coupling of genomic and 
degradomic techniques is required to elucidate the function/role of gut microbial 
proteases with regards to the environment they inhabit and to determine their potential 
involvement in disease. Exploration of these techniques and their implementation to 
investigate the gut microbiota and its degradome in disease surmises the main objective 
 
The main aims and hypotheses of this project are as follows:- 
 
1. To develop a simple, yet robust agar to eliminate the occurrence of false 
positive in functional metagenomic library screening for proteases-We 
hypothesise that current culture techniques for proteases lead to false positives 
(clear halo forming on skimmed milk agar) due to the hydrolysis of lactose in the 
milk and the subsequent pH drop. Using a fat-free, lactose free substitute should 
ameliorate this problem. (Chapter 3). 
 
2. To identify and functionally characterise the active protease gene(s) from a 
fosmid vector isolated using metagenomics from activated milk waste 
treatment plant. (Chapter 4). 
 
3. To conduct a culture-dependent analysis on protease producers within the 
gut microbiota. (Chapter 5). 
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4. To develop novel metagenomic tools to obtain characterised proteases from 
(gut) bacteria and to implement these tools to screen the gut microbiota for 
protease activity. We hypothesise that the use of a novel shuttle vector system 
utilising a Gram negative as well as a Gram positive host that has a demonstrated 
capacity to express and secrete proteases effectively will be much more efficient 
in capturing protease genes from the gut metagenome. (Chapter 5). 
 
5. To determine optimal conditions for faecal protease extraction and storage 
over time. (Chapter 6). 
 
6. To conduct a comprehensive comparison of protease activity in an IBD 
cohort and compare to a group of healthy volunteers. It is hypothesised the 
IBD cohort will harbour an increased level of protease activity as protease 
activity has been associated with a contribution to inflammation in the human 
gut. Protease activity has also been found to be elevated in diseases of a similar 
pathology such as IBS. 
 
7. To conduct 16S rRNA community profiling analysis for each cohort. 
Previous studies have found a dysbiosis of the gut microbiota in IBD. We 
hypothesise that the IBD cohort will show different microbial abundance and 
diversity when compared to the healthy cohort as a whole. We also hypothesise 
that compositional alterations in the gut microbiota will be associated with 
higher levels of protease activity. (Chapter 7). 
 
8. To further unravel the potential role of the gut degradome in the virulence 
of inflammation. As it has been demonstrated that inhabitants of the gut 
microbiota are capable of secreting proteases that act as virulence factors, we 
hypothesise that the proteases isolated from the IBD cohort will have an 
enhanced ability to behave as virulence factors compared to the healthy cohort 
due to compositions in the gut microbiota. (Chapter 7). 
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2.0 GENERAL MATERIALS AND METHODS 
 
Unless stated otherwise the following reagents were obtained from: 
 PCR reagents were supplied New England Biolabs (NEB) UK 
 Cloning reagents were supplied by ThermoFisher Scientific (Loughborough, 
UK) 
 Media and chemicals were supplied by Sigma Aldrich (Dorest, UK) 
 Primers were supplied by Sigma Aldrich (Dorset, UK). 
 
2.1 Bacterial Strains and plasmids 
The bacterial strains and plasmids used in this thesis, along with their growth 
requirements and the chapters to which they are relevant are  indicated in Table 2.1. 
 
 
 
Table 2.1 Bacterial strains, growth conditions and plasmids used in this thesis. LFSMA: 
Lactose free skimmed milk agar, LB:
 
Luria-betani agar, 
 
MRA: de Man Rogosa and 
Sharpe agar FM: Functional metagenomic, TSA: Tryptone soy agar,  Amp: Ampicillin, 
Cm:Chloramphenicol, Km: Kanamycin, neo: Neomycin 
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Species/ 
plasmid 
Use Media Temp Antibiotic Ref/Source Chapter 
B. subtilis MY2016 Positive control for protease activity LFSMA
 
30 Amp (100μg/ml) 
Marchesi Culture 
collection 
3,5 
E. coli  MegaX 
DH10B™ T1R 
Electrocompetent cells  
Host for metagenomic library LB 37 
Cm (12.5μg/ml) 
 
Epicentre, Madison, WI, 
USA 
5 
Glycoside hydrolase 
clones 
Testing LFSMA LFSMA
 
37 Cm (12.5μg/ml) [1] 3 
L. bulgaricus Testing LFSMA 
MRS/LFSMA 
(anaerobic jar) 
37 n/a 
University College Cork 
culture collection 
3 
pGEMt®T-easy vector Sub-cloning n/a n/a 
Amp (100 
μg/ml) 
Promega, Madison, WI, 
USA 
4 
pNZ44 FM library construction n/a n/a Cm (5 μg/ml) [2] 5 
S. thermophilus Testing LFSMA 
MRS/LFSMA 
(anaerobic jar) 
37 n/a 
University College Cork 
culture collection 
3 
XL1-blue super-
competent subgrade E. 
coli 
Subcloning and screening 
LB 
 
 
37 
Amp (100 
μg/ml) 
Agilent, Berkshire, UK 4,5 
B. subtilis WB800N Host for metagenomic library TSA 30 
Km or neo (10 
μg/ml) 
 
MoBiTec 5 
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pET-42a Expression of M1-1 n/a n/a Km (10 μg/ml) 
Marchesi Culture 
collection 
4 
P. aeruginosa PAO1 To obtain LasB gene TSA 37 n/a 
Mahenthiralingam culture 
collection 
5 
E. faecalis (isolated in 
this work) 
To obtain gelE gene and positive 
control for TER and permeability 
assay 
LFSMA 37 n/a This work 5,7 
Burkholderia ambifaria 
AMMD 
To test whether it forms halos on LF-
SMA 
LFSMA 37 n/a 
Mahenthiralingam culture 
collection 
4 
Burkholderia 
cenocepacia PC184 
To test whether it forms halos on LF-
SMA 
LFSMA 37 n/a 
Mahenthiralingam culture 
collection 
4 
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2.1.1 Storage and maintenance of bacterial strains 
All stocks of bacterial isolates were prepared by taking freshly grown isolates from their 
appropriate solid media which had been grown at appropriate temperatures (30°c or 
37°C) overnight. Subsequent colony growth was re-suspended in appropriate liquid 
media containing 8% v/v DMSO and mixed to form a bacterial suspension prior to 
storage at -80°C. 
 
2.2 Plasmids 
Plasmids used in this thesis are also shown in Table 2.1 
2.2.1 Plasmid Extraction 
Plasmid and fosmid preparations from E. coli were carried out using the Qiaprep spin 
mini prep kit (QIAGEN LTD. West Sussex, UK) according to the manufacturer’s 
protocol on cells from an overnight culture (no more than 16 hours at 37°C and shaking 
at 150 rpm) from a single colony from a fresh plate, in 5-10 mL of LB broth 
supplemented with the appropriate antibiotic. Following extraction, plasmids were 
viewed under UV light on a 0.8% (w/v) agarose gel supplemented with 1μg/ml ethidium 
bromide. 
2.2.2 Storage and maintenance of plasmids 
Bacteria used to maintain the plasmids after transformation were stored in the same 
manner as all other bacterial isolates with appropriate antibiotics. 
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2.3 Human Stool Samples 
2.3.1 Sample collection  
Institutional ethical approval was obtained prior to the study and was granted by Cardiff 
School of Biosciences, Cardiff University (Cardiff University’s Research Ethics 
Committee). Participants gave written consent following retrieval of a participant 
information sheet detailing all aspects of the study and what their samples would be 
used for.  
 
Faecal samples were collected from healthy male and female individuals (n=11) from 
Cardiff University and individuals suffering from IBD, male and female (n =13) were 
recruited as part of another study at St Mary’s Hospital, Imperial College London. All 
samples were processed and stored following correct protocol as determined by the 
Human Tissue Act (HTA) 2004 and samples were all anonymised. 
 
Samples were collected using disposable trays; participants were advised to ensure no 
urine was collected in the tray alongside the faecal sample. Trays were deposited 
anonymously in a fridge at 4 ˚C until DNA extraction (the same day). The remaining 
sample were thoroughly mixed and divided into 1 g samples in sterile universal tubes 
and immediately frozen at -20°C. An overview of the participants is provided in Table 
2.2. Both male and female participants were analysed. The various medications for 
treatment of those with IBD are also listed. Patients that had not received antibiotic 
treatment in the last year were selected. 
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Table 2.2 shows available participant information including participant sex, diagnosis of 
IBD; CD:- Crohns disease, UC; Ulcerative colitis along with a harvery bradshaw 
activity index (HBAI) and Simple clinical colitis Activity index (SCCAI) value which 
are used to quantify the symptoms of Crohn’s disease and ulcerative colitis respectively. 
A value of greater than or equal to 5 represents a clinically active disease. ‘H’ means 
healthy participant. Medications for IBD treatment and other ailments are also indicated. 
Following is a brief description of the purpose of each drug  
a 
immunosuppressive drug, 
b
 TNF inhibitor, 
c
 anti-inflammatory, 
d 
monoclonal antibody against TNF-α, e steroid, f 
calcium and vitamin d supplement, 
g 
antimuscarinic, 
h
 proton pump inhibitor, 
I
 
painkiller, 
j
anti-inflammatory, 
k
 hypolilidemic drug to lower cholesterol, 
l
 to control 
diabetes, 
m
 painkiller, 
n
 statin used to lower cholesterol, 
o
 probiotic, 
p
 treatment for 
herpes simplex virus, 
q
 treatment for inflammation of joints, 
r
 anti-inflammatory, 
s 
opoid 
receptor antagonist, 
t 
anti-histamine, 
u
 anti-inflammatory,  
v
 opoid painkiller, 
w
 
supplement, 
x
 painkiller. The healthy participants had no long term medications and no 
significant medical history. 
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Sample Code Gender Diagnosis HBAI SCCAI Medications Medical history 
IBD 1 F CD 5  Azathiaprine
a
, 
Adulimumab
b 
Nil 
IBD 2 M UC  0 Azathiaprine, Asacol
c 
Nil 
IBD 12 F CD 5  Azathiaprine, 
infliximab
d
 
Nil 
IBD 16 M CD 18  Prednisolone
e
, 
Azathiaprine, adcal
f
, 
mebeverine
g
, 
omeprazole
h
 
Nil 
IBD 18 F CD 11  Adulimumab, analgesia
i
 Nil 
IBD 19 F UC 0 6 Prednisolone, pentasa
j
, 
simvastatin
k
 
hypercholesterolaemia 
IBD 25 F CD 0  Pentasa, insulin
l
, 
aspirin
m
, pravastatin
n
 
Diabetes, 
hypercholesterolaemia 
IBD 26 M UC 0 5 Nil Nil 
IBD 27 F CD 1  VSL3
o
, Azathiaprine, 
aciclovir
p
, 
sulphasalazine
q
 
Osteoarthritis 
IBD 28 M UC  2 Asacol Impaired glucose 
tolerance 
IBD 29 M UC  2 Predisolone, 
predisolone enemas, 
mesalazine
r
, naltrexone
s
 
Nil 
IBD 30 F CD 1  Loratidine
t
, 
balsalazide
u
, codeine 
phosphate
v
, 
glucosamine
w
 
Allergies/hayfever, 
osteoarthritis 
IBD 31 M UC  7 Azathiaprine, pentasa, 
omeprazole, 
paracetamol
x
 
Allergic rhinitis 
S1 M H n/a n/a nil nil 
S2 M H n/a n/a nil nil 
S3 M H n/a n/a nil nil 
S4 F H n/a n/a nil nil 
S5 F H n/a n/a nil nil 
S6 M H n/a n/a nil nil 
S7 F H n/a n/a nil nil 
S8 M H n/a n/a nil nil 
S9 M H n/a n/a nil nil 
S10 M H n/a n/a nil nil 
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2.4 DNA Extractions  
2.4.1 From bacterial cells 
DNA was extracted from 1 ml of overnight bacterial culture grown in appropriate liquid 
media inoculated from a single colony grown from solid media. Cells were pelleted by 
centrifugation at 4000 x g for 2 min. The pellet was resuspended in 100 µLTE buffer 
(10mM Tris/HCL, pH8, 10mMEDTA, pH8) and transferred to a 2 mLscrew cap 
microcentrifuge tube containing 0.5 mL 0.1 mm diameter zirconium beads (Biospec 
Products, Bartlesville, Oklahoma) and 500 µL lysis buffer (50 mM Tris-HCL, pH8, 70 
mM EDTA, pH8, 1% (w/v) SDS) with 20 µl 20 mg/ml proteinase k (Sigma Aldrich). 
Bacterial cells were lysed by a 30 sec pulse on the fast prep bead beater and incubation 
at 37°C for activity of proteinase K degradation of protein. Saturated Ammonium 
acetate (200 µl) was added followed by vigorous shaking by the vortex. Chloroform 
(600 µl) was added and vigorously mixed by vortex again. Tubes were centrifuged at 
14,000 x g for 5 min. Clear supernatant, 700 µL, was transferred to a sterile 1.5 mL 
microcentrifuge tube followed by addition of isopropanol (700 µl) and thoroughly 
mixed by hand before incubation at -20°C for 30 min. Tubes were centrifuged at 14,000 
x g for 10 min and the supernatant was removed taking care not to disturb the white 
pellet. The pellet was washed with ethanol (100 µL) and air dried in a laminar flow 
hood. The DNA was resuspended in 200 µLTE buffer. 
2.4.2 From faeces 
DNA was extracted from faecal samples as soon as possible. Samples were always kept 
cool prior to extraction to minimise degradation of DNA. DNA was extracted using the 
QIamp DNA stool kit (Qiagen) according to the manufacturer’s protocol with slight 
modifications; an additional bead beating step was implemented following addition of 
the first buffer using 0.5 g 0.1 mm zirconia/silica beads (BioSpec products Inc, 
Bartlesville, OK 74005, USA) were added to the tubes and subject to 3 x 1 min bead 
beating using the FastPrep®-24 (MP Biomedicals, Solon, OH 44139, USA). 
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2.4.3 Chelex rapid preparation of DNA for colony PCR 
A sterile toothpick was inserted into a freshly grown (overnight) bacterial colony, picked 
and resuspended in 100 µL5% chelex® (Biorad, Hertforshire, UK; autoclaved) by 
pipette rapidly and swirling. The sample was subject to 3 cycles of heating at 98°C for 5 
min and cooling at 4°C for 5 min to extract the DNA. The sample was centrifuged 
briefly (>12,000 g) to pellet, cellular debris and the clear supernatant was removed as 
the DNA extract ready for subsequent use. 
2.5 Restriction digests 
2.5.1 Partial digest of genomic DNA 
Partial digest of genomic or metagenomic DNA was carried out as follows; 20 µL 10X 
restriction enzyme buffer and 2 µL BSA (10 mg/mL) was added to the genomic or 
metagenomic DNA (200 µL, ≥ 0.1 µg/µl). A 40 µL aliquot was added to one tube and 
20 µL aliquots were added to 9 further tubes. Tubes were kept on ice from this point. 
Restriction enzyme was added (10 units/ µL) to tube 1 and mixed by pipette aspiration. 
20 µL of tube 1 was added to tube 2 and mixed and 20 µL of tube 2 was added to tube 3. 
This process was repeated up to tube 9 and tube 10 was with no restriction enzyme to 
serve as a negative (no-digest) control. Tubes were incubated for 1 hour by at the 
optimum temperature for restriction enzyme activity. Digested DNA was viewed under 
UV light on a 1.5% (w/v) agarose gel supplemented with 1μg/mL safeview DNA smears 
of appropriate size were extracted with a gel extraction kit (Qiagen) according to the 
manufacturer’s protocol.  
2.5.2 Restriction enzyme digestion of plasmid DNA 
To plasmid DNA (up to 1 µg/mL), restriction enzyme buffer (2 µL) was added followed 
by addition of restriction enzyme (1µL). Deionised water was added to a total volume of 
20 µL and the sample was incubated overnight at the optimum temperature for that 
particular restriction enzyme. Digested plasmids were visualised under UV light on a 
0.8% agarose gel supplemented with safeview and compared against uncut plasmid. To 
purify the digested plasmid, samples were passed through a Microcon YM-100 
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centrifugal filter unit (Merck Millipore, Darmstadt, Germany) according to the 
manufacturer’s protocol.  
 
2.5.3 Polymerase chain reaction of 16S rRNA genes 
PCR reaction for amplification of the 16S rRNA gene from bacteiral isolates and 
metagenomic DNA was conducted using the universial 16S rRNA gene primers:- 27F  
(5’- AGAGTTTGATCMTGGCTCAG-3’) and 1492 R ( 5’- 
TACGGYTACCTTGTTACGACTT-3’) [3]. Amplification was performed in a 25 µL 
reaction volume consisting of forward and reverse primers (0.2 µM of each), dNTPs (2 
µM of each dNTP), 1X taq buffer (10 mM Tris-HCl, 50mM KCl, 1.5mM MgCl2, pH 8.3 
at 25°C),1x Bovine Serum Albumin (NEB), Taq DNA polymerase (1.25 units), template 
DNA (1 ng-1 µg good quality DNA) and nuclease-free water. PCR conditions were as 
follows; an initial denaturation step of 95 ˚C for 5 min followed by 30 cycles of heating 
at 94 ˚C for 30 s as a further denaturation step, 55 ˚C for 30 s for primer annealing and 
72 ˚C for 2 min with a final extension step at 72 ˚C for 5 min. Following amplification, 
PCR product was examined by electrophoresis in a 1 % agarose gel with 1 µg/mL 
safeview and visulaised using UV light. 
PCR products were purified using the Qiagen PCR purification kit according to their 
protocol.  
2.6 Development of competence in bacterial isolates 
 
2.6.1 Development of competence in E. coli 
The E. coli cells used for transformations were purchased as chemically competent 
(XL1-Blue supercompetent cells) or electrocompetent cells (MegaX DH10B T1
R
 
Electrocompetent cells). 
 
  
 
73 
 
2.6.2 Development of competence in B. subtilis WB800N 
For B subtilis WB800N, competence was achieved as follows; a single colony that had 
been growing on a TSA neo
10 
plate, ideally for a few days, was used to inoculate 10 mL 
of MM competence medium (10 mL SMM medium: (NH4)2SO4 0.2 % w/v, K2HPO4 
1.4 % w/v, KH2PO4
 
0.6 % w/v, Na3C6H5O7 0.1 % w/v and MgSO4 · 7H2O 0.02 % w/v 
supplemented with 0.125 mL 40 % w/v glucose, 0.1 mL 2 mg/mL tryptophan solution, 
0.06 mL 1M MgSO4, 0.01 % 20 % w/v Casamino acids and 0.005 mL 0.22 % w/v Fe-
NH4 citrate  in a 100 mL flask) overnight. The sizes of the vessel used for the culture 
were found to be critical for successful development of competence in order for enough 
aeration during growth. Overnight culture (0.6 mL) was used to inoculate 10 mL fresh 
MM competence medium which was incubated at 37 ˚C for 3 hours. From this point 
forward, it was critical to maintain the temperature of the cells at 37 ˚C. To develop 
competence, after this 3 hour incubation, 10 mL Starvation medium was added (10 mL 
SMM medium with 0.125 mL 40 % w/v glucose and 0.06 mL 1M MgSO4) and 
incubation was continued for 2 hours at 37 ˚C. 
 
2.7 Transformation procedures 
2.7.1 Chemical Transformation of E. coli 
XL1-Blue supercompetent (Agilent) were transformed according to the manufacturer’s 
protocol. 
2.7.2Chemical transformation of B. subtilis WB800N 
B. subtilis WB800N was chemically transformed immediately following development of 
competence as described in section 2.6. Following 2 hours of incubation in starvation 
medium, 1-5 µL of plasmid DNA was mixed with 0.4 mL competent cells in 14 mL, 
pre-warmed (37 ˚C) sterile VWR falcon tubes (Leicestershire, UK). Cells were shaken 
for 45 min-1 hour before plating on selective medium ( TSA supplemented with 5 µg/ 
mL Cm). 
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2.7.3 Electrotransformation procedure 
MegaX DH10B T1
R
 Electrocompetent cells (Life Technologies, Paisley, UK) were 
transformed according to the manufacturer’s protocol.  
2.8 Activity based screening  
2.8.1 Preparation of semi skimmed milk agar (SMA) and Lactose-free skimmed 
milk agar (LF-SMA) 
SSMA was prepared as follows: 10% (w/v) semi-skimmed milk solution was prepared 
in deionised water and autoclaved at 121°C for 15 min. 1.5% (w/v) purified agar 
(Thermo scientific) was also prepared in deionised water and autoclaved at 121°C for 15 
min. Upon sterilisation, both were kept at 55°C in a water bath, then the semi-skimmed 
milk solution was added to the agar to give a final volume of 1% (w/v) semi-skimmed 
milk. 
 
Lactose-free semi-skimmed milk powder was obtained from Valio (suomikauppa.fi) and 
agar was prepared in the same manner as described above to give a final concentration 
of 1% (w/v). Purified agar could be replaced by any agar that supports the growth of a 
particular organism. Zones of clearing around an inoculated organism or protein extract 
indicated protease activity (LF-SMA) and β-galactosidase activity or protease activity 
(SMA). 
 
2.8.2 Preparation of crude cell free extracts  
In order to prepare crude cell free extracts (CCFE) for protease assays, cells were grown 
overnight in appropriate media supplemented with the appropriate antibiotic. An aliquot 
(1%) of this starting culture was used to inoculate 50 mL of fresh media and grown to an 
optical density of 0.5 (600nm). After this point cultures were left to grow for a further 3 
hours. Cells were harvested by centrifugation at 4000  x g for 10 min. The pellet was re-
suspended in 2 mL of phosphate buffered saline (PBS) and each sample was bead beaten 
(0.1 mm diameter glass beads, 0.5g) for 30 seconds and repeated a further 2 times with 
cooling on ice for 5 min between each beating. Samples were centrifuged at 20,000 x g 
for 10 min and the resulting supernatant was taken as the cell free extract. 
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2.9 Measuring protease activity 
2.9.1 Azocasein assay 
General protease activity was determined by measuring the release of acid-soluble 
substance from azocasein (Sigma-Aldrich) over a period of 3 hours after precipitation. 
Azocasein (5 mg/mL) was prepared in 50 mM Tris-HCL, pH 8. The protease samples 
(100 μL) were added to the azocasein solution (100 μL). The mixture was incubated at 
37°C and the reaction was terminated by the addition of 400 μL of 10 % (w/v) 
trichloroacetic acid (TCA). Protein was precipitated by centrifugation at 12,000 x g for 5 
min and the resulting supernatant was transferred to a clean tube containing 700 μL 525 
mM NaOH. The absorbance was measured using a spectrophotometer at 442 nm. Each 
reaction was carried out in triplicate. Negative controls were prepared by setting up a 
reaction and immediately terminating the reaction with TCA. The resulting precipitate 
was taken as a negative control. To minimise background interference, a further 
negative control was set up with just water.  Proteinase K (Sigma Aldrich) was used as a 
positive control.   
 
In order to determine the optimum temperature for protease activity, the previously 
described assay was carried out, but incubated at the desired temperatures. The reactions 
were terminated and protein precipitated as described above. Similarly, to deduce pH 
optima, the pH of the azocasein solution was varied from 3 to 11 using Sodium acetate 
(pH range 3-5), Tris-HCL (pH range 6-8) and Glycine sodium hydroxide (pH range 9-
11). 
2.9.2 Azo-coll assay 
Azo-coll, an azo-dye impregnated collagen was purchased from Sigma Aldrich and used 
to measure collagenase activity in faecal protein extracts. The assay was carried out as 
previously described [4] with the protease under examination being the faecal protein 
extract (1 mg/mL). Negative and positive controls were prepared as described in 2.9.1. 
Where TCA wasn’t used, samples were just immediately measured on the 
spectrophotometer.  
  
 
76 
 
2.9.3 Keratin azure assay 
Keratin azure was used to measure keratinase activity of the faecal protein extracts. 
Keratin azure (44% w/v) was purchased from Sigma Aldrich and was prepared in 50 
mM Sodium Phosphate buffer at pH 7.5. Protease extract was added and the solution 
was incubated at 37°C for 3 hours. Samples were centrifuged at 12,000 x g for 10 min 
and absorbance was measured at 595nm. Negative and positive controls were prepared 
as previously described. 
 
2.10 Protein extraction  
 
2.10.1 Total and extracellular protein extract from faecal samples 
Faecal sample (1 g) was thawed and a 10 % faecal slurry was prepared using sterile PBS 
by thorough mixing on a Genies Whirlimixer™. To prepare the crude total protein 
extract, the faecal slurry was divided into 2 mL RNase and DNase free lysing matrix 
tubes (MP Biomedicals) containing 1.4 mm ceramic spheres, 0.1 mm silica spheres and 
one 4 mm glass sphere. Samples were kept on ice throughout. The samples were subject 
to bead beating using a FastPrep-24 bead beater (MP Biomedicals) at a speed of (6.0 
m/s) for 30 s with a period of 5 min on ice between each beating. Following beating, 
samples were centrifuged at 20,000 x g for 30 mins at 4 °C. The supernatants from the 
bead beaten tubes were filtered through a 30 µm filter tube (Whatman, 113V, GE 
Healthcare Life Sciences, Buckinghamshire, UK). The filtrate was taken as the total 
protein extract. For the extracellular only samples, this centrifugation step was 
conducted immediately instead of the bead beating step. Supernatant, after filtration, 
was transferred to new sterile tubes and taken as the crude protein extract. NaN3 was 
added aseptically to each sample to a final concentration of 0.05% w/v neat samples, 10-
fold and 100-fold dilution were used to estimate protein concentration using the 
bicinchononic method (BCA) according to the manufacturer’s instructions (PIERCE, 
Rockford, IL, USA) and samples were normalised to1 mg/mL protein. Samples were 
kept on ice at all times and subsequent protease assays were conducted within 24 hours. 
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2.11 SDS PAGE 
 
SDS-PAGE was performed using the Laemelli methods with a 12% polyacrylamide gel. 
Gels were stained with InstantBLue™ Coomassie based protein staining solution 
(Fermentas, UK). 
2.12 Statistical Analysis 
Results were usually represented as the mean ± S.E.M. Statistical significance between 
means of data was determined by the student’s T test or ANOVA if data was parametric. 
For non-parametric data, the Mann Whitney-U test was used instead. All Correlation 
analysis was conducted to determine the Pearson correlation coefficient (parametric 
data) or the Spearman rank correlation coefficient (non-parametric data) of two 
variables. All analyses were conducted in R software [5]. 
 
2.13 Cell Culture 
2.13.1 Handling of frozen cell suspension and Preparation of initial low density cell 
stock 
Frozen vials of the human colon epithelial HT-29 cell line were initially obtained from 
Sigma (Sigma-Aldrich) and stored in the vapour phase of liquid nitrogen. For 
preparation of initial cell stock, a vial was rapidly thawed (approximately 2 min) with 
gentle agitation in a 37 °C water bath while keeping the ‘O-ring’ and cap out of the 
water to reduce the possibility of contamination. The vial was sterilised decontaminated 
by spraying with 70% ethanol and transferred to a BSL-2 aseptic laminar flow hood 
where all proceeding operations were carried out. The vial’s contents were transferred to 
a centrifuge tube containing 10 mL complete culture medium which comprised; 
McCoy’s 5a medium supplemented with 10% fetal bovine serum (FBS) and 5% 
penicillin-streptomycin solution (ATCC®, Middlesex, UK) and centrifuged at 
approximated 125 x g for 8-10 min.  The resultant pellet was resuspended in complete 
growth medium at a ratio of and 1 mL cell suspension was removed for cell count and 
viability performed using a haemocytometer. The cells were dispensed into a T-25cm
2
 
culture flask (Corning Life Sciences, Amsterdam, The Netherlands ) at a cell density of 
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approximately 1.6 x 10
5
 cells/cm
2
. Cells were routinely maintained at 37 °C in 5% CO2 
atmosphere in a suitable incubator. Cells were observed daily under an inverted 
microscope (make/model) to ensure the culture was not contaminated and were sub-
cultured upon reaching 50% confluence (approximately 5.5 x 10
4
 cells). 
2.3.2 Cell line maintenance and Sub-culturing Procedure 
After growing the cells overnight the medium was removed from the culture flask and 
cells were washed with 2 mL Dulbecco’s phosphate buffered saline (Life Technologies) 
and 2 mL 0.25% (w/v) Trypsin-0.53 mM EDTA solution (ATCC®) was added quickly 
after washing. Cells were observed under an inverted microscope for cell layer 
dispersion, if cells were difficult to detach, flasks were incubated at 37 °C for 5-15 min. 
Fresh complete growth medium (6 to 8 mL) was added to the flasks and cells were 
aspirated with gently pipetting. Appropriate aliquots of the cell suspension (using a 
subcultivation ratio of 1:10 to 1:12) were added to new culture vessels and incubated at 
37 °C in 5% CO2 atmosphere. 
2.3.3 Cryopreservation 
Cells were harvested as described in sub-culturing procedure. Prior to cell detachment, 
the cryopreservation medium was prepared as follows; complete growth medium was 
supplemented with 5% (v/v) DMSO and kept on ice until use. Cell density and viability 
was recorded and the cells were centrifuged at 125 x g for 5 min at room temperature. 
The media was carefully removed by using an automatic pipette to leave the cell pellet. 
Cryopreservation media was added so as to achieve a cell density of between 3.0 X 10
6
 
to 4.0 X 10
6
 cells/mL and cells were resuspended with gentle pipetting. Cells were 
dispensed in 1 mL aliquots into cryovials (Thermo-Scientific) and equilibrated at 4 °C 
for a maximum time of 10 min. 
 
The day prior to cell cryopreservation, 250 mL isopropanol (Sigma-Aldrich) was added 
to a “Mr. Frosty” freezing container (Sigma-Aldrich) and placed at 4 °C overnight. On 
the day of cryopreservation, after equilibration at 4 °C cryovials were inserted into the 
slots in the “Mr Frosty” and transferred to a -80 °C freezer and left overnight. The next 
day the cryovials were transferred to the vapour phase of a liquid nitrogen freezer. 
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3.0 A ROBUST PLATE ASSAY FOR DETECTION OF EXTRACELLULAR 
MICROBIAL PROTEASE ACTIVITY IN METAGENOMIC SCREENS AND 
PURE CULTURES 
 
The analyses and discussion within this chapter has been published in; [1] 
(Morris, L.S., Evans, J., and Marchesi, J.R. (2012) A robust plate assay for detection of 
extracellular microbial protease activity in metagenomic screens and pure cultures. 
Journal of Microbiological Methods 91, 144-146.) 
3.1 INTRODUCTION 
 
It is estimated that we are currently only able to cultivate as little as 1% of 
microorganisms from the any diverse environments of which they inhabit [2] . This 
realisation that there is a deficiency in current culture techniques to isolate most 
microorganisms from most  environments has led to the emergence and progression of 
cultivation-independent techniques specifically ‘-omic’ sequencing based technologies 
to explore the composition, diversity, structure, activity and genetic makeup of 
microbial communities [3]. The use of shotgun metagenomic sequencing and genomic 
sequencing (explained in full in chapter 1.0) has become a baseline technology for 
microbial community characterisation; however there are a number of limitations 
associated with the technique, particularly with regards to unearthing novel genetic data. 
Firstly, sequencing metagenomics is reliant on comparison of generated data to 
previously annotated sequences that are publicly available, should the generated 
sequence share low homology to any annotated sequence data, novel genes are likely to 
often be disregarded as ambiguous data. Unknown data can sometimes account for up to 
70% of sequence generated from sequencing projects [4, 5] and while current resources 
available to annotate sequence data are progressing, they remain insufficient to cope 
with the enormous amounts of data being generated by the increasing number of 
metagenomic sequencing projects being conducted worldwide [5]. Secondly, rarely can 
an identified gene be comprehensively annotated in terms of their biochemical and 
functional capacity due to the fact that entire genes sequences are not often identified. 
Even if samples share significant homology with known genes then their function is still 
only putative and remains to be proven, validation of function of identified genes has to 
be conducted with further experimental analysis mainly involving expression of the 
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newly identified gene.  Gene targeting methods have been implemented in order to 
circumvent this ambiguity. This process involves primers or probes that are designed 
following multiple alignments of conserved regions of sequences that encode a 
particular gene of interest [6]. There primers are used to screen and amplify 
metagenomic DNA samples for this gene of interest and further genomic walking 
techniques may be implemented in order to capture the entire functional, and potentially 
novel gene. This genome mining techniques has proved useful, but clearly a substantial 
amount of priori knowledge is required and thus rarely are novel, non-homologous 
genes identified. 
 
To counteract the limitations of shotgun metagenome sequencing and directed PCR-
amplification for the purposes of identifying novel functional genes, a form of 
phenotypic screening of metagenomic DNA is required to identify novel genes and 
characterize their functional capacity. Functional metagenomics (FM) provides an 
alternative, function-driven means for unearthing the vast and relatively untapped 
biological resources of the microbial world. Its’ ability to do so has been demonstrated 
with the discovery of novel and biotechnologically useful molecules [7] [8] and 
clinically relevant antibiotic resistance genes [9]. FM is a methodological strategy to 
perform such metagenomic DNA screening, and relies on screening clones harbouring 
random fragments of metagenomic DNA (mgDNA). Clones are transformed or 
transfected with plasmids containing mgDNA. Individual clones are screened for chosen 
functional capabilities; this screening relies on the heterologous gene expression of the 
randomly inserted DNA and a method for high-throughput screening of clones 
 
For a successful functional metagenomic screen, an observable and measurable 
phenotype to identify the expression and secretion of novel bio-products is needed, and 
research in to FM is limited by the ease and efficiency of the system used to identify the 
product of interest. Screening approaches for FM libraries range from the relatively 
‘low-tech’ methods previously used to study and characterise the functions of pure 
cultures to the development of novel, high-throughput sophistacted FM library screening 
approaches. ‘Low-tech’ approaches include the identification of phenotypic alterations 
in factors such as colony morphology, colony pigmentation, motility etc. and then the 
use of chemical dye incorporated into agar as indicator medium such as the 
incorporation of BCIP (5-Bromo-4-chloro-3-indolyl phosphate) into a growth media 
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allows for the detection of alkaline phosphatase activity. Many enzymes require more 
sensitive means for identification such as High Performance Liquid Chromotography 
(HPLC) or the development of chromogenic or fluorescent substrate [10]. Research, 
particularly in the biotechnology field, is progressing towards the development of novel, 
high-throughput techniques for FM library screening Rabausch and colleagues 
developed a system known as metagenome extract thin-layer chromatography analysis 
(META) which allows the detection of glycosyltransferases [10]. Williamson and 
colleagues developed the METREX system, a novel intracellular system used to screen 
metagenomic clones involved with inserts associated with quorum sensing. Here, the 
host contained a biosensor for quorum-inducing molecules. Upon sensing, the cell 
produces GFP which is detected by fluorescent microscopy or fluorescence-based cell 
sorting. This suggests that similar methods could be implemented for unearthing other 
biologically active small molecules in metagenomic libraries [11]. Similarly, a substrate-
induced gene expression (SIGEX) system was also developed. With this method, an 
operon-trap GFP expression vector is used to construct a metagenomic library. The 
entire library is subjected to a substrate-specific gene induction. Upon expression of 
such substrate-specific genes, the GFP is also expressed. High-throughput detection of 
GFP and consequently substrate-specific genes is carried out with fluorescence-activated 
cell sorting (FACS), allowing for detection of novel catabolic operons [12]. Uchiyama et 
al. also developed Product-induced gene expression (PIGEX) which shares the concepts 
of SIGEX except relies on the enzyme product and are unresponsive to the substrate. 
Here, the GFP reporter gene was downstream of the BenR gene; a gene encoding 
benzoate transcriptional precursor. However, the number of enzymes identified using 
what are considered the relatively ‘low-tech’ methodologies and the potential they have 
had both in unearthing novel functions of bacteria from diverse habitats and also in 
industry outweighs the discoveries made from the more complex techniques indicating 
that there is still a place for simple, robust and efficient screening means.  
 
The  function of particular interest in this body of research is microbial proteases as 
these are an important target for metagenomic screening due to their extensive 
possibility for use in industry [13] and also mainly due to their role as virulence factors 
[14-16]and putative role as initiators of inflammation of the gut epithelia [17-19]. 
However there is a current deficit in metagenomic screens successfully isolating these 
enzymes. While there are a number of reasons for this scarcity (discussed further in 
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chapter 5), one problem that we aim to resolve with this research is the current issue of 
false positives arising from the use of skimmed milk agar as a standard means for 
screening metagenomic libraries for proteolytic activity. Previous research by Jones et 
al. [20] found that an initial 231 metagenomic clones deemed positive for protease 
activity by the formation of distinctive halos of clearing around colonies on standard 
skimmed milk agar (SMA) were in fact, glycoside hydrolases which produced acetic 
acid from lactose fermentation  and the pH drop was responsible for the phenotype, not 
protease activity. The demonstrated ineffectiveness of this agar has lead us to question 
the validity of putative proteases detected using this method, for example Pailin et al., 
[21] used SMA to identify extracellular protease activity in strains of the lactic acid 
bacteria; Streptococcus thermophilus and Lactobacillus bulgaricus. 
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AIMS  
 
It can be concluded that while SMA could be appropriate for identifying lactose 
utilisation and the presence of galactosidase enzymes, it is not a sufficiently robust a 
screening technique for protease activity and an alternative needs to be developed in 
order to save time and money and to ultimately be an effective screening means for 
functional metagenomic screening. The aim of this research was to develop a simple and 
easy to prepare media as the substrate for detecting protease activity to allow 
discrimination against acid production.  
Thus, the main aims of this research are:- 
 
1. To develop a simple and robust media for the detection of extracellular 
proteases. We hypothesise that a milk-based media free of lactose (LFSMA) and 
other compounds that may interfere with a protease screen will be a much more 
robust means for screening for protease activity. 
 
 
2. To utilise the developed media and test microorganisms previously deemed 
positive for extracellular protease activity. 
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3.2 RESULTS  
3.2 .1 Agar plate assay 
Skimmed milk agar was compared with a new version of milk-based agar that has been 
developed utilising lactose-free milk powder based on the hypothesis that many 
putatively positive protease producing isolates were in fact glycoside hydrolases and the 
positive phenotype observed was as a result of lactose fermentation as opposed to 
protein degradation. 
It was found that the strains used were capable of degrading skimmed milk agar but not 
lactose-free milk agar. Similarly the metagenomic clones had a corresponding outcome 
whereas for the bacterial strains known to be proteolytically active; a positive phenotype 
was observed on both types of media (Figure. 3.1).  
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Figure 3.1. Plate assays for protease activity. From top left; B. subtilis MY2016 
clearing LFSMA and a negative control, Top middle; S. thermophilus 859 and L. 
bulgaricus2483 failing to clear LFSMA, Top right; a glycoside hydrolase positive 
metagenomic clone failing to clear LFSMA, bottom left; two glycoside hydrolase 
positive metagenomic clones clearing SMA, bottom middle; S. thermophilus 859 
clearing SMA, bottom right; L. bulgaricus 2483 beginning to clear SMA. 
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3.3.2 Azo-casein assay 
For further confirmation that the proteolytic  phenotype observed on SMA was in fact as 
a result of glycoside hydrolase activity and not proteases, cultures were further subject 
to azocasein assay (Figure. 3.2).B. subtilis MY2016 was shown to degrade the azocasein 
substrate at an average relative activity of 74% and glycoside hydrolase metagenomic 
clones showed less than 20% activity.  
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Figure 3.2. Protease activity as measured by the release of acid-soluble substance 
from azocasein (5 mg/ml) in HCl buffered Tris to a pH of 8.0 incubated at 37° C for 4 
hours. Results are shown as the mean value of the results that were in triplicate and are 
shown as a relative percentage of total protease activity Centre lines show the medians; 
box limits indicate the 25th and 75th percentiles as determined by R software; whiskers 
extend 1.5 times the interquartile range from the 25th and 75th percentiles. 1= B. subtilis 
MY2016, 2 = Glycoside hydrolase clone, 3= glycoside hydrolase clone.  
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3.3 DISCUSSION 
 
While functional metagenomics is clearly a promising technique for identifying novel 
microbial compounds, the process still faces a number of issues. Any steps towards 
mitigating these issues can only be seen as a positive for the future of metagenomics. 
In this study, we review the efficacy of standard skimmed milk agar as a means for 
identifying extracellular proteases since previous research has suggested skimmed milk 
is not a sufficiently robust screening means [20]. 
 
We compared this agar with a new version of milk-based agar that we have developed 
utilising lactose-free milk powder based on the hypothesis that many putatively positive 
protease producing isolates were in fact glycoside hydrolases and the positive phenotype 
observed was as a result of lactose fermentation as opposed to protein degradation. 
 
It was found that the strains used were capable of degrading skimmed milk agar but not 
lactose-free milk agar. Similarly the metagenomic clones had a corresponding outcome 
whereas for the bacterial strains known to be proteolytically active; a positive phenotype 
was observed on both types of media (Figure. 3.1). 
 
From our study, Valio™ lactose-free milk agar was found to be an effective and robust 
agar for correctly identifying proteases by way of distinct zones of clearing around a 
bacterial colony. From the screens undertaken in this study no false positives arose with 
the use of this type of agar. We would suggest that this agar would be much more 
appropriate for future screening of metagenomic libraries for protease activity. The 
robustness of this agar will allow for more efficient characterisation of enzyme activity 
which can then lead to identification of clinically or industrially relevant proteases. 
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3.4 MATERIALS AND METHODS  
3.4.1 Strains and culture conditions 
Bacillus subtilis MY2016 was used as a positive control for protease activity on all types 
of agar used in this study since it is known to secrete a number of extracellular 
proteases. Theses cultures were routinely grown on all agar at 30°C.  
Strains of Streptococcus thermophilus 2483 and Lactobacillus bulgaricus 859 were 
obtained from the culture collection of University College cork, Department of 
Microbiology. Cultures were revived on MRS agar (Thermo Scientific, Oxoid) and 
incubated at 37°C in an anaerobic chamber (Merck, Darmstadt, Germany) and examined 
after 48 hour incubation. 
False protease positive gylcoside hydrolase metagenomic clones were obtained from a 
previous metagenomic library [20] and were routinely revived from freezer stock on LB 
(Luria-bertani) agar supplemented with 12.5 μg/ml chloramphenicol. 
 
3.4.2 Preparation of media used in this study 
Agar plates (skimmed milk agar and valio ™ lactose free skimmed milk agar were 
prepared as described in the general methods section (Chapter 2.0) 
 
3.4.3  Azo-casein assay to confirm protease activity 
Azocasein assays were performed as described in the general methods section (Chapter 
2.0). 
 
3.4.4 Statistical analysis 
Box plots of the relative percentage of protease activity determined following azocasein 
assay were generated using BoxPlotR [22] and the RColorBrewer package [23]. 
To determine statistical significance between the triplicate measurement of acid soluble 
substance released from the azocasein assay. A trypsin standard was used and incubated 
for the same period of time for generation of relative activity data. Normality tests were 
determined using R Software [24]. Statistical significance was determined using the 
Mann Whitney U test in R software also.  
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4.0 SCREENING, ISOLATION AND CHARACTERISATION OF 
TWO FUNCTIONAL METAGENOME-DERIVED 
METALLOPROTEASES ISOLATED FROM A MILK WASTE 
TREATMENT PLANT 
 
The analyses and discussion within this chapter has been published in; [47] 
(Morris, L.S.and Marchesi, J.R. Current functional metagenomic approaches only 
expand the existing protease sequence space, but does not presently add any novelty to 
it. Current Microbiology 284.) 
 
4.1 INTRODUCTION 
 
Proteases are degradative enzymes responsible for catalysing the hydrolysis of the 
peptide bonds between sequences of amino acids. Though ubiquitous and essential in all 
living organisms, those produced by the microbial world often take a primary position in 
our interest due to their relative ease of genetic manipulation, physiological and 
biochemical traits and genetic diversity [2] making them important and cost effective 
biocatalysts in the mass production of many commercial products such as food, 
detergents, textiles and pharmaceuticals [2, 3]. In addition to their application in 
industry, microbial proteases are also clinically relevant as proteases are thought to 
account for up to 5% of the genome [4] of infectious organisms and are often associated 
with the pathology of certain human diseases acting as significant virulence factors 
aiding the onset of infection [4, 5]. Recent research has suggested this number may be 
much higher [6]. The advance of culture-independent techniques for studying microbial 
communities may result in the isolation of novel proteases, potentially in many in 
microorganisms that we are currently unable to culture. Hence, culture-independent 
techniques are to be implemented if we are to recognize the true extent and capability of 
microbial proteases and from there, understand their physiological roles in the 
environments they inhabit. Culture-independent techniques, namely functional 
metagenomics (FM) are currently the only methodologies capable of unearthing novel 
genes. FM has aided the discovery of a plethora of novel compounds (please see table 
5.1 chapter 1.0) from diverse ecosystems from soil to marine sponges to the human gut. 
The technique has also allowed us to elucidate how bacterial communities have adapted 
to their particular environment [7]. However, as discussed further in the succeeding 
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chapter, successful FM projects are limited due to the reliance of heterologous 
expression and secretion of the protein encoded by the inserted foreign DNA. 
Consequently, positive ‘hits’ (the frequency of detecting a positive clone) remain fairly 
low. When embarking on a project that aims to isolate proteolytic enzymes, this 
frequency is even lower for reasons described in depth in the proceeding chapter, but in 
brief; surrogate hosts may not have the cellular machinery required to faithfully 
transcribe and translate a particular proteases gene, proteases of the host organism may 
recognise and degrade foreign (inserted) protein, there is also a likelihood that the active 
product exerts a toxic effect on the surrogate host. Until recently there was also 
insufficient screening means for proteases [8], but our recent research has proven that 
the use of lactose free skimmed milk agar is a robust substrate for screening for 
proteases and minimises false positives [1](Chapter 3.0). Several research groups have 
been successful in their quest to unearth proteases from various bacterial metagenomes 
[9-16]. However, firstly the study by Purohit et al., created a metagenomic library and 
uncovered a protease using degenerate PCR with primers designed following alignment 
of conserved region of characterised halophilic Bacilli proteases [16]. Secondly, while 
most of these studies claim novelty, most of the protease isolated actually share 
significant homology with already characterised proteases. For example the serine 
protease isolated by Biver and colleagues [11] is from a well characterised MEROPS 
[17] group of proteases; the S8 serine protease group or subtilase family and shares 69% 
homology with a subtilis-like proprotein convertase from Desuflobacter postatei 
(accession number WP_004070934).  Similarly, the serine protease isolated by Pushpam 
and colleagues [9] shared 89% similarity with another S8 secreted peptidase A from 
Shewanella sp. (accession number HM370566). Perhaps it is not really feasible to call 
such proteases ‘novel’ as they only expand the current gene space and do not represent 
new sets within this space. Thus, the necessity for the re-evaluation of current functional 
metagenomics methods and the need to document the isolation and characterisation of 
proteases found using these techniques is apparent if we are to develop these methods 
and ultimately access the full repertoire of the microbial degradome. 
 
Many studies utilise the methods of enriching for bacteria with certain metabolic 
capacity which is the trait or target under analysis before creating their metagenomic 
library. For example, Lussier et al.,[18] used a sequencing fed-batch reactor (SFBR) 
enriched for bacteria that were able to grow at alkaline pH at thermophilic temperatures 
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and were successful in isolating clones with lipase activity (however, it is also important 
to note that they intended to isolate proteases as well, but were unsuccessful). Similarly, 
Elend and colleagues [19] enriched for bacteria with lipolytic activities. They inoculated 
media, supplemented with mineral oil, with an industrial soil sample and were 
subsequently successful in isolating 2 novel esterase genes. Gabor et al., [20] enriched 
for amidase genes by complimenting a leucine auxotrophy in the surrogate host. 
However, as alluded by Lussier et al., and Elend et al.[18, 19] this strategy of 
enrichment for particular species can lead to a loss in diversity and present much more 
of a challenge with some ecosystems where, for example, the majority of the community 
are strict anaerobes. 
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AIMS 
 
In this research, an ecosystem was chosen with the hypothesis that it would be enriched 
for proteases; a dairy waste water treatment plant which clearly has high levels of 
casein. 
 
The aims of this research were as follows:- 
 
1. Sub-clone two putative protease sequences derived from a fosmid clone 
exhibiting protease activity derived from a previously constructed metagenomic 
library from DNA extracted from this waste treatment and assess the sub-clones 
for recapitulation of a protease phenotype utilising the robust media developed in 
chapter 3.0. 
 
2.  Conduct a comprehensive sequence analysis and comparison of the two derived 
putative protease sequences. 
 
 
3. Conduct biochemical characterisation of the sub-clones. 
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4.2 RESULTS  
 
4.2.1 Sequence analysis of M1-1 and M1-2 putative protease-encoding sequences 
From the screening of approximately 28,000 fosmid clones, 1 positive metagenomic 
clone was isolated and sequenced. GeneMark software was used to deduce putative open 
reading frames within the protease positive 38 kb fosmid. Two open reading frames that 
potentially encoded the protease genes most likely responsible for the proteolytic 
phenotype observed were deduced by BLAST analysis and termed M1-1 (complement 
(18489..20057)) and M1-2 (complement (20297..22117))(Figure 4.1; Accession number 
for the fosmid is HF548541). M1-1 encoded a protein of 523 amino acids in length with 
a predicted molecular weight of 55.53 kDa. M1-2 encoded a protein composed of 606 
amino acids with a predicted molecular weight of 63.79 kDa. Putative promoter sites 
were found in both M1-1 and M1-2 as were potential signal peptide regions. 
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Figure 4.2 Annotation of the fosmid insert from which the two putative proteases were 
identified and cloned. The table below the figure shows the nearest BLASTP matches to 
each ORF within the fosmid insert and the host species in square brackets. 
 
 
M1-1 sequence comparison against GenBank showed M1-1 shared greatest sequence 
identity (55%) with a probable aminopeptidase from Chromobacterium violaceum, but 
also with leucyl aminopeptidases present in many members of the Burkholderia genus 
of Proteobacteria (Fig. 4.2).  M1-1 contained a EE sequence at position 358-363 and the 
HXD (where X is any non-conserved amino acid) sequence at position 326-329 (Fig. 
4.3a).  Both sequences are highly conserved zinc ligand motifs associated with a family 
of metalloproteases as characterised by the MEROPS database as M28 or the 
aminopeptidase-like family of which an aminopeptidase of Streptomyces griseus is the 
prototype and includes both amino and carboxy-peptidases. 
 
M1-2 also shared greatest similarity to a family of metalloproteases. The conserved 
regions found in M1-1 were absent in M1-2 (Fig. 4.3b). M1-2 was, however, found to 
contain a HEVSH sequence at position 353-366 and a GGINEAFSD sequence at 
positions 382-390 (Fig. 4.3b). HEXXH and GXXNEXXSD are highly conserved 
regions amongst zinc metalloproteases belonging to the M4 family the former being a 
zinc-binding motif, the latter, a third zinc ligand motif. M1-2, according to the BLAST 
database, was found to share greatest amino acid sequence similarity to a neutral 
protease from Collimonas fungivorans and to a class 4 metalloproteases from 
Chromobacterium violaceum (62% identity and 63% identity respectively) and also 
showed similarity to a number of proteases from the Aeromonas genus (Fig. 4.2) all of 
which belong to the M4/thermolysin family. It also showed a sequence similarity (56% 
identity) to a previously described metagenome-derived metalloprotease; MprA [21]. 
The majority of the ORFs clustered within the Proteobacteria and in the class β-
proteobacteria (Figure 4.1).  
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 pro-aminopeptidase_protease_[Aeromonas_punctata]
 elastase_[Aeromonas_hydrophila_subsp._hydrophila_ATCC_7966]
 elastase_[Aeromonas_caviae_Ae398]
 protease_[Aeromonas_veronii_B565]
 metalloprotease_[Aeromonas_sobria]
 protease_[Aeromonas_veronii_bv._Sobria]
 Putative Protease M1-2
 Neutral_protease_[Collimonas_fungivorans_Ter331]
 class_4_metalloprotease_[Chromobacterium_violaceum]
 class_4_metalloprotease_[Chromobacterium_violaceum_ATCC_12472]
 Zinc_metalloprotease_(elastase)_[Hahella_chejuensis_KCTC_2396]
 gi|83645773|ref|YP_434208.1| aminopeptidase [Hahella chejuensis KCTC 2396]
 gi|88799869|ref|ZP_01115442.1| predicted aminopeptidase [Reinekea sp. MED297]
 Putative protease M1-1
 gi|260776231|ref|ZP_05885126.1| bacterial leucyl aminopeptidase precursor [Vibrio coralliilyticus ATCC BAA-450]
 gi|34495511|ref|NP_899726.1| aminopeptidase [Chromobacterium violaceum ATCC 12472]
 gi|167584650|ref|ZP_02377038.1| leucyl aminopeptidase [Burkholderia ubonensis Bu]
 gi|254250014|ref|ZP_04943334.1| hypothetical protein BCPG_04896 [Burkholderia cenocepacia PC184]
 gi|170697155|ref|ZP_02888250.1| leucyl aminopeptidase [Burkholderia ambifaria IOP40-10]
 gi|171315436|ref|ZP_02904673.1| leucyl aminopeptidase [Burkholderia ambifaria MEX-5]
 gi|172064012|ref|YP_001811663.1| leucyl aminopeptidase [Burkholderia ambifaria MC40-6]
 gi|115359222|ref|YP_776360.1| leucyl aminopeptidase [Burkholderia ambifaria AMMD]
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Figure 4.2 Phylogenetic tree of M1-1 and M1-2 sequences and their closest genetic 
matches as deduced from BLAST. This cluster analysis was based upon a neighbour-
joining method as described in materials and methods. The tree includes the bacterial 
protease and the host organism name. 
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Figure 4.3. A Positions of the His-Leu-Asp (HLD) and Glu-Glu (EE) regions found in 
the M1-1 sequence and some of the closest genetic matches as deduced from BLAST, 
all of which are members of the M28 family of aminopeptidases in MEROPS database. 
B: Positions of the His-Glu-Val-Ser-His region (HEXXH) and Gly-Gly-Ile-Asn-Glu-
Ala-Phe-Ser-Asp (GGXXNEXXSD) region found in M1-2 and some of the closest 
genetic matches deduced by BLAST all of which, including M1-2, belong to the M4 
family of metalloproteases in the MEROPS database. Key to genus abbreviations; A – 
Aeromonas, B – Burkholderia, C – Chromobacterium, H – Hahella, and V – Vibrio. 
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Comparison with the PFAM database, MEROPS and CDD displayed very different 
enzyme structure and domain architecture (figure 4.4). The aminopeptidase M28 domain 
was at position 218-399 sharing homology to the same domain found in other members 
of the M28 family as also contained the regions for predicted active sites. M1-1 also had 
a pre-peptidase domain at the C terminus, a sequence that is not present in the active 
protease as it gets cleaved upon secretion. M1-2 was found to have a much more 
complex modular structure consisting of a thermolysin protein precursor at the N-
terminus which is hypothesised to be involved in inhibiting premature activation of the 
enzyme [22]. The thermolysin region is highly conserved amongst the M1-2 BLAST 
sequences mentioned previously (figure 4.2). The thermolysin region was followed by a 
PepSY domain, a region believed to have inhibitory and chaperone properties [23, 24] 
and the catalytic domains containing the active site and zinc binding sites. Similarly to 
M1-1, M1-2 had a pre-peptidase C-terminal domain that was not part of the active 
protease. In addition using PFAM, 3 domains were identified for M1-2, which 
correspond to the protein fragments shown in the induced lane in Figure 4.5. 
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Figure 4.4 The domain architecture of; A M1-2 and B putative protease M1-1. SP: 
signal peptide, FTP: fungalysin/thermolysin propeptide, PepSY; peptidase domain (M4) 
and YpeB of B. subtilis, PPC; pre-peptidase C-terminal domain. 
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Figure 4.5 SDS-PAGE of the cell free extracts of E. coli Xl1-Blue cells harbouring the 
pGEM ®T-Easy vector with M1-2 sequence after IPTG induction and non-induced 
samples. SDS-PAGE was performed using the Laemmli method with a 12% w/v 
polyacrylamide gel. Gels were run with protein standard (Prestained Protein Molecular 
Weight Marker 20 to 120 kDa) and stained with InstantBLue™ Coomassie based 
protein staining solution (Fermentas, UK). Black arrows indicate bands present in the 
induced sample and therefore representing the cleaved region of M1-2 (B ~30kDa) and 
the active protease region of M1-2 (A ~32kDa) 
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4.2.2 Activity based screening of sub clones 
Upon sub-cloning, transformants were screened on LF-SMA to assess the recapitulation 
of the protease phenotype on a robust agar.  M1-2 was able to recapitulate this 
phenotype, however, M1-1 did not.  The SDS-PAGE on cell-free extract on M1-2 
exhibited two bands present in the induced and not present in the non-induced samples 
with apparent molecular masses of ≈32 kDa and ≈21kDa (Figure 4.5). 
 
4.2.3 Characterisation of M1-2 protease 
The optimal temperature for M1-2 activity was 42°C after incubation for 4 hours 
(Fig. 4.6a). Activity was below 30% of maximum at temperatures of 4, 10, 20 and 60°C 
and lower than 50% activity was observed at 50°C. The optimal pH for M1-2 activity 
was 8.0 (Fig. 4.6b). 
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Figure 4.6 A: The Effect of temperature on protease activity as measured by the release 
of acid-soluble substance from azocasein (5 mg/ml) in HCl buffered Tris to a pH of 8.0 
incubated at 4°C, 10°C, 20°C, 30°C, 40°C, 50°C and 60°C for 4 hours. Results are 
shown as the mean value of the results that were in triplicate and are shown as a relative  
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 continued from previous page 
percentage of protease activity. B: The Effect of pH on protease activity as measured by 
the release of acid-soluble substance from azocasein (5 mg/ml) at varying pHs using 
sodium acetate for pH 3.0-5.0, Tris-HCl for pH 6.0-8.0 and glycine-NaOH for pH 9.0-
11.0 incubated at 37°C for 4 hours. Results are shown as the mean value of the results 
that were in triplicate and are shown as a relative percentage of protease activity. 
 
 
The effects of the metal ions and reagents on M1-2 activity described in experimental 
procedures can be seen in Table 4.1. Activity was slightly enhanced upon the addition of 
Mg
2+
, Ni
2+
 and Co
2+
, but inhibited by the addition of Zn
2+
. Both 1 mM and 10 mM 
concentrations of the metal ion chelator EDTA reduced activity to below 30% activity 
and 1 mM SDS reduced activity to 35%. When 50 mM Zn
2+
 was added to 10 mM 
EDTA activity began to increase to >30%, but at lower concentrations (1 mM EDTA 
and 10 mM ZnCl2) the protease was further inhibited. 
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Table 4.1: The effects of metal ions and chemical reagents on protease activity as 
described in Material and Methods. Effect was measured using the release of acid-
soluble substance from azocasein (5 mg/ml) in HCl buffered Tris to a pH of 8.0 
incubated at 37°C for 4 hours. Results are shown as the mean value of the results that 
were in triplicate and are shown as a relative percentage of protease activity. 
 
Metal ion or 
reagent 
Concentration (mM) % Relative 
Activity 
None None 100 
EDTA 1 26 
EDTA 10 24 
EDTA / ZnCl2 1 mM EDTA /10 mM ZnCl2 12 
EDTA / ZnCl2 10 mM EDTA / 50 mM 
ZnCl2 
32 
CaCl2  1 97 
ZnCl2  1 19 
MgCl2 1 104 
CoCl2 1 102 
NiSO4 1 105 
SDS 1 35 
 
 
  
 110 
 
4.3 DISCUSSION 
 
Functional metagenomics provides the potential to access some of the currently vastly 
uncharacterised or unknown microbial resources from any environment by-passing the 
need for laboratory culture techniques. Its potential has been demonstrated so far with 
the identification of novel proteins, antibiotics and antibiotic resistant genes [25, 26], 
however, the frequency of successful functional metagenomic screens is still very low as 
there are currently a number of limitations particularly when screening for proteolytic 
clones as was the aim of this research. These limitations include the possibility that a 
foreign protease gene may exert a toxic effect on surrogate host proteins possibly 
resulting in host cell death thus hindering protease recovery and also as the chosen 
surrogate host may not be capable of transcribing and/or translating this foreign protein 
leading to no active product. A further current limitation of functional metagenomics is 
the insufficient screening means [8]. Any steps towards mitigating these issues can only 
be seen as a positive for the future of metagenomics. 
 
 From our study, Valio™ lactose-free milk agar was found to be an effective and robust 
agar for correctly identifying proteases by way of distinct zones of clearing around a 
bacterial colony. From the screens undertaken in this study no false positives arose with 
the use of this type of agar. We would suggest that this agar would be much more 
appropriate for future screening of metagenomic libraries for protease activity. The 
robustness of this agar has and will allow for more efficient characterisation of enzyme 
activity which can lead to identification of clinically or industrially relevant proteases in 
the future. Here, a metagenomic library was created from the metagenome of a milk 
waste treatment plant in Cork, Ireland in a large fosmid vector with E. coli as the 
surrogate host. Following screening of the subsequent metagenomic clones on normal 
SMA one fosmid was found to confer a proteolytic phenotype. Sequence analysis of this 
38kb fosmid revealed two putative protease sequences that may have been responsible 
for this phenotype.  The sequences were analysed to find signal peptides, potential 
promoter sites, domains and motifs (figure 4.4) and were also aligned with their closest 
genetic matches as determined by Protein BLAST searches to deduce phylogeny and to 
determine to which protease family they belonged. The sequences were subcloned into 
another strain of E.coli which was found to be capable of synthesising and secreting one 
of the two foreign protease sequences found, exemplifying both the usefulness, but also 
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limitations of E.coli as the standard host for cloning. LF-SMA was used to avoid the 
problem described by Jones and co-workers [8] and was successful in identifying M1-2 
as recapitulating a proteolytic phenotype, allowing subsequent characterisation and 
identification. An alternative vector; pET-42a had to be implemented for M1-1 
following no recapitulation of a protease phenotype in pGEM®T-easy. This vector is 
useful for the quick cloning and high level expression of protein in a host bacterial cell. 
However, this method still proved fruitless and no phenotype was observed though it 
was still deemed necessary to analyse the sequence and phylogeny to either disrepute 
this sequence as a protease, or to provide answers for the lack of expression to aid the 
progress of metagenomics. 
 
Sequence analysis revealed both sequences to be extracellular zinc-dependent 
metalloproteases which are a diverse group of proteases. Phylogenetic analysis using a 
neighbour-joining method concluded M1-1 and M1-2 to be phylogenetically distinct 
demonstrating the varying evolutionary lineages of metalloproteases and was in 
accordance with the family separation of the two proteases as exhibited by the MEROPS 
database and the dissimilar modular structures suggesting the sequences did not come 
from the same organism. 
 
M1-2 was shown to belong to the highly heterogeneous M4 family of proteases. The 
closest genetic matches of M1-2 include metalloproteases from Chromobacterium 
violaceum, Collimonas fungivorans and Aeromonas species. M1-2 was also found to 
share 56% sequence identity to a previously metagenome-derived metalloprotease found 
in soil [13] Since the closest identity to M1-2 include proteases from soil inhabitants, 
water inhabitants it can be suggested that this M1-2 may provide the genetic capability 
to utilise a diverse array of substrates from different ecological niches. It is well 
established that waste treatment plants provide an intermediary for horizontal gene 
transfer [27],[28] so such genetic material may have easily passed from one 
microorganism to another. Since the closest genetic matches to M1-2 are also ubiquitous 
in soil and aquatic environments there is good chance of horizontal gene transfer of 
genetic material in an environment such as a waste treatment plant. It is also important 
to note that of the closest genetic matches for M1-2 all proteases came from members of 
the Proteobacteria which may be an indicator as to why E. coli was able to express M1-
2 successfully. This potential inability of E. coli to express M1-1 but it’s ability to 
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express M1-2 and the information we have learnt from sequence analysis of M1-2 has 
useful implications for the host selection for future metagenomic screens, since 
phylogeny can be a good indicator of genetic capacity and whether or not it would be a 
suitable surrogate host for the expression of DNA from the environment under scrutiny. 
 
M4 family characterisation is based on the protease thermolysin from Bacillus 
thermoproteolytcius, thus members of this family are generally metalloendopeptidases 
that exhibit a degree of thermotolerance. Characterisation of M1-2 temperature optima is 
commensurate with this thermostable characteristic that was comparable to the tolerance 
shown by members of the M4 family [29] M4 require Zn
2+
 ions for catalytic activity and 
Ca
2+ 
ions for stability. M1-2 activity was unsurprisingly inhibited when the ion chelator 
EDTA was added and activity was slightly re-instated upon the addition of ZnCl2 and 
CaCl2 (Table 2). Although, surprisingly activity was decreased to 19% (Table 2) in the 
presence of an excess of zinc ions though previous research has shown that an excess of 
the corresponding ion needed for activity (in this instance, zinc) activity was reduced 
due to over-binding of the ion to the active site consequently inhibiting activity [30]. 
 
As they do require Zn
2+
 ions, though not in excess, for activity, all members of the M4 
family contain the amino acid zinc-binding motif: HEXXH which was present in the 
sequence of M1-2 and its closet genetic matches as deduced by a Protein BLAST search 
all of which were metalloproteases belonging to the M4 family. Although they are a 
highly heterogeneous group, the catalytic site amongst M4 proteases is actually highly 
homogeneous. M1-2 putative catalytic site was shown to share (98%) identity with other 
members of M4 thus we can confirm that the M1-2 sequence is a zinc-dependent 
metalloprotease that is the most credible candidate responsible for the proteolytic 
phenotype observed from the first screen of the metagenomic library and also that at 
least the catalytic domain must be ubiquitous throughout many environmental bacteria.  
 
M1-1 may not have been responsible for the proteolytic phenotype initially observed by 
the metagenomic fosmid; it still cannot be disregarded as a protease as many of the 
related proteases were leucyl aminopeptidases from Burkholderia (Fig. 3) suggesting 
E.coli may not have been capable of synthesising this gene. Thus, regardless of whether 
or not the M1-1 sequence confers a protease, this research has highlighted that in order 
to access the full repertoire of extracellular microbial protease function, it is may not be 
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sufficient to rely on current standard screening techniques nor E. coli as the standard 
host and since a similar sequence to M1-2 has been previously isolated [13] the 
functional metagenomic techniques currently used may favour the expression of certain 
types of proteases over others indicating that it would be advantageous to develop 
metagenomic methods that allow for an expansion of host range for more competent 
expression of novel genes.  
 
Recent culture-independent analysis by deep-sequencing approaches has enabled us to 
recognise the genetic diversity and potential of the gut microbiota. However, identifying 
functional characteristics from metagenomes could be more helpful in deducing 
microbial-host interactions and the impact they have with regards to pathogenesis and 
disease aetiology [31]. In this instance, we were interested in the role of proteases for 
reasons described previously. The ultimate aim of this research is to understand 
proteolytic functions within the human gut microbial metagenome as within the human 
gut, microbial proteases have been largely untapped as resources, and have been 
implicated with the pathology of inflammatory bowel disorders, diarrhoeal disease and 
colon cancer. There are many other proteolytically significant bacteria residing in the 
human gut of which the effects of proteolysis on the host are largely unknown. It is also 
likely that secondary metabolites as a result of protein degradation in the human gut by 
the gut microbiota leads to a build up of toxic compounds such as phenolic compounds, 
ammonia and amines [32]. Hence we have the motivation for attempting to further 
uncover the degradome of the gut microbiota which will be achieved by culture-
dependent analysis of proteolysis in the gut microbiota to deduce diversity and 
taxonomy, and improving and developing the standard techniques that are currently 
implemented, and proving fairly unproductive for protease screening. Our novel 
techniques are based on the development and utilisation of a Gram positive host; 
Bacillus subtilis strain WB800N which is protease deficient but chosen as a suitable 
surrogate host due to its GRAS (generally regarded as safe) status and the ability of the 
wild type to produce and secrete numerous proteases. A Gram negative host (E. coli) 
will be used for maintenance as the pNZ44 vector currently being used for library 
construction (Chapter 5.0) has both Gram positive and Gram negative replication origins 
Libraries can be initially screened on our LF-SMA developed in this research (Chapter 
3.0). 
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4.4 MATERIAL AND METHODS 
 
4.4.1 Bacterial strains, plasmids and growth conditions 
The strains and plasmids used throughout this study along with conditions for 
growth/use are listed in Chapter 2.0, table 2.1.  Plasmid and fosmid preparations on E. 
coli were carried out using the Qiaprep spin mini prep kit (QIAGEN LTD. West Sussex, 
UK) according to the manufacturer’s protocol on cells from an overnight culture.  A 
fosmid library (28032 clones (pCC1Fos), in E. coli EPI300) was constructed as 
described previously [8, 33] using high molecular weight DNA isolated from a settling 
tank’s activated sludge.  This library was screened on skimmed milked agar, containing 
chloramphenicol (12·5 μg ml−1) as described in [14].  Since false positives are a 
possibility of this assay [8] positive clones were further tested to ensure they did not 
produce acetic acid and were able to degraded casein. 
 
The fosmid insert(s) from any positive clones was sequenced by MWG (Ebersberg, 
Germany) and GeneMark [34] used to predict the putative open reading frames, which 
were annotated using the BLAST suite of tools [35]. Putative protease were compared to 
the MEROPS peptidase database [36] and signal peptides identified using the SignalP 
3.0 Server [37]. Promoter prediction was determined using the Promoter 2.0 Prediction 
software [38]. Potential structures and domains were compared to sequences in the 
Conserved Domain Database (CDD) [39] and Pfam database [40].  Molecular 
evolutionary analysis of the two putative protease sequences and their ten closest 
protease matches following the BLAST analysis was inferred using Neighbor-Joining 
algorithms [41] in MEGA version 5.0 [42].  Taxonomic analysis of the ORFs was 
determined using the web-server WebMGA [43]. 
 
PCR reactions to amplify protease sequences from the fosmid were performed on a 
C1000™ Thermal cycler. Primers were designed to amplify the open reading frames. 
Reactions were routinely 25μl prepared with 0.2 μM primers (M1-1 forward;5’- 
GGACAGTTCGCGCAAGCCCT-3’, M1-1 reverse; 5’-
TGCCATGCTTCATGCTAGAAATGC-3’, M1-2 forward; 5’-
AGGATATAGAAAGCATCCCG-3’ and M1-2 reverse; 5’-
GCTGGGGCGGTTCTGCGTAA-3’), 1U of NEB Taq DNA Polymerase (New England 
Biolabs® Inc. Ipswich), 1X standard reaction buffer (10 mM Tris-HCl, 50 mM KCl, 1.5 
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mM MgCl2, pH 8.3 at 25°C), 1X Bovine Serum Albumin (NEB), 0.2 μM dNTPS, sterile 
H2O and template DNA (≈10 ng fosmid DNA). PCR conditions were as follows: 
Heating at 94°C for 5 mins followed by 30 cycles of heating 94°C for 30s, 60°C for 45s 
and 72°Cfor 2 mins and a final step of 72°C for 7 mins. PCR products were analysed on 
a 0.8% (w/v) gel with ethidium bromide (1 μg/ml). PCR products were purified using 
the Qiagen PCR purification kit according to their protocol. For products that were to be 
cloned into pET-42a, the following primers were used to include NdeI and XhoI sites 
and PCR conditions were as described as above M1-1 forward;5’- 
GGCCTCGAGGGACAGTTCGCGCAAGCCCT-3’, M1-1 reverse; 5’-
TGCCATGCTTCATGCTAGAAATGC-3’, M1-2 forward; 5’-
AGGATATAGAAAGCATCCCGGTATACGGC-3’ 
 
4.4.2 Sub-cloning and activity based screening  
Following amplification by PCR of the putative protease open reading frames and 
flanking regions to include potential promoter sites the purified inserts were treated with 
T4 DNA polymerase (Fermentas, UK) according to the manufacturer’s protocol in order 
to fill in any 5’ or 3’ overhangs. The insert was ligated into the pGEM®T-easy 
(Promega, Southampton, UK) at a 3:1 insert to vector ratio using T4 DNA ligase 
(Promega). The subsequent ligation mixture (2µl) was used to transform E. coli XL1-
Blue supercompetent cells (Agilent, Wokingham, UK) according to the manufacturer’s 
protocol. Following identification of transformants positive for the insert by blue-white 
screening on LB plates supplemented with 0.5 mM IPTG and 100 μg/ml ampicillin, 
white colonies were re-screened on a lactose free skimmed milk agar (LF-SMA) which 
was prepared as previously described [44] supplemented with the appropriate antibiotic. 
 
 
4.4.3 Preparation of cell free extract and enzyme characterisation 
Cells were grown overnight in LB media supplemented with the 100 μg/ml ampicillin. 
1% (v/v) of this starting culture was used to inoculate 50 ml of fresh media and grown to 
an optical density OD600 = 0.5. The culture was divided into a non-induced control and 
IPTG induced culture in which IPTG was added to a final concentration of 0.5 mM and 
both were left to grow for a further 3 hours. Cells were harvested by centrifugation at 
1500 x g for 10 mins. The pellet was re-suspended in 2 ml of phosphate buffered saline 
(PBS) and each sample was bead beaten for 30 secs, 3 times with 0.5g of 0.1mm glass 
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beads. Samples were centrifuged at 20,000 x g for 10 mins and the resulting supernatant 
was taken as the cell free extract. Protein was quantified by the method of Bradford with 
bovine serum albumin as the standard [45]. Sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE) was performed according to Laemmli 1970 on a 12% 
w/v gel [46]. 
 
Protease activity was determined by measuring the release of acid-soluble substance 
from azocasein (Sigma-aldrich, Poole, UK) as described in the general materials and 
methods section (Chapter 2.0 section 2.9.1) 
 
In order to determine the optimum temperature for protease activity, the previously 
described assay was carried out, but incubated at the following temperatures; 4°C, 10°C, 
20°C, 30°C, 40°C, 50°C and 60°C for a period of 4 hours. The reactions were 
terminated by addition of 10% (w/v) TCA and protein precipitated as described above. 
Similarly, to deduce pH optima, the pH of the azocasein solution was varied from 3 to 
11 using a sodium acetate (pH range 3-5), Tris-HCL (pH range 6-8) or glycine sodium 
hydroxide (pH range 9-11) buffer system. 
To investigate the effect of specific metal ions and chemical reagents, 100 μl of protease 
sample was incubated for 3 h with 100 μl azocasein in the presence of varying 
concentrations of ethylenediaminetetraacetic acid (EDTA), sodium dodecyl sulphate 
(SDS) CaCl2, CoCl2, NiSO4 and ZnCl2. 
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5.0 DEVELOPMENT OF FUNCTIONAL METAGENOMIC TOOLS 
AND SCREENING THE GUT MICROBIOME FOR PROTEASE 
ACTIVITY 
 
5.1 INTRODUCTION 
 
We now understand that while bacterial culture methods are extremely useful in 
discerning phenotypic characteristics of microorganisms, current techniques are not 
substantial to support the growth of the vast majority of microorganisms from a given 
environment. Our attempts to assess the microbial diversity via culture methods leads to 
a bias view of the bacteria that are actually present; those that grow are usually those 
that are the most successful at growing on nutrient rich, synthetic media, these 
successful growers or ‘weeds’ as they are commonly referred [1] are rarely the 
numerically dominant species in that particular environment [2]. This culture bias has 
become known as ‘The great plate count anomaly’[2]. 
 
Polymicrobial infections such as that found in cystic fibrosis (CF) sufferers are a key 
example to show how culture-dependent diagnostics can overlook important pathogens. 
In this example, the most commonly isolated bacteria through routine aerobic culture are 
Staphylococcus.aureus, Haemophilus influenza , Burkholderia cepacia and 
Pseudomonas aeruginosa and were therefore thought to be the key players in infection 
[3]. However, recent molecular based studies have shown that the CF lung has a much 
greater species richness and many inhabitants are anaerobic such as Prevotella spp. and 
Streptococcus spp. and therefore would have been overlooked using standard aerobic 
culture conditions [4].  Some of these anaerobes may be of clinical significance [5] and 
therefore may have implications for antimicrobial therapy of pulmonary infection in CF 
patients. This example highlights how significant the issue of culture bias can be. 
 
The human gut microbiota, a microbial habitat discussed at length previously 
(Introduction, Chapter 1.0) is another notable example of where culture bias can 
influence how we view the microbial community. In the early studies of the human gut 
microbiota researchers such as Finegold and colleagues [6] found only 113 difference 
bacterial species in the gut compared to the excess of 1000 species that recent culture-
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independent sequencing technologies have now revealed there to actually be [7]. 
Culture-independent studies are therefore the favoured approach these days for studying 
microbial diversity and density of a given environment. 
 
The emergence of Metagenomics, a term first coined by Handelsman and colleagues [8] 
provided a great opportunity to overcome the culture bias by directly studying the entire 
genome, or metagenome of the bacteria taken from a particulate environment be it soil, 
deep sea sediment, coral reef, hot springs or the human gut to name but a few.  The 
resulting transformants can be analysed by one of two ways: sequencing analysis or 
functional analysis.  
 
Functional metagenomics (FM) circumvents some of the limitations associated with 
shotgun metagenomic sequencing by providing a form of phenotypic identification; 
metagenomic clones are screened for a specific function identified by a measurable 
phenotype. FM therefore relies on the heterologous gene expression of the random 
metagenomic insert, and subsequent high-throughput screening for the desired 
functional characteristic. With this methodology, no prior genetic knowledge is required 
and so it is currently the only method that enables the identification of completely novel 
genes [9], making it an invaluable tool particularly when applied to complex and 
limitedly characterised environments. It has been shown to have the capabilities of 
identifying many novel genes, including those of medical significance for example 
Courtois et al. screened a metagenomic library generated from soil microbial DNA and 
unearthed novel polyketide antibiotic genes [10] research such as this helps prove FM to 
be a promising approach for drug discovery, which is of particular significance in an age 
where the rate of antibiotic resistance amongst microorganisms is faster than the 
discovery of new drugs to combat them. Conversely, Allen et al. implemented FM to 
Alaskan soil samples and discovered the first example of a bi-functional β-lactamase 
gene [11] providing insight into the extent of antibiotic resistance without the selection 
pressures of humans. Thus, understanding functions of microorganisms aids us in 
understanding how they have adapted to life in a particular environment and also allows 
the stimulation of new hypotheses [12]. Clearly, this process shows potential for not 
only furthering our knowledge of the microbial world, but also for effective drug 
discovery, and unravelling resistance mechanisms and mechanisms of disease. 
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However, despite the many advantages of FM, when compared to metagenomic 
sequencing, the process is far more intensive with the frequency of a positive hit 
remaining low; for a successful metagenomic screen a gene has to be successfully 
ligated into a vector, transformed into a surrogate host where it must be transcribed and 
translated into the fully functioning protein which must be secreted from the cell and its 
function demonstrated [9]. In many cases, clone libraries of tens of thousands of clones 
must be screened to get enough coverage (enough clones to represent the amoutnof 
DNA in a particular sample) in order to be able to identify clones with a positive 
phenotype. Perhaps the skewed ratio between effort put in and data generated is the 
reason for the current relative shortage of FM publications when compared to those 
related to sequencing metagenomics(SM) since here, an expansion of reads of genetic 
information can be generated, cost and time effective using high-throughput sequencing. 
 
 
Figure 5.1. Number of publications over the last 10 years when using the ISI Web of 
Knowledge and carrying out the simply searches; "Functional Metagenomics" and 
"Sequencing Metagenomics". Note the different ‘y’ axis scale for each graph showing 
that there have been many at least twice as many publications on sequencing 
metagenomics compared to functional. 
There are four broad areas to consider when striving for a successful metagenomic 
project and these are; DNA extraction method and insert size, choice of vector, the 
surrogate host used for heterologous expression of metagenomic DNA, and the 
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screening approach for the product of interest. DNA extraction methods to obtain high 
yield, highly pure and un-bias DNA from the environment in question is of tantamount 
importance for both FM and SM.  Insert size is also dependent on the biological 
molecule in question and considerations for both have been discussed at depth in 
Chapter 1.0. While the choice of vector (plasmids, fosmids, cosmids and Bacterial 
Artificial chromosomes or BACs) is partly dictated by the insert size, it may also be 
dictated by the choice of surrogate host used in the study. While the majority of FM 
screens to date have implemented a single host system for expression of metagenomic 
DNA, work such as that by Ekkers and colleague suggest that the use of multi-host 
expression systems would be more efficient in the ability to express foreign DNA [13]. 
One of the most significant hindrance of FM is the necessity of the surrogate host to 
heterologously express metagenomic DNA originating from a plethora of 
microorgansims of extensive genetic diversity. The surrogate host, which is most 
commonly E. coli, may be unable to correctly express such DNA. The reason for which 
some host bacteria may not be able to express certain genes can be attributed to a 
number of factors, including different preferences for different codon usage during 
translation commonly referred to as the codon usage bias (CUB). The significance of 
this usage, in terms of FM, means that codons present in an inserted gene may not be 
recognised by the host organism and so will not become translated correctly and as a 
result, may not be expressed at all [14, 15]. Further to the problem of heterologous 
expression includes the necessity for the presence of cis regulatory elements that are 
non-coding regions of DNA that still have an essential role in DNA transcription such as 
promoter sequences which would result in no product being expressed and trans-acting 
elements such as signal peptides which would result in failure to secrete the product [13, 
16]. Moreover, even if a surrogate host were able to successfully express the exogenous 
DNA, as the DNA is potentially originally from an organism of unknown taxonomy, 
there is likelihood that the gene product could infer a toxic effect on the host, directly 
killing the host or at least causing some form of growth inhibition hindering the screen. 
  
Despite these difficulties, FM has been implemented to successfully isolate many 
hydrolytic enzymes (See Table 1.1 Chapter 1.0). There have been a number of solutions 
to the problems of heterologous expression of exogenous DNA in E. coli. For example, 
Leggweie et al., alleviated the problem of cis-acting factors by developing an inducible 
dual promoter transposon system termed MUExpress which would randomly insert into 
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metagenomic DNA and E. coli could express inserted genes regardless of their 
orientation within the vector [17]. 
 
However in comparison, FM projects isolating the group of hydrolytic enzymes that we 
are most interested in; proteases, for reasons described elsewhere (Chapter 1 section 1.3 
and Chapter 7) remain relatively sparse (please see table 5.1 and compare to table 1.1 of 
Chapter 1 which shows enzymes isolated from most recent FM publications).  
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Table 5.2 Protease enzymes that have been isolated using functional metagenomics and 
if and how they were further validated so we can be certain that the protease phenotype 
observed was that of proteases and not other hydrolytic enzymes. 3 of the 9 studies 
failed to isolate any proteases. The majority of studies also implement skimmed milk 
agar as the screening means. 
Protease 
Identified 
Environment 
Screening 
mechanism 
Validated? Reference 
Alkaline serine 
protease 
Goat skin 
surface 
metagenome 
Skimmed milk 
agar 
Zymography and functional 
characterisation by azocasein 
assay 
[18] 
Subtilisin-like 
serine protease 
Red sea 
Atlantis-II 
brine pool 
Skimmed milk 
agar 
No further functional 
characterisation, 
pyrosequencing used to 
assess sequence 
[19] 
Oxidant-stable 
serine protease 
Forest soil AZCL-casein 
Functional characterisation 
by azocasein assay 
[20] 
Serine protease 
x 2 
Gobi and 
Death valley 
Deserts 
Skimmed milk 
agar 
Functional characterisation 
by azocasein assay 
[21] 
Metalloprotease 
x 2 
Soil 
Skimmed milk 
agar 
Further screens on 
azoalbumin and azocasein 
assay 
[22] 
Subtilisin-like 
serine protease 
Coastal 
sediment 
Skimmed milk 
agar 
Casein [23] 
Unknown type, 
3 x protease 
clones 
Antarctic soil 
Skimmed milk 
agar 
No [24] 
No protease 
phenotype 
observed 
Soil 
Skimmed milk 
agar 
N/A [25] 
No protease 
phenotype 
observed 
Human gut 
Skimmed milk 
agar 
N/A [26] 
No protease 
phenotype 
observed 
Enriched 
Biomass 
Skimmed milk 
agar 
N/A [27] 
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A number of research groups have aimed to isolate proteases using FM techniques and 
have failed at this endeavour; (Table 5.1[22, 25, 28]). Purohit and Singh [29] 
successfully isolated an alkaline protease from a metagenomic library created from a 
saline habitat. However they did not functionally screen their library. Instead, they 
designed degenerate primers from multiple alignments of the conserved region of other 
alkaline proteases from a species isolated from saline environments and conducted PCR 
to amplify target genes from the metagenome. Gene-targeting methods such as this are 
often implemented as an alternative to FM screening and are often successful [29-32]. 
However, this method requires a significant amount of a priori knowledge of sequence 
data in order to conduct an alignment of conserved regions as the basis for designing 
primers and therefore, rarely can non-homologous, novel genes be identified with these 
PCR-based methods. 
 
Aside from the problems associated with heterologous gene expression that affect all 
FM screens, particularly the recognition of signal peptides which would be crucial for 
observation of a proteolytic phenotype, a further explanation for this insufficiency is 
likely due to the inherent role of proteases; degrading protein, in that although a host 
organism may very well be able to express an exogenous protease, this protease may 
exert detrimental effects on the host due to degradation of essential intracellular protein 
such as cell wall and cell membrane components as well as many other potential targets. 
It has been demonstrated before that certain bacterial proteases have a lytic effect on an 
alternative expression host [33]. Additionally, extracellular proteases often require forms 
of posttranslational modification in order to become active, increasing the genetic 
capacity required by the surrogate host for exogenous protease expression. Thus, this 
emphasises the necessity of developing functional metagenomic techniques that aim to 
ameliorate the results that have so far been achieved. 
 
While E. coli has been shown capable of expressing bacterial genes of vast taxonomic 
diversity [9] most of these are Gram negatives. And these examples are from purified 
culture genome extractions not metagenomes. It has been suggested that exploration of 
broadening the surrogate host range beyond E. coli, and consequently expanding the 
genetic machinery for heterologous expression of foreign DNA should lead to a higher 
frequency of positive metagenomic screens [13, 34, 35]. For example Craig and 
colleagues constructed an FM library in E. coli and transferred to five different 
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proteobacteria as hosts for their FM screen. The library in each host was screened for 
altered pigmentation, altered colony morphologies and antibacterial activity. In total > 
35 colonies displayed an altered pigmentation, 8 colonies showed antibiosis and 2 
showed altered morphology, of these, E. coli accounted for 2  colonies conferring 
antibiosis and after retransformation, only one of these colonies recapitulated that 
phenotype [36]. Many of the compounds isolated were not active in the E. coli host 
demonstrating the usefulness of utilising alternative hosts. Martinez et al., have also 
demonstrated that different hosts harbour different expression capabilities and also 
highlight that the environment under scrutiny is an important consideration when 
developing alternative host systems [35].  
 
Studies such as those by Eckburg et al., [37], Turnbaugh et al., [38] and Andersson et 
al., [39] have highlighted that  Gram positive bacteria can make up a significant 
proportion in the human gut. Gram positive bacteria have different mechanisms for the 
secretion and activation of surface bound or extracellular protein [40] suggesting again 
that E. coli may not have the genetic capability to effectively express and secrete active 
proteases from the vastly Gram positive human gut.  
 
Bacillus species’ secretory pathways have been well characterised and have been used 
extensively in industry due to their high secretion capacity in the production of 
heterologous protein [41]. Bacillus subtilis has a GRAS (generally regarded as safe) 
status and is commonly used as a host for the large-scale production of industrial 
proteases and has a number of proteases itself, many of which are extracellular and 
therefore it has an effective and well-characterised means of protein secretion [42]. 
Also, it’s ease of genetic manipulation means a number of tools have been developed for 
B. subtilis, particularly regarding the development of modified strains, transformation 
procedures, and the development of vectors for transformation. However, its 
extracellular proteases pose a problem for FM screens for two reasons. Firstly, they 
potentially will recognise and degrade heterologous proteins and secondly, secretion of 
endogenous proteases will inhibit the screen for exogenous metagenomics proteases. 
These obstacles have been alleviated by the construction of genetically modified strains 
that are protease deficient strains of Bacillus subtilis such as WB800, a strain engineered 
to be deficient in 6 extracellular protease genes [43] and WB800N, a strain with 8 null 
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extracellular protease genes [44]. These strains have also been specifically designed for 
use with secretion vectors. 
 
A further problem includes that while many plasmids replicate stably in B. subtilis under 
normal conditions, upon insertion of recombinant DNA problems arise regarding 
structural and segregational stability. Instability is caused by the rolling circle mode of 
replication of plasmids with a single-stranded (ss) DNA intermediate [45]. During the ss 
DNA intermediate, short direct repeats and intervening DNA may often get deleted 
resulting in instability [46]. This problem can be ameliorated by the development of 
vectors with an expression cassette inserted into a non-essential gene such as the lacA 
encoding for β-galactosidase which allowed for controlled expression of inserted genes 
[47]. 
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AIMS 
 
We aim to further our understanding of proteases produced by the gut microbiota. One 
of the aims of this research will be to conduct a culture-dependent study to isolate 
protease producers from the cultivable gut microbiota to potentially compare to 
proteases isolated via culture-independent techniques. As determined in Chapter 4.0, it 
is clear that it is not suitable to solely rely on E.coli as a single surrogate host for 
functional metagenomics studies particularly when attempting to isolate proteases. 
Therefore, this research also mainly aims to explore new tools that facilitate the use of 
E. coli and B. subtilis as expression hosts for high-throughput FM library construction 
and screening specifically designed to isolate novel protease genes. These tools include 
the investigation of two strains of the alternative surrogate cloning host; B. subtilis for 
their use as hosts for FM screening for proteases. The most appropriate vector system 
was also to be explored, as well as determining optimum DNA insert sizes and 
fragmentation methods specifically for the expression of proteases.  
 
Therefore the main aims of this research are:- 
 
1. To conduct a culture-dependent analysis of proteolysis within the gut microbiota 
 
2. Determine the usefulness of B. subtilis WB800N as an expression host for FM 
library screening for proteases. 
 
3. Determine the most appropriate vectors for library construction. 
 
4. Compare the robustness and efficiency of a Gram negative and Gram positive 
expression system using already characterised protease genes. 
 
5. Determine the optimum DNA fragmentation methods and DNA fragment size 
for optimal protease capture from metagenomic libraries. 
 
6. Implementation of the inferred novel FM tools to screen the human gut 
microbiota for novel proteases. 
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Different vectors will be tested for the suitability of this research. Also from the Bacillus 
Genetic Stock Centre (BGSC) we have four E. coli-B. subtilis shuttle vectors; pNZ8048, 
pNZ44, pHCMC04 and pHCMC05 [45] which can easily be transformed into E. coli for 
maintenance and can be transformed into WB800N to further examine the phenotype 
conferred by the recombinant vector. 
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5.2 RESULTS  
5.2.1 B. subtilis WB800N adaptation for functional metagenomic screening for 
proteases  
B. subtilis My2016 caused proteolytic cleavage of azo-dye from azocasein however,  B. 
subtilis WB800N showed no activity (figure 5.2.1). Similarly, no proteolytic phenotype 
was observed when B. subtilis WB800N was cultured on Lactose-free skimmed milk 
agar, yet B. subtilis MY2016 showed a distinctive halo indicating proteolytic 
degradation of the media. These results show that it is the nprE and nprB neutral 
protease subtilisin, epr serine protease gene, bacillopeptidase F, WprA protease, and 
serine protease Vpr are responsible for extracellular proteolytic degradation in Bacillus 
subtilis although nrpE and Apre are responsible for approximately 70% of extracellular 
proteolytic activity and are the only two enzymes involved in protein degradation for 
nutritional purposes. The elimination of these protease gene undertaken by Wu et al., 
[43] whose research produced a strain of B. subtilis, with 8 proteases knocked out and 
with chromosomal resistance to chloramphenicol. This strain was further modified by 
Nguyen et al., [45] by insertion of a neomycin cassette into the chloramphenicol gene 
thus disrupting it rendering this new strain (B. subtilis WB800N) susceptible to 
chloramphenicol, but resistant to neomycin. This strain showed no observable 
proteolytic phenotype with the methods described. In addition, these protease genes 
were initially knocked out as they are known to recognise and degrade heterologous 
protein, the absence of such proteases and a proteolytic phenotype therefore makes B. 
subtilis WB800N  suitable surrogate hosts for functional expression of proteases from 
the microbial metagenome. A number of different bacillus transformation procedures 
were implemented in order to determine the most efficient. The only transformation 
procedures that was successful was the MM competence medium method which is 
described in the general materials and methods section and the MD method 
(supplementary materials) and the transformation efficiencies are shown in table 5.1 
alongside the transformation efficiencies of the E. coli hosts, when transformed with 
pNZ44 empty vector. The, MD medium method showed fewer colonies after 
transformation (table 5.1) and so was not used for future transformations. Most of the 
procedures resulting in no colonies after 12 and 24 hours of incubation although 
colonies did begin to develop after 48 hours, however, plasmid preparations of these 
colonies revealed no plasmid present and therefore it was presumed that these 
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transformation attempts had failed ) these methods are detailed here in supplementary 
materials 5.5.15.5.4). Transformation efficiencies for B. subtilis WB800N still 
remained far lower than the transformation efficiencies in both strains of E. coli. 
 
pNZ44, a vector originally designed by McGrath and colleagues [48] was the choice for 
use in this research due to the necessity for a low copy number plasmid to reduce gene 
dosage so as to be less toxic to the host, it has an origin of replication for both Gram 
negative and Gram positive organisms, it has a strong, constitutive promoter useful for 
optimal expression of recombinant protein [49]. The other plasmids were deemed too 
large for efficient tranformstion of large inserts and so were not used in this study.  
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Table 5.1 A comparison of transformation efficiencies between the protease deficient 
cloning host for this study; B subtilis WB800N with a commercially available 
chemically competent E. coli a commercially available electrocompetent E. coli that 
showed no positive phenotype on LF-SMA. 
a
100 µl transformation solution was plated, 
b 
200 µl was plated. Transformation efficiency was calculated using the following 
formula:  
 
TE = (no. colonies/ pg DNA) x (1 x 10
6
 pg/ µg) x (volume of transformants/volume 
plated) x dilution factor 
 
The number highlighted in bold represent the transformation efficiency when using 
recombinant pNZ44. 
 
  
Strain Transformants/10
6
 cells 
 
MD MM Electroporation Chemical 
1
a
 
 
2
b
 
 
1 
 
2 
 
B. subtilis 
WB800N 
0.32 0.29 0.76 0.26 0.38 0.56 2.28 1.5 n/a n/a 
Chemically 
competent 
E.coli 
n/a n/a n/a 6.75 3.2 
Electro-
competent 
E.coli 
n/a n/a 14.85 9.7 n/a 
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Figure 5.2.1 Protease activity assay using azo-casein as the substrate for wildtype B. 
subtilis MY16, and B. subtilis WB800N. The assay was also conducted using cell-free 
supernatant from both organisms. Significantly different results (P = ≦ 0.05) are 
represented with an ‘*’. 
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5.2.2 Culture-dependent Identification of Protease producing feacal bacteria  
 
Serial dilutions of faecal samples from three individuals were plated on LFSMA and 
incubated under aerobic and anaerobic conditions as described in 5.4. All samples 
exhibited a large amount of proteolysis on the agar. Dilutions of 10
-6
 were only useful 
for identifying single colonies that were secreting proteases into the medium. Colonies 
exhibiting a clear zone of clearing after 24 hour incubation were streaked to purity on 
LFSMA to ensure the protease phenotype was recapitulated. Isolates that exhibited 
different colony morphology, colour and size were selected. 16S rRNA gene sequence 
analysis revealed all aerobic isolates to share greatest sequence identity to members of 
the Enterococcus genera, specifically; most of them shared ≥ 98 % sequence identity to 
E. faecalis except for one isolate which showed highest sequence identity to 
Lactobacillus casei (Table 5.2). The anaerobic isolates were shown to share ≥ 75% 
sequence identity to members of the genera; Bacteroides and the Bifidobacteria except 
for one isolate which shared 92% sequence identity with a previously uncultured 
microorganism; clone ELU 0138 (Table 5.2). 
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Sample ID 16srRNA Gene ID  Identity (%) Query Coverage (%) E-value 
Aerobic isolate 1 Enterococcus faecalis 99 100 0.0 
Aerobic isolate 2 Enterococcus faecalis 99 100 0.0 
Aerobic isolate 3 Enterococcus faecalis 99 100 0.0 
Aerobic isolate 4 Enterococcus sp. 99 100 0.0 
Aerobic isolate 5 Enterococcus faecalis 98 100 0.0 
Aerobic isolate 6 Enterococcus faecalis 99 100 0.0 
Aerobic isolate 7 Enterococcus faecalis 99 100 0.0 
Aerobic isolate 8 Lactobacillus casei 97 100 0.0 
Anaerobic Isolate 1 Bacteroides fragilis 85 100 0.0 
Anaerobic Isolate 2 Bifidobacterium bifidum 93 97 0.0 
Anaerobic Isolate 3 Bifidobacteirum longum subsp longum 97 92 4e-10 
Anaerobic Isolate 4 Bifidobacterium pseudcatenlatum 75 92 2e-10 
Anaerobic Isolate 5 Uncultured organism clone ELU0138 92 87 6e-14 
Anaerobic Isolate 6 Bacteroides thetaiotaomicron 91 98 2e-13 
Table 5.2 The results of 16S rRNA gene analysis on protease producers isolated after aerobic and anaerobic culture on faecal 
sample dilutions from 3 individuals. Results of organisms identified with the greatest sequence similarity are shown. 
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5.2.3 Comparison of Expression of Characterised Proteases in a Gram negative 
and a Gram positive host 
In order to test the hypothesis that the Gram positive host B. subtilis WB800N was 
better suited for expression of proteases from the gut metagenome, the ability of this 
strain to express characterised protease genes from both Gram negative and Gram 
positive organisms was tested against E. coli. The well characterised proteases; NprE 
(Bacillus subtilis MY2016), GelE (Enterococcus faecalis isolated from this aerobic 
study), LasB (Pseudomonas aeruginosa PAO1) were used in this study. The organisms 
were first screening on LFSMA to ensure they exhibited a proteolytic phenotype. Cell-
free supernatants were also plated to ensure the organisms were actively secreting 
proteases (figure 5.2.2).  The protease genes were PCR amplified from DNA extracted 
from pure cultures of the relevant microorgansisms including flanking DNA regions and 
restriction enzyme sites (see materials and methods; primer information). After cloning 
into pNZ44 the plasmids were transformed into B. subtilis WB800N and E. coli XL1 
blue supercompetent cells (Agilent, Berkshire) transformants were picked into 96 wells 
plates using a Flexys® colony picking robot (Genomic Solutions) and also screened on 
LFSMA for protease activity. B. subtilis WB800N with pNZ44-gelE recapitulated a 
proteolytic phenotype. The clones with a positive phenotype were streaked to purity and 
the plasmids were extracted upon recapitulation of the phenotype once again. PCR were 
performed using the primers deigned to amplify the multiple cloning site region of 
pNZ44 and amplified product was sequenced. Similarly, the purified plasmids were re-
digested with an appropriate restriction enzyme, which does not cut in the inserted 
protease gene sequence and the putative protease product was sequenced using the 
appropriate primers for that protease gene. pNZ44-B.subtilis-nprE frame 1 shared 100% 
identity and 99% coverage with gelatinase E of numerous E. faecalis strains including E. 
faecalis 62, E. faecalis H81 and E. faecalis GM and shared 100% homology with the 
active site regions and metal ligands that are needed for activity (table 5.2 and figure 
5.2.3). pNZ44-E.coli-gelE that did not exhibit a protease phenotype, but did share 
sequence similarity with sequenced gelE genes. However, for unknown reasons, the 
active site residues and/or the metal ligand binding sites both needed for protease 
activity were not present in the translated sequence that gave positive hits for gelE 
(figure 5.3). 
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B. subtilis WB800N also conferred a protease phenotype when transformed with pNZ44 
containing the nprE neutral protease gene and once again E. coli did not. The sequences 
E. coli nprE sequences lacked homology in certain areas of the sequence (figure 5.2.3) 
and while the active site residue (HEXXH) was conserved, the metal ligand binding 
residue (E) was absent suggesting the protease could not bind metal ions for activity. 
 
No positive phenotype was observed for any clones with pNZ44-LasB in either host. 
Surprisingly, both sequences shared homology regarding the active site residues and 
metal binding regions of the proteases potential mis-tranlsation may not be a cause for 
lack of protease expression.   
 
Figure 5.2.2 Protease activity of; E. faecalis (A; top right quarter) E. faecalis cell free 
supernatant (A top left quarter), B. subtilis MY2016 (A; bottom right quarter) B. subtilis 
MY2016 cell –free supernatant (A; bottom left quarter) and P. aeruginosa PAO1 (B; 
right) and P. aeruginosa PAO1 cell free supernatant (B; left). 
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Table 5.3 The results of homology searches of the deduced sequences of gelE, lasB and nprE after cloning in chemically competent E.coli 
and B. subtilis WB800N using NCBI BLASTn. The top 3 matches are shown along with the Accession number (in brackets), the 
percentage identity, E-value and the query coverage. 
Sample BLAST ID 
Identity 
(%) 
E-
value 
Query 
Coverage 
GelE in E. coli 
1.E. faecalis (gelE) complete cds (D85393.1) 
99 
 
0.0 
97 
 
2. E. faecalis (gelE) complete cds (M37185.1) 98 0.0 97 
3.E. faecalis GM (gelE) complete cds EF105504.1) 98 0.0 97 
GelE in B. subtilis 
WB800N 
1.E. facecalis 62 (gelE) (CP002491.1) 
99 
 
0.0 
 
99 
 
2. E. faecalis GM (gelE) complete cds (EF105504.1) 
 
99 0.0 98 
3. E. faecalis H81 (gelE) partial cds (EU862241.3 
 
99 0.0 98 
LasB in E. coli 1.P. aeruginosa DNA complete genome, strain NCGM199 (Ap014622.1) 99 0.0 90 
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2.P. aeruginosa NCGM2 S1 DNA complete genome AP012280.1 99 0.0 90 
3.P. aeruginosa A2 elastase precursor (LasB) gene complete cds (JQ235840.1) 98 0.0 89 
LasB in B. subtilis 
WB800N 
1.P. aeruginosa RP73 complete genome (CP006245.1) 99 0.0 90 
2.P. aeruginosa DH2 complete genome (CP006245.1) 99 0.0 90 
3.P. aeruginosa strain ATCC 25619 elastase gene, complete cds (JX040483.1) 99 0.0 90 
NprE in E. coli 
1.B. subtilis subsp. subtilis strain AG1839, complete genome (CP008698.1) 100 0.0 99 
2.B. subtilis neural protease gene complete cds (U30932.1) 100 0.0 99 
3.B. subtilis nprE gene encoding neutral protease (KP01985.1) 100 0.0 99 
NprE in B. subtilis 
WB800N 
1.B. subtilis subsp. subtilis strain AG1839, complete genome (CP008698.1) 100 0.0 99 
2.B. subtilis neural protease gene complete cds (U30932.1) 100 0.0 99 
3.B. subtilis nprE gene encoding neutral protease (KP01985.1) 100 0.0 99 
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Figure 5.2.3 Alignments of the translated amino acid sequences of gelE, lasB and nprE along with their closets matches as determined by 
the NCBI Blastp program. Active site residues and metal ligand binding residues are outlined in order to determine whether missing regions 
could potentially be responsible for lack of expression of the protease gene. 
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5.2.4 Use of a Gram negative-Gram positive shuttle vector system to screen the 
human gut for proteases 
The metagenomic library was constructed using genomic DNA extracted from the 
faeces of a healthy human volunteer. Faecal samples were collected and DNA 
extractions were extracted as described in the general materials and methods sections 
(Chapter 2.0). The genomic DNA was partially digested using FatI as described in 
Chapter 2.0 and run on a gel (supplementary figure 5.5.5). The digested DNA of 
appropriate size was cloned into the digested pNZ44 plasmid which featured a 
chloramphenicol selection marker. The library was transformed into E. coli and B. 
subtilis WB800N. Transformants were selected by plating on TSA supplemented with 
chloramphenicol (5 μg/mL) and replica plated into 96-well plates using a colony picking 
robot (Genomic Solutions). A total of 19,200 clones were picked in E. coli and 9600 
were picked in B. subtilis WB800N. Restriction digest analysis and sequencing of 10 
clones from each library revealed the average insert size in E. coli to be ~ 994.9 bp 
giving an estimated library size of 19.1 Mb. In B. subtilis WB800N the average insert 
size was ~1103 bp giving an estimated library insert size of 10.5 Mb. B. subtilis 
WB800N remained particularly difficult to transform. Each library was screened 
initially on LFSMA for protease activity. However, no proteolytic clones were observed 
in any of the clones. 
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5.3 DISCUSSION 
 
In the quest to unravel the vastly untapped resources of the microbial world, functional-
based metagenomics remains currently the only potential means for unearthing 
completely novel compounds. In this research, our main interest lies with proteolytic 
enzymes isolated from bacteria for a range of reasons described elsewhere in this thesis 
(Chapter 1.0 and Chapter 7.0) particularly relating to the human gut. However, progress 
of FM is stinted by its dependence on the heterologous expression of foreign DNA and 
the numerous problems associated with this. While research into ameliorating the 
limitations of FM are well documented [17, 27, 50] even though the problem of an 
inefficient screening means for proteases has been improved [51] (Chapter 3.0) the 
problems associated with heterologous expression of proteases remain. In this research, 
we aimed to investigate an alternative host system for the expression of host proteases as 
a step towards accessing the degradome of the human gut microbiota. It was also 
deemed necessary to conduct our own culture-dependent analysis of the faecal 
degradome seeing as the overriding objective of this thesis was to further our knowledge 
of proteases in the human gut microbiota. Faecal samples from healthy individuals were 
also used to aerobically and anaerobically culture bacteria on lactose free skimmed milk 
agar as described in materials and methods and chapter 3.0. Colonies that exhibited 
proteolytic activity were streaked to purity, followed by DNA extraction, 16S rRNA 
gene amplification by PCR and sequencing this gene. All proteolytic isolates from 
aerobic cultures showed greatest sequence homology to Enterococcus faecalis (Table 
5.2.2). E. faecalis is a facultative anaerobic bacterium that is commonly isolated from 
the human gastrointestinal tract [52, 53] and previous culture dependent studies on 
proteolytic faecal bacteria have isolated this microorganism too [54] so it is not 
surprising that here, E. faecalis was isolated aerobically. E. faecalis is usually 
considered a commensal or even a beneficial bacteria of the gut and certain strains have 
been used as probiotics for example one of the most well established is Symbioflor 1 
(SymbioPharm, Herborn, Germany) which aids stimulation of the immune system to 
target recurring respiratory infections [55] and certain E. faecalis bacteriocins (e.g. the 
AS-48 bacteriocin of E. faecalis strain UGRA10) have been shown to exert 
antimicrobial activity against food-borne pathogens and spoilage agents such as Listeria 
monocytogenes [56].  
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However, on the contrary to these benefits, certain strains of E. faecalis are also 
recognised as significant pathogens implicated in disorders such as; bacteremia and 
endocarditis [57] and has been shown to induce inflammation in mouse models for IBD 
[58] and compromise epithelial barrier integrity [59] and strains often have multi-drug 
resistance [60]. Virulence of pathogen E. faecalis is commonly attributed to  cytolysin, 
lipoteichoic acid aggregation substances [61], but also the activity of extracellular 
proteolytic enzymes, namely the zinc-dependent metalloprotease gelatinase (gelE) and a 
serine glutamyl protease (sprE) which have been implicated in IBD [62] and 
translocation across intestinal epithelia [63]. Research using E. faecalis mutants for the 
gelE and sprE genes have also shown to a significant reduction in protease activity [63] 
suggesting that it was one of these enzymes responsible for the protease phenotype used 
to isolate the organisms in this study.  
 
The most numerous proteolytic bacteria identified following anaerobic culture were 
identified as Bacteroides spp. and Bifidobacterium spp. (Table 5.2.2b) following a 
BLAST homology search. This result is not surprising as Bacteroides spp. and 
Bifiobacterium spp. are well documented to be protease producers and are dominant 
members of the distal gut microbiota [64] and the Bifidobacterium species found in this 
studied have been isolated in other studies that aimed to isolate bifidobacterial species 
from human faecal samples before [65]. 
 
Similarly to the case of E. faecalis, Bacteroides spp. are often considered a mutual 
symbiont of the human gut, for example, the induced secretion of angiogenin by 
Bacteroides thetaiotaomicron [66], but they can also be the causative agents of 
significant infections. The phenomena of this transition from a commensal to a 
pathogenic phenotype may be caused by two factors; firstly, the vast genetic repertoire 
of the gut microbiota leads to extensive horizontal gene transfer of valuable genes that 
confer advantages to life in the gut. Secondly, organisms such as E. faecalis and 
Bacteroides spp. have vast genomic potential [67] [68] with different genes switched on 
to generate a pathogenic phenotype. Again, proteases of Bacteroides spp. are heavily 
implicated in pathogenesis, particularly in the species; B. fragilis of which the major 
enterotoxin is a zinc metalloprotease often referred as fragilysin which has been shown 
to be capable of breaking down intestinal brush border hydrolases [69] and degradation 
of E-cadherin, a transmembrane glycoprotein involved in epithelial cellular adhesion 
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[70] resulting in a loss in epithelial barrier integrity (‘leaky’ gut) and diarrhoea. 
Interestingly one isolate shared greatest sequence similarity to a previously uncultured 
microorganism [71] suggesting that perhaps this media, under anaerobic conditions was 
sufficient to support the growth of this potentially novel microorganism.  
 
The results here further demonstrate that LFSMA is useful for culturing bacteria and 
screening for protease activity. Analysis of the  MEROPS peptidase database, however, 
(http://merops.sanger.ac.uk/) [72] shows  that some of these isolated organisms have 
hundreds of proteases so it is impossible to know which protease is responsible for the 
phenotype observed, and prior sequence knowledge would be needed to find out. 
Suggesting a metagenomic approach is important for identifying specific genes. 
 
B. subtilis strains WB800 and WB800N were initially used to begin to develop 
metagenomic tools to implement in screening the gut microbiota for proteases. Neither 
strains inferred a proteolytic phenotype on LFSMA after 3 days of incubation and both 
showed significantly less activity that then wild type after azocasein assay analysis. 
Firstly, this suggests that the 6 protease genes knocked out were responsible for the 
protease phenotype observed by wild type B. subtilis and that both strains would be 
appropriate hosts for extracting proteases from the gut metagenome. While strain 
WB800 was determined to not be a consideration for interference with protease screens 
and would likely not affect heterologous protein, the strain contains chromosomal 
resistance to chloramphenicol, the selective resistance marker of all the shuttle vectors 
currently available for the organisms in this study. Whereas strain WB800N has a 
neomycin cassette inserted into the cat gene (conferring chloramphenicol resistance) 
thus rendering the strain resistant to neomycin but not chloramphenicol. Due to its 
compatibility with the vectors strain WB800N was consequently deemed more 
appropriate for this study and was used for all further experiments. However, no 
research has been previously carried out into the effect of the absence of such proteases 
on competence development and thus transformation efficiency. Initially, there was 
significant difficulty when trying to successfully transform WB800N, probably due to 
their large size and low copy number. The several transformations (see section5.4) that 
were attempted prior to estasblishemt of a successful protocol, helped to optimise the 
conditions for this new strain. Culture vessel size proved to be an important factor 
indicating that the strain required significant aeration when growing. The absence of 
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tryptophan had a great effect and needed to be included in the transformation medium. 
Several transformation methodologies were attempted in order to determine the greatest 
transformation efficiency. Transformations were tested using empty vector and 
mg(metagenomic) heterologous vector since the addition of small inserts (1-10kbp) into 
the bacteria were hypothesised to put a certain amount of stress and energy usage on the 
bacteria and potentially decrease transformation efficiencies. Transformation 
efficiencies of B. subtilis WB800N were compared with commercially available strains 
of E.coli (XL1-blue and Mega X DH10B™ T1R electrocompetent cells). 
 
An external collaboration with the Laboratory of Professor Jeffrey Errington at 
Newcastle University, a laboratory with expertise in the genetics of B. subtilis, helped to 
determine the optimal transformation conditions for the genetically modified strain of B. 
subtilis. Growing B. subtilis WB800N in MM increased transformation efficiency 3 fold 
(Table 5.1) compared to using the MD media protocol when plating 200 µL of the 
transformation mix. Transformation efficiency decreased upon addition of heterologous 
plasmid approximately 1.5 fold when using the MM protocol and nearly 3- fold when 
using the MD protocol. It was found that 3 µL of plasmid or ligation reaction gave 
optimal efficiency when plating 200 µL (Table 5.1). It was also determined that mutant 
strains of Bacillus subtilis are particularly sensitive to temperature alterations when put 
under the ‘stress’ of competence induction via starvation media and transformation 
[73] . When all steps of the process were carried out at 37°C optimal transformation was 
observed. However, if the bacteria were subject to temperature deviations from 37 °C, 
very few to zero colonies were observed after incubation (table 5.1). Therefore all 
subsequent transformations were carried out in constant temperature rooms at 37°C 
using the MM protocol described previously (Chapter 2.0). 
 
In order to test the hypothesis that the Gram positive host B. subtilis WB800N was 
better suited for expression of proteases from the gut metagenome, the ability of this 
strain to express characterised protease genes from both Gram negative and Gram 
positive organisms was tested against E. coli. The well characterised proteases; nprE 
(Bacillus subtilis strain 168), gelE (Enterococcus faecalis isolate from aerobic culture-
dependent study previously conducted in this research), lasB (Pseudomonas aeruginosa 
PAO1) were PCR amplified from DNA extracted from pure cultures of the relevant 
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microorgansisms including flanking DNA regions and restriction enzyme sites (see 
materials and methods; primer information). After cloning into pNZ44 the plasmids 
were transformed into B. subtilis WB800N and E. coli XL1 blue supercompetent cells 
(Agilent, Berkshire) transformants were picked into 96 wells plates using a Flexys® 
colony picking robot (Genomic Solutions) and also screened on LFSMA for protease 
activity. B. subtilis WB800N with pNZ44-nprE recapitulated a proteolytic phenotype as 
it did for pNZ44-gelE but no positive phenotype was observed for pNZ44-lasB. E. coli 
Xl1-blue expressed no signs of protease activity on LFSMA for any of the protease 
genes. The heterologous expression of gelE has been attempted in E. coli before [74, 75] 
with similar unsuccessful results and it has been hypothesised that E. coli cannot 
recognise the Gram positive signal sequence for protein secretion. This theory is further 
supported by the evidence that gelE has been successfully heterologously expressed not 
only in gelE deficient strains of E. faecalis, but also in alternative Gram positive hosts 
such as Lactococcus lactis, Streptococcus pyogenes [75] and now from this study; B. 
subtilis. Following sequence analysis of the translated gelE sequence in both hosts It 
was revealed that in B. subtilis WB800N the active sites and metal binding regions 
needed for protease activity were conserved with the amino acid gelE sequence of 
numerous strains of E. faecalis however E. coli had failed to express this region of the 
gene which may be an explanation for the lack of expression observed.  
 
Similarly, heterologous expression and secretion of the nprE gene has been successful in 
protease-deficient strains of Bacillus stearothermophilus and B. subtilis MT-1 [76] and 
now from this study, B. subtilis WB800N. Results from a previous study suggest that 
failure of E. coli to express nprE is due to the lytic effect of the gene product on the host 
cells [33] NprE has been successfully expressed in E. coli, but only upon removal of the 
ribosomal binding site [33] which would not be useful for a functional metagenomic 
screen. NprE has been successfully cloned into Lacotococcus lactis subsp. lactis [77] 
another Gram positive organism, eukaryotic microorganisms, namely Saccharomyces 
cerevisiae, have also been explored for the expression of proteases such as that encoded 
by nprE. However, it has been found that the eukaryotic host could not secrete nprE 
until manipulation of the sequence with a yeast invertase signal peptide [78] and 
although this resulted in successful secretion, the protein was still not active due to high 
glycosylation of the protein [78]. This suggests that perhaps eukaryotic hosts are not 
appropriate for FM screening of bacterial metagenomes specifically for protease activity 
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due to forms of post-translational modification. NprE in E. coli failed to express a 
protease phenotype and sequence analysis suggests that this may be due to the lacking 
translation of the metal binding regions of the amino acid sequence. This may also be a 
defence mechanism by the E. coli host to avoid self-lysis.  
 
When transformed with pNZ44-LasB neither hosts demonstrated a protease phenotype 
despite apparent amino acid sequence homology (figure 5.3). LasB has been 
successfully expressed in E. coli in a previous study [79].  However, it was found that 
LasB expression is dependent on several genes including an autoinducer [80] and a LasR 
positive regulatory gene [81]. This is the most likely expression explains the problem 
with expression in both hosts in this study. Other studies have also observed that E. coli 
was unable to secrete the active elastase protease into the extracellular medium, but 
upon cell lysis, protease activity was observed [82]. High levels of post translational 
modifications were also witnessed when lasB was cloned into Pichia pastoris, however, 
in this instance, glycosylation did not inhibit protease activity [83] suggesting perhaps a 
eukaryotic host is appropriate for proteases that require numerous genes for expression 
and activity. 
 
A metagenomic library was created in both surrogate hosts and screened for protease 
activity on LFSMA. It is estimated that proteases constitute 2-3% of the genomes of 
commensals [72] and ~ 5% of the genomes of pathogens [84]. Therefore large libraries 
are needed in order to ‘capture’ a protease gene. The isolation of proteases via FM 
techniques remains a challenge and to date, no proteases have been isolated from the 
human gut using these techniques. Unfortunately, this research was also unable to 
isolate proteases from the human gut microbiota. However, this research has highlighted 
some further issues and limitations with the techniques implemented which will 
significantly help to determine alternative strategies for improving screens in the future. 
Firstly, the fact that large libraries are needed for successful for FM screens is very 
apparent. This may go some way in explaining the lack of proteases isolated following 
screening on the FM library in this research. Especially considering in the few projects 
that have successfully isolated proteases that tens of thousands of clones were screened, 
for example Wichmann and colleagues [85] screened a library comprising over 6 million 
clones for antibiotic resistance genes and Jeon and [86] colleagues screened over 
600,000 clones to isolate genes encoding lipase enzymes. Specifically for FM studies 
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that have successfully isolated proteases, over tens of thousands of clones had to be 
screened. For examples Pushpam and co-workers [18] screened 70,000 clones to isolate 
1 protease clone and Waschowitz et al., [22] screened 80,000 clones to isolate two 
protease genes. Less than 30,000 clones, as is the case with this study, is likely not a 
large enough library to isolate proteases. The B. subtilis WB800N library in particular 
only harboured 9600 clones too and very few FM studies have ever isolated novel genes 
with this fewer clones. However, there was little that could be done with this factor as, 
although a successful transformation procedure was implemented the B. subtilis strain 
WB800N remained difficult to transform throughout the study, transformations often 
resulted in no colonies at all, and the transformation efficiency was very low. Other 
strains devoid of extracellular proteases may be more appropriate for FM screens for 
proteases circumventing the relatively inefficient transformation methods that had to be 
implemented here. For example, Nguygen and colleagues suggest Brevibacillus brevis 
as a suitable host for the expression of foreign proteins [45] and methodologies for 
expression of foreign protein have proven highly efficient [87]. However, the issue here 
cannot be definitively attributed to the hosts used for FM library construction. Instead, it 
is likely that the insert size of the library was just too small to capture protease genes 
which suggests that more efforts need to be implemented in order to ensure only large 
DNA fragments are ligated into the cloning vector. Introducing a size –dependent 
separation of DNA molecules procedure, such pulse field gel electrophoresis (PFGE) or 
size exclusion chromatography might ameliorate this issue.  
As previously discussed in Chapter 4.0, enrichment techniques may also be 
implemented to enhance the number of bacteria with the target metabolic trait. Future 
directions for unearthing these elusive enzymes may include such a strategy, for 
example, using faecal samples from animals with a high protein diet or to use samples 
from a population that is known to be high in proteolysis. In a proceeding chapter 
(Chapter 7.0) it has been found that protease activity with the gut is significantly higher 
in those suffering from IBD as well as diarrhoeic IBS [88, 89]. An interesting study 
conducted by Rampelli et al., [90] also revealed that there is an age-related increase in 
proteolytic activity within the gut microbiota and that Centenarians had a gut microbiota 
significantly enriched for proteolytic function. It could be hypothesised therefore, that 
this population offers an attractive target for obtaining samples for future FM library 
construction to screen for proteases. 
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A final discussion point here would be that perhaps more success would be had with a 
more direct method for mining for proteases such as that conducted by Purohit and 
colleagues  [29]. In this study, they were particularly interested in alkaline proteases of 
halophillic bacteria from saline habitats. They took a data mining strategy to PCR 
amplify proteases genes from DNA extracted from this habitat. The argument against 
such a strategy is the requirement of a significant amount of a priori knowledge in order 
to be able to develop degenerate primers and conduct PCR, and as a consequence, you 
can never get a gene that is truly novel. While this is true, FM techniques are also failing 
to isolate truly novel genes too, as described in Chapter 4.0. Purohit et al., did manage to 
isolate a protease gene that exhibited different characteristics to the proteases used to 
generate the primers [29] suggesting the techniques may work for isolating proteases 
with novel functions.  
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5.4 MATERIALS AND METHODS  
5.4.1 Culture-dependent analysis of protease-producing bacteria in the gut 
microbiota 
 
In order to identify proteolytic bacteria within the gut microbiota that we are able to 
cultivate, aerobic and anaerobic conditions were utilised to facilitate the growth of as 
many proteolytic organisms as possible. Faecal samples (1 g wet weight) from three 
individuals were serially diluted in sterile Ringer’s solution and dilutions were prepared 
up to 10
-8
. Dilutions for the aerobic culture were plated in triplicate onto LFSMA and 
observed after 12 hours and 24 hours incubation at 37 °C. For anaerobic culture, all 
procedures were conducted in a Gallenkamp anaerobic cabinet containing 10 % H2, 
10 % CO2 and 80% N2 atmosphere. LFSMA plates were preincubated in the anaerobic 
cabinet for 48 hours prior to inoculation. Anaerobic plates were incubated in the 
anaerobic cabinet for 7 days. Production of secreted proteases was indicated by zones of 
clearing around colonies. These colonies were selected and streaked to purity under their 
appropriate conditions to ensure recapitulation of the protease phenotype. Upon 
validation, freezer stocks of each isolate were prepared as described in the general 
methods section (Chapter 2.0). A chelex PCR to amplify the 16S rRNA gene was also 
performed on each isolate as described in the general methods chapter (section 2.5.3). 
The presence of amplified 16S rRNA gene was verified by gel electrophoresis using a 
1 % gel and visualisation with UV. Samples were purified using a QIAquick PCR clean-
up kit (Qiagen) according to the manufacturer’s instructions. The sequence of the16S 
rRNA from each isolate was carried out by Eurofins MWG Operon (Ebersberg, 
Germany) Sequences were compared against the BLAST database [91] and closest 
matches were recorded.
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5.4.2 Amplification of gelE, nprE and lasB by PCR 
In order to attempt to express characterised proteases from 3 microorganisms in E. coli 
and B. subtilis WB800N, the genes encoding the proteases were amplified by PCR. 
Firstly, each organism with the known protease (P. aeruginosa PAO1, E. faecalis isolate 
from this study and wild type B. subtilis MY16)  were grown on appropriate agar plates 
(see table 2.1 Chapter 2.0). DNA extractions were then performed as described in 
chapter 2.0 using the appropriate liquid media for each organism. PCR was performed to 
amplify gelE from E. faecalis, nprE from B. subtilis and lasB from P. aeruginosa. The 
primers are shown in table 5.4 and include restriction enzyme sequences used for 
cloning into pNZ44.  
 
Table 5.4. Primer sequences for amplification of gelE, lasB and nprE. The restriction 
enzyme sites are underlined and the particular enzyme is mentioned in brackets. The 
source of the primer is also mentioned although these sequences have different or no 
R.E sites. 
 
 
The amplification of gelE was conducted as described by Waters et al., [75]. Following 
extraction of  DNA the PCR was carried out in triplicate with the following conditions: 
initial denaturation at 94°C for 30 s, 55°C for 30 s, and 72°C for 2 min repeated 25 
times; and then 72°C for 30 s. The products (~1.5 kb) were pooled and purified using 
the QIAquick purification kit (Qiagen) according to their instructions.  
 
Target 
Primer 
name 
Primer Sequence Ref 
gelE gelE F 5’>GAACCATGGTAAGGAAGGAGTTAATTGTTTGATGAAG<3’ 
(NcoI) 
[75] 
gelE gelE R 5′>CTTCTGCAGTTTCATTCATTGACCAGAACAGATTC<3′ (PstI) [75] 
lasB lasB F 5′>CGCCATGGATGAAGAAGGTTTCTACGCTT<3 (NcoI) [83] 
lasB lasB R 5′>GCGCATGCTTACAACGCGCTCGG<3 (SphI) [83] 
nprE nprE F 5’>GCGGCTCCATGGCTCTTTATGCAA <3’ (NcoI) [78] 
nprE nprE R 5’>CAAAATAAAGTAGCATGCGCCGCCGCCAC<3’(sphI) [78] 
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Following DNA extraction from P. aeruginosa PAO1, the lasB was amplified based on 
the reaction outlined by Han and colleagues [83] the PCR was carried out in triplicate 
under the following conditions; initial denaturing at 96°C for 5 min; subsequent 25 
cycles of denaturing at 96°C for 40 s, annealing at 58°C for 30 s, and extension at 74°C 
for 2 min; and a final extension at 72°C for 5 min. The PCR products were analysed on 
a 1% (w/v) agarose gel by electrophoresis for the correct target band of ~1.5 kb in length 
[83]. The triplicate samples were again pooled and purified in preparation for the 
succeeding cloning steps. 
 
To amplify the nprE gene from the DNA extracted from B. subtilis MY2016 the PCR 
was also carried out in triplicate using the following conditions; 95°C for 2 min 
followed by 25 cycles of 94°C for 30s, 52°C for 30s, 72°C for 2 min and a final 
extension step of 72°C for 5 min. PCR products (~1.5 kb) were pooled and purified.  
 
Reactions for the amplification of all PCR products consisted of the same volumes and 
concentrations of PCR reagents as described in Chapter 2.0 (Section 2.5.3). 
 
5.4.3 Cloning and screening of gelE, nprE and lasB into pNZ44 
Following purification of PCR product, restriction digests with the appropriate enzyme 
(table 5.4) were performed on both the PCR product and purified pNZ44 to generate 
complementary sticky ends for efficient cloning. Plasmid and PCR product were 
purified once again and ligated at a 3:1 insert to vector ratio using T4 DNA ligase 
(Promega, Southampton, UK) according to the manufacturer’s instructions except with 
an overnight incubation at 14 °C for ligation to occur. The ligation mixture (5 µl) was 
used to transform E. coli XL1 blue and B. subtilis WB800N according to the 
transformation procedures described in Chapter 2.0 (section 2.7). The transformation 
mix (200 µl per plate) was plated onto TSA supplemented with the appropriate 
antibiotic and incubated overnight at 37 °C. Transformants were picked using a Flexys® 
colony picking robot (Genomic Solutions, Cambridgeshire, UK) or by hand if there 
were few transformants using sterile toothpicks into freshly prepared freezer broth (per 
Litre: 10 g tryptone, 5g yeast extract, 10g NaCl, 44 mL ultrapure glycerol, 1.8g 
KH2PO4, 6.7g K2HPO4, 0.5g Sodium Citrate, 0.9g (NH4)2SO4 adjust to pH 7.0 using 5N 
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NaOH and adjust the total volume to 1 L using dH2O. Sterilise by autoclaving and after 
cooling, add 400 µl 1M MgSO4) in 96-well plates. Duplicates of each plate were also 
prepared. The 96-well plates were used to inoculate LFSMA and following incubation, 
successful heterologous expression of the protease genes was indicated by the formation 
of clear halos around the colony. Triplicate positives and triplicate negative colonies 
were isolated and the plasmids were purified and restriction digests were performed to 
confirm an insert. Inserts were sub-cloned into the pGEM ®T-Easy vector and 
sequenced. Sequence analysis was conducted using NCBI BLASTn and BLASTp suites 
[91]. 
5.4.4 Metagenomic library construction and screening 
Faecal samples were collected (Chapter 2.0 section 2.3.1) and genomic DNA was 
extracted from the samples as described in Chapter 2,0 (section 2.4.2). Extracted DNA 
was checked by running on a 1 % (w/v) agarose gel supplemented with 1 µg/mL 
safeview. DNA was subject to partial digest as described in chapter 2.0 (Section 2.5.1) 
(Supplementary figure 5.1) and DNA of the appropriate size (3-10 kb) (supplementary 
materials figure 5.2) was extracted using a QIAquick gel extraction kit (Qiagen) 
according to the manufacturers’ instructions. pNZ44 was extracted as previously 
described (Chapter 2.0, 2.2.1) and digested (2.5.2). Digested plasmid (supplementary 
figure 5.2) was purified once again and ligated with digested gDNA (1-10 kb) at a 3:1 
insert to vector ratio using T4 DNA ligase (Promega) according to the manufacturer’s 
instructions except with an overnight incubation at 14 °C for ligation to occur. The 
ligation mixture (5 µl) was used to transform E. coli XL1 blue and B. subtilis WB800N 
according to the transformation procedures described in Chapter 2.0 (section 2.7). The 
transformation mix (200 µl per plate) was plated onto TSA supplemented with the 
appropriate antibiotic and incubated overnight at 37 °C. Transformants were picked 
using a Flexys® robot (Genomic solutions) or by hand into freshly prepared freezer in 
96-well plates. Duplicates of each plate were also prepared. The 96-well plates were 
used to inoculate LFSMA to screen for protease activity. 
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5.6 SUPPLEMENTARY MATERIAL  
 
5.6.1 ‘Paris’ medium protocol for B. subtilis WB800N transformation 
Inoculate 50ml MG1 medium (per 50 mL; 0.5ml casamino acids (2% (w/v)); L-
tryptophan to 50 μg/mL) with a fresh colony of B. subtilis WB800N in a 250 mL 
Erlenmeyer flask and adjust the OD650 to ~ 0.7. Incubate the culture for 3 hrs at 37 °C 
with shaking at 200 rpm. Dilute the culture 10-fold using 50 mL pre-warmed MG2 
medium ( per 100 mL; 0.5 mL casamino acids and 10 µg/mL L-tryptophan) and 
incubate for a further 90 min. To freeze competent cells pellet the cells by 
centrifugtation at 5000 g for 5 min at 20 °C. Remove the supernatant and mix it with 8.5 
% (v/v) glycerol and 0.5% (w/v) glucose. Immerse a micorcentrifuge tube in liquid 
nitrogen and resuspend the cell pellets in the supernatant-glycerol-glucose mixture. 
Aliquot the suspension into the microcentrifuge tubes and store at – 80 °C. To transform 
the cells, thaw an aliquot of cells quickly in a 37 °C water bath and dilute 10-fold in 
transformation buffer (2 mL (MM x5 media: per litre:(NH4)2SO4, 10g; K2HPO4, 
74g; KH2PO4, 27g; trisodium citrate) 0.2mL 1 M MgCl2 0.25 mL 20 % w/v glucose 
0.1 mL 0.1 M EGTA and H2O to 10 mL) with gentle mixing. Add 100 µL diluted cells 
to 1-10 µL plasmid (up to 1 µg) and incubate for 20 min at 37 °C with no shaking. Add 
500 µL of LB medium and incubate for 1.5 hrs at 37 °C with shaking at 150 rpm and 
plate transformants on selective media. 
 
5.6.2 Spizizens protocol for B. subtilis WB800N transformation 
Inoculate B. subtilis WB800N, which has been growing for a few days, in 5 mL HS 
medium (10 mL 10 X spizizens salts: per Litre 20 g (NH4)2SO4, 140 g  K2HPO4, 60 g 
KH2PO4, 1 g sodium citrate, make up to 1 L with ddH2O and autoclave and add 0.1 mL 
1 M MgSO4. 2.5 mL 20 % w/v glucose, 5 mL 0.1 % w/v L-tryptophane, 1 mL 2 % w/v 
casein hydrolysate,5 mL 10% w/v yeast extract, 10 mL 0.4 % histidine and 0.1 mL 2 % 
ferric ammonium citrate and make up to 100 mL with ddH2O) and incubate at 37 °C 
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with shaking at 150 rpm for 16 hours. Inoculate fresh HS medium (50 mL) with 0. 5 mL 
of the overnight culture and shake at 37 °C at 200 rpm and monitor the culture using 
OD650 until the culture enters early stationary phase (usually 4-5 hours). After such time, 
inoculate 20 mL starvation medium (10 mL 10 x Spizizens salts, 2.5 mL 20 % w/v 
glucose, 0.5 mL 0.1 % w/v L-tryptophan, 0.5 mL 0.2 % casein hydrolysate, 5 mL 2 % 
w/v yeast extract, 0.25 mL 1 M MgCl2 and 0.05 mL 1 M CaCl2 and make up to 100 mL 
with ddH2O and autoclave) with 1 mL cells and incubate at 30 °C with shaking at 100 
rpm for 2 hrs. Add 10 µM 0.1 M EGTA and incubate for 5 min at room temperature. 
Add up to 1 µg plasmid and incubate for 2 hrs at 37 °C while shaking at 150 rpm. After 
incubation, plate transformants on selective media.  
5.6.3 MD Medium protocol for B. subtilis WB800N transformation 
Prepare MD medium with 10 X PC (per Litre: 107 g K2HPO4,60 g KH2PO4, 10g Na3 
citrate.5H2O and 8.5 g Na3.2H2O) and add 5 mL to MD medium ( per 50 mL: 2.5 mL 
40% w/v glucose, 1.25 mL 2 mg/mL L-tryptophan, 250 µL 2.2 mg/mL ferric 
ammonium citrate, 2.5 mL 50 mg/mL L-aspartate, 150 µL1M MgSO4 make up to 50 mL 
with ddH2O and pH to 7.0 with KOH and filter sterilise). Add MD medium (10 mL) to a 
sterile 250 mL flask and supplement with 50 µL 20% (w/v) casamino acids. Store the 
remaining MD medium at 37 °C. Inoculate the flask of MD with a small loopful of 
freshly streaked B. subtilis WB800N. Incubate the culture at 37 °C with vigorous 
shaking until the OD600 reaches 1-1.5. To induce competence, add MD medium (10 mL) 
lacking casamino acids and shake at 37 °C for a further 1 hr. Add competent cells (800 
µL) to up to 1 µg/mL plasmid and shake at 37 °C for 20 min and add 25 µL casamino 
acids (20% w/v). Shake at 37 °C for 1 hr and plate on selective media. 
5.6.4 Electrotransformation protocol of B. subtilis WB800N 
Electrotransfomation of B. subtilis WB800N was attempted using the protocol as 
described by Xue et al., [92]. Briefly, an overnight culture of B. subtilis WB800N grown 
in LB medium supplement with 0.5 M sorbitol was diluted 16-fold into fresh LB-
sorbitol medium and incubated at 37 °C with shaking at 250 rpm until the culture 
reached an optical density of 0.85-0.95 (OD 600). Cells were incubated on ice for 10 min 
and centrifuged at 4,000 g for 5 min at 4 °C and washed four times in ice-cold 
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electroprotation medium (0.5 M sorbitol, 0.5 M Mannitol, 10 % (v/v) glycerol). After 
washing, cells were suspended in 1/40 of the starting culture volume with cold 
electroporation medium. Plasmid DNA (>50 ng was added to 60 µL of cells in a cooled 
electroporation cuvette (0.2 cm-gap, Bio-rad Laboratories, Ltd, Herts, UK and kept on 
ice for 1 min. An electrical pulse was applied to the cells using a Bio-rad Gene Pulser 
electroporation unit (Bio-rad) at 1.6 kV, 200 Ω resistance and 25 µF capacitance. 
Recovery medium (LB with 0.5 M sortbitol, 0.38 M Mannitol) was added to the cells 
after electroporation and the mixture was transferred to 15 mL falcon tubes (VWR) and 
incubated at 37 °C with shaking at 200 rpm for 3 hours before plating on selective media 
and overnight incubation. 
5.6.5 Plasmid (pNZ44) digest 
pNZ44 was routinely digested with NcoI or SphI restriction enzymes. To ensure plasmid 
had been efficiently digested, product was run on a 0.8 % w/v agarose gel alongside a 2-
log DNA ladder (NEB). Linearised plasmid should have been ~ 3 kb in size. 
 
 
Figure S 5.1 A; non-digested (circular) pNZ44, B; plasmid digested with NcoI 
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5.6.6 Genomic DNA partial digest 
After DNA extraction from faecal samples, gDNA was partially digested with FatI or 
NIaIII. Fragments of 3-10kb were cut out of the gel and purified. 
 
 
Figure S 5.2 Partial digest of gDNA using FatI 4 cutter restriction enzyme. DNA 
fragments of size 3-10kb were excised from the gel using a sterile scalpel and prepared 
for succeeding FM library construction steps. 
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6.0 THE EFFECT OF STORAGE CONDITIONS ON THE 
REPRODUCIBILTIY OF PROTEIN CONCENTRATION AND 
PROTEASES FOR ANALYSIS OF THE FAECAL MICROBIOTA 
6.1 INTRODUCTION 
The human gut harbours microorganisms whose collective genomes out numbers our 
own by at least 100 to 1 genes [1]. The implementation of ‘omic’ based technologies, in 
particular, metagenomics have hugely advanced our understanding of the human gut, 
and have allowed the elucidation of the core, broad adaptive functions of the gut 
microbiota For example, Qin and colleagues defined the minimal gut metagenome and 
unearthed core species that were indicative of a healthy gut [2] Gloux and colleagues 
implemented a functional metagenomic approach to study β-glucuronidase activity in 
the human gut microbiota and revealed a class of β-glucuronidase enzymes that were 
specific to species of the gut suggesting these enzymes were part of a functional core 
and had adapted specifically for life in the human gut [3]. Similarly, Jones and 
colleagues implemented a functional metagenomic approach to screen the human gut 
metagenome for bile salt hydrolases (BSH). Functional BSH were identified in all major 
divisions of bacteria and it was deduced that BSH activity appeared to be a conserved 
adaptation to life in the human gut [4]. However the implications of such functions in 
specific bacteria and their specific interaction with host cells in homeostasis or in the 
development of disease are far from being understood. Consequently a coupling of a 
variety of experimental approaches is required to elucidate these functions and 
interactions, including functional metagenomics, deep sequencing approaches and 
importantly function-based assay. Studying the specific functions of bacterial molecules 
and enzymes, behaving as they would in their normal environment, may give us a much 
better understanding of what the genes identified using the powerful deep-sequencing 
based techniques, are actually capable of conducting. Pathogens have been identified 
and dealt with by understanding and isolating the molecules and their mechanisms of 
their interaction with our cells that consequently contribute to pathogenesis. By this 
strategy we have tried to develop novel ways to combat the pathogen.  Therefore 
perhaps it is fair to say that a more directed function based analysis of microbial 
functions (i.e. not just sequence-based analysis alone) would be a key step in unravelling 
the role of the gut microbiota in health and disease [5]. 
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Faecal samples are often used as a surrogate for the gut microbiota [6] and offer a non-
invasive, cost-effective and repeatable means of accessing the gut microbiota from both 
humans and animals. The use of faecal samples in pinnacle projects such as that 
conducted by Eckburg et al., [6] on the human large intestine have provided a wealth of 
information regarding the gut microbiota. Information generated from Eckburg’s study 
has shown that mucosa-associated bacterial communities, isolated from different 
positions along the human gut, and faecal samples, do differ from each other within 
individuals. UniFrac analysis revealed a distinct clustering of the data between mucosal 
and faecal samples within an individual compared to between different individuals. The 
insights gained from this study clearly indicate that faecal samples can be used as an 
easy, safe and reputable proxy for describing both intra- and inter-personal differences 
in the gut microbiota composition and function [7]. 
 
Arguably one of the most important steps in metagenomic studies is that of the isolation 
of DNA to obtain a non-bias representation of the microbiota in that particular sample. 
Optimal methods for DNA extractions to confer the best yield, high quality, large 
fragment size and unbiased DNA that is representative of the entire microbiota [8] have 
been studied in depth and these processed have been discussed at length in Chapter 5.0 
(and for more information please see [8-12]). Long term storage of DNA extracted from 
faecal samples as well as other environments have also been extensively studied [13-15]. 
For example Lauber et al., used barcoded pyrosequencing to assess the stability of the 
gut microbial community using 16S rRNA gene analysis from faecal samples stored at 
20°C, 4°C -20°C and -80°C for 3 and 14 days. They concluded that microbial 
communities were not significantly affected by storage temperature or duration [16] 
Carrol et al., took this further by conducting a comprehensive analysis of the stability of 
the human gut microbiota using 454 pyrosequencing from DNA sample stored at room 
temperature for 24 hours and after storage at -80 °C for 6 months having also 
determined the microbial community structure as immediate as possible to DNA 
extraction to determine whether there could be an immediate loss in certain faecal 
bacteria before the sample was processed. It was however, concluded that samples did 
not significantly change after storage in both conditions suggesting that the microbiota 
was retained and there was no significant loss in diversity [17]. An abundance of 
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research has been conducted in this area, and it is generally considered that DNA sample 
and other enzymes are best kept at sub-zero temperatures. 
 
As the frequency of metaproteomic studies increases, as does the necessity to develop 
optimal protein extraction methods [18-20]. However, proteins can exist in many 
different biological forms, even if isolated from the same environment and so 
developing a general extraction method for proteins is particularly difficult [21]. 
Additionally, protein samples for metaproteomics often do not need to maintain their 
function, whereas clearly in activity-bases studies, this is of paramount importance.  
 
The use of faecal samples, from both human and animal subjects, to obtain DNA and 
enzymatic functions has been proven to be an extremely useful and invaluable tool for 
studying the functions of the gut microbiota. The direct study of microbial functions 
such as specific enzyme activities as they behave in their natural environment may also 
be of significant use in furthering our understanding of microbe-host interactions. 
Studies on the functional activity or levels of certain cells, protein/enzymes, hormones 
etc. has provided invaluable insights into the broad areas of gut health, disease aetiology 
and disease pathogenesis. For example, there are a number of measurable faecal 
biomarkers for intestinal inflammation such as calprotectin [22] and lipocalin 2 [23]. 
Faecal hormones (such as glucocorticoids) levels can be used to monitor stress in 
animals [24]. Monitoring faecal microbial enzymes activities such as that of beta-
glucuronidase and beta-glucosidase have helped to show how diet can change 
physiological activities of the gut. Freeman and colleagues showed that dietary fibre 
decreased faecal beta-glucosidase activity which appeared to have a protective role 
against the development of experimental colitis in a rat model of colon cancer [25]. 
Similarly, Flores et al., observed bacterial taxonomic correlations with decreased or 
increased levels of beta-glururonidase and beta-glucosidase demonstrating how 
alterations in the gut microbiota also alters their overall functional capacity and this has 
implications on host gut health. 
 
A number of studies have focused on carbohydrate metabolising functions of the gut 
microbiota, however, the gut harbours an expanse of other molecules both endogenous 
and dietary. The degradation of such molecules by the host ,and by the gut microbiota, 
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particularly the consequences of degradation regarding host health, remain relatively 
unexplored. Macfarlane and colleagues hypothesised that as large quantities of soluble 
protein, ammonia and volatile fatty acids had been found in the large intestine, that 
proteolysis must be occurring at substantial levels in the gut [18]. Their culture 
dependent study and a culture dependent study conducted previously as part of this 
thesis (please see Chapter 5.0) on the bacterial contribution to proteolysis in the large 
intestine identified, several proteolytic species of bacteria isolated form the human gut, 
including Bacteroides vulgatus, B. fragilis, B thetaiotaomicron, spp. Propionibacterium 
spp. Streptococcus spp and Staphylococcus spp. as well as Enterococcus faecalis and 
Bifidobacterium spp. demonstrating the bacteria are likely to be significantly 
contributing to proteolysis in the gut. A comparison of faecal protease activity before 
and after bacterial cell disruption has also shown an increase in protease activity 
indicating large quantities of proteases are released by bacteria in the gut [26]. 
 
Digestion of dietary protein leads to an array of end products including short chain fatty 
acids, amines, phenols, indoles and thiols; some of these compounds have been shown 
to have toxic properties [27] and have been implicated in diseases of the gut including 
Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) [28]. Protein 
degradation by microorganisms in the human gut has also been linked with colon cancer 
[29] and specific bacterial proteases have been shown to influence invasiveness of colon 
tumour cells [30] and may be directly linked to progressing the cancer [31].  
 
Microbial proteases represent approximately 5% of the genomes of infectious organisms 
[32] and approximately 2% of the genomes of commensal [33] and their contribution to 
disorders of the human gut are discussed at length in chapter 7.0.Proteolytic activities 
have been studied by direct methods extensively by labs such as Macfarlane and 
colleagues and have given us valuable insights into functionality of the healthy gut [18] 
and to some extent, on the unhealthy gut [28]. Most studies on proteases and how they 
may be impacting the host are carried out on pure cultures of specifically chosen 
microorganisms which may not actually be numerically dominant in the gut [34-36]. 
While these studies are incredibly insightful, and demonstrate how significant microbial 
proteases and their interactions with host cells are, it is also useful to study enzymatic 
functions as a separate entity i.e.  proteases, or as a collective; the degradome, as they 
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are found in a particular environment at any one time point. Stool samples offer this 
non-invasive insight into proteolytic activity of the human gut microbiota as it may be 
occurring in situ.  
 
Some of the major aims of this thesis was to conduct a comprehensive comparison of 
faecal protease activity in a cohort of IBD patients compared to healthy volunteers with 
the hypothesis that proteases may be acting as virulence factors in IBD, or protein 
degradation by the gut microbiota in IBD patients maybe indirectly contributing to gut 
inflammation through a variety of pathways and different substrate metabolism (Chapter 
7.0). However, to give a comprehensive and non-bias insight, all the analysis cannot be 
carried out after fresh extractions from fresh stool samples. Therefore, prior to 
embarking on a study of specific enzyme activity and it’s clinical significance certain 
parameters have to be optimised to minimise variability in results [5]. As previously 
mentioned a substantial amount of work has been conducted on DNA and increasing 
amount of protein for proteomics. However, optimal methods for extraction of enzymes 
from faecal samples, and their reproducibility after long term storage remains relatively 
ignored. Well established protein storage methods often involve the irreversible 
inhibition or denaturation of proteases to prevent proteolytic degradation of protein that 
do not require a functionally active protein. Studies are often focused on obtaining the 
best yield and purity and while purity and yield are important here, the protein still 
needs to be intact and fully functioning, hopefully as they would be in situ. 
 
The parameters that may give variable results first need to be identified and controlled to 
ensure that results are reputable. It is widely known that maintaining protein for 
extended periods of time can cause stability issues. Protein becomes susceptible to 
denaturation and alterations upon extraction; there are many effects that can cause a 
protein to become denatured and thus cause a protein extract to decrease dramatically in 
concentration. Such factors include dramatic changes in temperature, repeat freeze thaw 
cycles, contamination and the activity of proteases. Temperature changes can cause 
denaturation by disrupting the secondary and tertiary structure of proteins, while 
disruption of protein structure is normally considered a result of temperature increase 
whereby hydrogen bonds and hydrophobic interactions are disrupted, which is why it is 
more useful to maintain a protein sample, purified or mixed at cooler temperatures. 
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Contamination is also an issue, therefore normally some form of antimicrobial agent 
such as sodium azide (NaN3) is added, but care must be taken that this does not affect 
the protein’s activity. For long term storage of protein extracts some sort of 
cryoprotectant such as glycerol has to be added at concentrations of 10-50% (v/v) and 
samples should be frozen and thawed as quickly as possible to avoid denaturation of 
protein. Reducing agents such as Dithiothreitol (DTT) may also be added to prevent 
oxidation of cysteine as the thiol group of cysteine is highly reactive. 
 
In this study, buffers where designed so as not to interfere with protein concentration 
measurements (purified bovine serum albumin ,BSA, is often added to protein samples 
for increased stability and to prevent binding to the storage vessel, however in this 
instance, BSA would then alter protein concentration estimations so could not be 
added). Protease activity was assessed following long term storage of a crude protein 
extract from human faecal samples. Alterations in protein concentration were also 
monitored as well as the effect of repeated freeze-thaw cycles was determined with an 
aim to specifically study faecal protease activity levels following various lengths of 
storage. The effect of the long term storage of whole faecal specimens as a means of 
accessing the faecal degradome after long periods of storage was also determined.   
 
Unfortunately, the principles that must be applied for storage of basic protein extracts 
cannot be adhered to in a study where the sole purpose is to assess protease activity. For 
example, many standard protein storage practices involve addition of a protease 
inhibitor cocktail to prevent degradation of protein. Obviously, a protease inhibitor 
cannot be added to a sample in which the proteases themselves are of sole interest, so it 
will have to be taken into account that there may be some degradation of sample protein 
by endogenous proteases. Also, any compounds that may affect protein concentration 
measurements (e.g. BSA is often added to stabilise protein solutions) could not be used 
as this would introduce biases in subsequent assays.  
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AIMS 
 
Previous research documented here (Chapter 5.0) has focused on the use of DNA and 
metagenomics techniques to study the proteolytic potential of the gut microbiota 
however it has become apparent that functional analysis is also necessary. The overall 
aim was to determine what happens to protease activity when faecal samples are stored 
to enable effective and consistent studies of the gut microbiota degradome (Chapter 7.0) 
and this was achieved by a series of sub-aims which were as follows: 
 
1. Determine how bead beating affects protein recovery from faecal samples. 
 
2. Determine whether the preservative, sodium azide (NaN3), has any impact on 
protein extraction or protease activity. 
 
3. Determine how PBS with a variety of additives such as glycerol and DTT affects  
protein concentration and protease enzyme  extracted from a faecal samples 
during long-term storage. 
 
4. Assess whether storing whole faecal samples at sub-zero temperatures allows 
reproducible measurements of protein concentration and protease activity for use 
in future experiments. 
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6.2 RESULTS 
6.2.1 Effect of number of bead beatings on protease activity 
The effect of the number of bead beating steps on protease activity are shown in figure 
6.2.1 Results represent the mean ± S.E.M of triplicate results  from participants (n = 3).  
Protein concentration became significantly different after 3, 4, 5 and 6 bead beating 
steps (figure 6.2.1, P < 0.05) when compared to activity after one beating. Protease 
activity was also significantly higher after 3 beatings when compared to 2 beatings 
however no difference was observed after 4, 5 and 6 beatings compared to 2 beatings 
suggesting that more than 3 beatings may be deleterious to protease activity.
 
Figure 6.2.1 A boxplot of the mean of triplicate data + standard error of the means. 
Statistical significance was determined by non-parametric multiple comparison testing 
using a Holm adjustment method to control for family wise error rate. Significantly 
higher protease activity was observed after 3, 4, 5 and 6 rounds of bead beating (P = 
0.0065, 0.0196, 0.0430 and 0.0639 respectively) when compared to 1 round of bead 
beating. Significantly higher activity was also observed after 3 beats compare to 2 beats 
(P= 0.0377). 
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6.2.2 Effect of NaN3 on protease activity 
The effect of sodium azide on protein concentration after extraction and protease 
activity was determined by conducting an azo-casein hydrolysis assay from a normalised 
input of protein (1 mg/mL). To remove bias from differences in protease activity 
between individuals, % relative activity was calculated separately for each sample based 
on 100% activity being the hydrolysis of azo-casein after double the incubation time (4 
hours). Data was found to be normally distributed and statistical significance was 
determined by the student’s t- test in R software. 
 
No significant difference found between protease activity (figure 6.2.2) when NaN3 was 
used and when it was absent. Suggesting it does not affect these measurements at this 
concentration and so can be used in a buffer to store proteases as an antimicrobial agent. 
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Figure 6.2.2 Effect of 0.05% NaN3 on protease activity.  Centre lines show the medians; 
box limits indicate the 25th and 75th percentiles as determined by R software; whiskers 
extend 1.5 times the interquartile range from the 25th and 75th percentiles. Statistical 
significance was determined by the student's t-test. (P>0.05) 
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6.2.3 Stability of protein concentration and protease activity of faecal protein 
extract over time 
To monitor the reproducibility of protein concentration estimates after extraction and 
storage over time, a crude protein extract was prepared from fresh faecal samples from 3 
individuals as described in methods. Protein concentration measurements were recorded 
by Bicinchoninic acid assay (BCA) assay after fresh extraction, 24 hours of storage in 
each buffer and following measurements at 1 week, 1 month, 6 months and finally 1 
year. As protein concentrations are diverse according to different individuals, in order to 
be able to compare the data as a cohort, the % decrease in protein concentration was 
calculated for each samples compared to the protein concentration measurement taken 
after the initial extraction. The resultant data was used to determine whether there was a 
significant correlation between the level of % change in protein concentration and the 
duration of storage and the original data can be observed in supplementary materials 
(figure S1). Firstly, non-parametric correlation analysis was implemented to determine 
whether there was a statistically significant correlation and non-parametric pairwise 
comparisons using the Mann Whitney –U test were conducted in R to elucidate the 
impact of length of storage and buffer type on protein concentration estimates. All 
samples exhibited a significant correlation between decrease in protein concentration 
and storage time, regardless of buffer type displayed by the results of the spearman rank 
correlation coefficient (rho)(figure 6.2.3 A and B) which was conducted to determine if 
there was correlation between the two variables (length of storage and protein 
concentration or protease activity). Both the extracellular and total protein extracts 
stored in buffer 1 displayed a significant % decrease in protein concentration after 1 
week of storage at -20 °C (P =<0.003 for both). Total protein extract stored in buffer 2 
showed a significant % decrease in protein after 1 month (P<0.002) and extracellular 
protein stored in buffer 2 showed a significant % change in protein concentration after 3 
months (P < 0.004). 
 
To determine the stability of faecal proteases isolated after crude protein extraction over 
time following extraction in, and subsequent storage in two different buffer 
compositions, protease activity measurements were conducted using a colorimetric azo-
casein substrate with 100 µl of protein sample which had been diluted to 1 mg/mL. It 
was observed that different individual’s display various levels of protease activity and so 
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in order to be able to compare the data as a cohort, the % change in protease activity 
over time was calculated for each samples compared to the protein concentration 
measurement taken after initial extraction. The resultant data was used to determine 
whether there was a significant correlation between the level of % change in protease 
activity and the duration of storage. Firstly non-parametric correlation analysis was 
implemented to determine whether there was a statistically significant correlation 
between length of storage and protease activity and then non-parametric pairwise 
comparisons were conducted in R to elucidate the impact of length of storage on 
protease activity and also whether the different buffers showed differences in their 
ability to maintain protease activity. 
 
All samples demonstrated a significant correlation between length of storage and the % 
change in protease activity as demonstrated by the spearman rank correlation coefficient 
calculated (figure 6.2.3 C and D) suggesting that protease activity in all samples was 
affected deleteriously by the length of storage. Total protein stored in buffer 1 and buffer 
2 displayed a significant decrease in protease activity after 1 week of storage (P = 
0.0032 and P = 0.0034 respectively) whereas the extracellular protein protease activity 
displayed more stable protease activity which only began to show significant changes 
after 1 month of storage in buffer 1 (P = 0.00424) and after 3 months of storage when 
stored in buffer 2 (P = 0.00379). These data indicate that both buffers are only 
appropriate for storing total protein isolated from faecal samples for a short period of 
time (1 week) before they begin to show changes from their original activity and 
therefore further function-based analyses on these samples would not be reputable. 
Extracellular proteases appear to be more stable in these buffers. 
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from previous page  
Figure 6.2.3. A= the relationship between length of storage and the % decrease in 
protein concentrations of crude protein extract after bead beating (total protein) in two 
different buffers; blue=buffer 2 and pink = buffer 1. B = decrease in extracellular protein 
after storage. C=The relationship between length of storage and the % decrease in 
protease activity in total protein samples stored in the two different buffer and 
normalised to 1 mg/mL. D= Extracellular protein protease activity. Centre lines show 
the medians; box limits indicate the 25th and 75th percentiles as determined by R 
software; whiskers extend 1.5 times the interquartile range from the 25th and 75th 
percentiles, outliers are represented by dots. n = 9 sample points. 
 
 
6.2.4 The effect of freezing temperature of whole faecal samples and reproducibilty 
of protein concentration and protease acitivity 
Protein concentration was not affected by length of storage for any of the samples 
collected from the three different individuals (figure 6.2.4) nor was it affected by storage 
temperature suggesting that faecal protein remains stable when frozen as part of the 
original biologcal sample at sub-zero temperatures. 2/3 samples displayed no signifciant 
alterations in protease acitivty following normalisation to 1 mg/mL protein over the 
entire period of the study at both of the storage temperature (figure 6.2.5, A and C), 
however samples collected from individual 2 exhibited a significant change in 
proteolytic activity follwing three months of storage at both sub-zero temperatures 
(figure 6.2.5, B). 
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from previous page  
Figure 6.2.4 Effect of freezing temperature of whole faecal sample protein 
concentration estimates 
The effect of freezing temperature and the length of storage on whole faecal samples 
and their protein concentration. Boxplots indicate the results of triplicate data, Centre 
lines show the medians; box limits indicate the 25th and 75th percentiles as determined 
by R software; whiskers extend 1.5 times the interquartile range from the 25th and 75th 
percentiles. The data were analysed by Wilcoxon signed ranked tests in R software to 
assess whether protein concentration deviated from the concentration measured upon 
fresh extraction.  
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from previous page  
Figure 6.2.5 Relative protease activity (%) after protein extraction of faecal 
samples stored for one year at -20 °C and -80°C. The effect of both freezing 
temperature and the duration of storage of faecal samples on protease activity after 
normalisation to 1 mg/mL protein following protein estimations. Boxplots indicate the 
results of triplicate data, centre lines show the medians; box limits indicate the 25th and 
75th percentiles as determined by R software; whiskers extend 1.5 times the interquartile 
range from the 25th and 75th percentiles. % relative activity was determined using 1 
mg/ml proteinase k incubated with the same substrate for 2 hours. The data were 
analysed by Wilcoxon signed ranked tests in R software to assess whether protease 
activity deviated from the activity measured upon fresh extraction. The time at which 
activates became significantly different to original activity (fresh samples) are indicated 
along with their respective P-values. 
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 6.3 DISCUSSION  
 
The Gut microbiota has an enormous diversity in terms of both phylogeny and 
functionality [6, 37], therefore a diverse array of techniques including’-omic’ 
approaches as well as function-based assays need to be implemented if we are to fully 
understand the impact they are having on us, as their hosts. However, as highlighted by 
work such as that by Flores and colleagues in their study of the reproducibility of β-
glucuronidase and β-glucosidase enzymes in faecal samples after extraction and storage 
[5, 38], researchers cannot begin a study without first assessing the parameters that may 
be affecting the gut microbiota and the molecules they produce that may be under 
scrutiny in a particular study. Results should also be reputable and a normalisation of the 
way certain samples are stored for particular studies is required to reduce bias and to 
allow for comparison of studies across different research laboratories. 
 
An ultimate aim of this research is to assess proteolysis in the human gut my 
implementing novel tools to comprehensively analyse faecal protein samples for general 
protease activity and specific protease activity (Chapter 7). However, it is impossible to 
carry out these comprehensive analyses immediately on fresh protein extract. Therefore, 
before embarking on such research, certain parameters have to be met to try to minimise 
bias and to ensure future results are robust. In this chapter, the aim was to assess the 
stability of protein extracts isolated from faecal samples over time and to deduce which 
buffer composition, and whether freezing faecal specimens before processing, was 
appropriate for maintaining protein stability with an overall objective of maintaining the 
stability of the proteases within the sample since there are no ways of isolating unknown 
proteases from complex samples, such as human faeces as of yet. Due to the aims of this 
study, this meant that there could be no component of the buffer that would affect 
protein measurements nor inhibit or enhance potential protease activity. Therefore, the 
composition of the buffer could not include carrier proteins such as BSA which 
normally ameliorates the problem of low-level binding to storage vessels, metal 
chelators such as EDTA as this could affect the activity of some proteases, protease 
inhibitors because firstly they themselves are proteins and secondly, they will inhibit the 
activity of the proteases present, the prominent aspect of this study. It was also found 
that the reducing agent dithiothreitol (DTT), which prevents oxidation of cysteines, 
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severely skewed the protein concentration measurements so could not be used for 
further experimentation. Consequently, it was decided that the final buffer compositions 
to compare would be simply PBS supplemented with 0.05% (w/v) NaN3 (buffer 1 
compared to a 20% glycerol-PBS buffer also supplemented with 0.05% (w/v) NaN3 
(buffer 2). NaN3 is a potent antimicrobial and so it’s inclusion in the buffer was essential 
for activity as a broad spectrum anti-microbial to prevent microbial contamination of 
faecal protein extract. It was shown that NaN3 did not interfere with protease activity of 
the samples (Figure 6.2.2) and was successful in preventing microbial contamination 
evidenced by plating faecal protein extracts on to nutrient rich media and no bacterial 
growth occurring.Therefore it was concluded that NaN3 was a useful component of a 
buffer for storage and maintenance of protease enzymes extracts in a complex biological 
sample. 
 
The number of bead beating steps for optimal protein extraction was deduced by bead 
beating a sample from 1 to 6 times. The protein concentration and protease activity were 
measured for each of the bead beating samples and it was deduced that 3 bead beating 
steps was adequate to get maximum protein out of a sample without the addition of lysis 
enabling buffers (figure 6.2.1). 
 
Buffer 1 and buffer 2 were compared over a period of 1 year with protein concentration 
and protease activity recorded immediately upon extraction, after 24 hours stored at -
20°C and then after 1 week, 1 month, 3 months 6 months and finally 1 year to determine 
their expediency as buffers for protease storage. Following protein concentration 
measurements, protein concentrations were normalised to the same concentration for 
protease activity measurement. All samples in both buffers exhibited a negative 
correlation between both protein concentration and protease activity over time (figure 
6.2.2) and no sample displayed repeatable protein levels or protease activity after 1 year 
nor 6 months of storage suggesting it would not be advisable to use either buffer for 
long term storage of protein extract for protease based studies. Assessment of shorter 
term storage revealed that after 1 week of storage total protein extract began to 
significantly decrease in concentration in both buffers, but extracellular protein 
remained more stable for 1 month in buffer 1 and 3 months in buffer 2 suggesting that 
buffer 2 was more suitable for longer term storage of extracellular protein but also that 
extracellular proteins are more stable than intracellular proteins perhaps because 
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proteins that are secreted from cells are adapted to the harsher, less controlled 
environment of the gut lumen. 
 
The observed decrease in protein concentration is likely due to repeated freeze-thaw 
cycles, low-level binding to the storage tube and probably proteolytic degradation by 
proteases within the sample. The bicinchoninic acid solution for the assay contains a 
water soluble compound containing; bicinchoninc acid, sodium carbonate, sodium 
bicarbonate, sodium tartate and cupric sulphate pentahydrate and works in an alkaline 
environment. Peptide bonds in protein in the sample reduce ions (Cu
2+
) in the cupric 
sulphate to Cu
+
 which form a purple complex with the Bicinchoninic acid salt [39]. 
When the protein samples increase in temperatures it is likely that the proteases present 
will also be contributing to the decrease in protein concentration by hydrolysis of the 
peptide bond, thus destroying protein and fewer peptide bonds, the fewer reduce cupric 
ions and so a decrease in in intensity of the purple compound as fewer cupric ions are 
available to bind the bicinchoninic acid salt. Protease activity however, was also 
diminished in all samples over the period of a year, in fact, protease activity from the 
total protein extracted began to deteriorate after just 1 week of storage. The most likely 
cause of this drop in activity is the loss of their native structure due to denaturation due 
to the freeze-thaw cycles and sub-zero temperatures can also affect protein structure 
[40]. Therefore, despite the presence of a cryoprotectant, the enzymes can still be 
rendered inactive. The extracellular protein maintained activity for up to 1 month when 
stored in buffer 1 and for 3 months when stored in buffer 2. Thus the glycerol is clearly 
playing a part in maintaining extracellular protease activity, but this also indicates that 
the extracellular protein is more robust than intracellular protein.  It is likely that an 
increased concentration of glycerol would be more effective in maintaining both protein 
and consequently protease activity of faecal samples however; this would interfere with 
other assays (as well as the BCA assay and other protein quantification assays) and so is 
not ideal for studies aiming to evaluate protease activity.   
 
A lot of studies involving the human gut microbiota involve the storage of whole faecal 
samples and different storage conditions can sometimes affect experimental outcomes. 
The effect of storage condition on faecal samples and concentration of other microbial 
molecules as a result of freezing have been studied [5, 41], but the effect of freezing 
entire faecal samples has on protease activity is yet to be deduced, until now. Here, 
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faecal samples from 3 healthy individuals were stored at -20 and -80°C. Protein was 
extracted and protein concentrations and general protease activity were measured 
immediately prior to any freezing, after freezing for 24 hours and subsequently after 1 
week, 1 month, 3 months 6 months and 1 year. It was found that for all samples isolated 
from the 3 individuals there was no significant reduction in protein concentration even 
after a year of storage at both -20 and -80 °C (figure 6.2.3). Protease activity remained 
stable for the entire study period as well when faecal samples were stored at either 
temperature (figure 6.2.5) for two of the individuals studied. One sample however, 
displayed a reduction in activity after 3 months at both storage temperatures (figure 
6.2.4 B) although it is noteworthy that this sample displayed higher protease activity 
than the other two samples suggesting self-proteolysis was playing a part in this 
reduction of protease activity.  
 
Therefore, from this study it could be advisable that for future studies of protease 
activity in the human distal gut, if protein is extracted, a buffer comprising of a high 
concentration of cyroprotectant along with an antimicrobial, both of which do not alter 
protein concentration or protease activity, and storage at -20°C is suitable. If samples are 
required for extensive analysis which is likely to take more than 1 day, samples can be 
extracted in a glycerol-PBS buffer in a neutral pH and will remain stable for up to 1 
week.  
 
However, protein concentrations and protease activity measurements are more reliable 
when carried out analysis on frozen faecal samples. Following analysis of the results of 
this study it would be recommended that upon retrieval of faecal samples, 1g samples 
should be dispensed into appropriate, sterile storage vessels for future protein 
extractions. This approach will be more appropriate for storage in terms of space and 
importantly will help avoid repeat freeze thaw cycles of the entire sample and decrease 
the chance of contamination. Also, care must be taken with samples exhibiting 
significantly higher levels of protease activity compared to the rest of the cohort after 
storage for longer than 3 months as samples kept this long may not be representative of 
the gut microbiota from that individual. Though to conclude, human faecal samples 
offer a highly reproducible means of accessing protease activity of the human distal gut 
even after long periods of storage at sub-zero temperatures. 
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6.4 MATERIAL AND METHODS 
6.4.1 Buffer composition and preparation.  
All buffers were made up in molecular grade water (18 MΩ) and where possible steam 
sterlized at 121°C for 15 mins, where heat labile ingredients were presnt buffers were 
filter sterilised (0.2 micron). Four buffers were used in this chapter and the composition 
for each one is shown in Table 6.1.  All reagents used were available from Sigma 
(Poole, UK) unless otherwise stated.   
Table 6.1 Buffer Composition 
Buffer Buffer composition 
1 PBS, 0.05% NaN3 
2 PBS, 10% glycerol, 0.05% NaN3 
3 PBS, dithiothreitol, 0.05% NaN3 
4 PBS, 10% Glycerol, Dithiothreitiol, 0.05% NaN3 
6.4.1 Collection of faecal samples 
Assays to detect and quantify enzymatic activities were developed and optimized with 
faecal speicmens from laboratory volunteers (n = 3). Faecal  samples were collected as 
descibed in the general materials and methods section (Chapter 2.0, section 2.3.1) 
6.4.2 Protein extraction 
Protein extractions were conducted as described in general methods section (Chapter 
2.0, section 2.10.1). 
6.4.3 Protein concentration measurements and Protease assays 
These were conducted with the bicinchoninic acid assay and using the colorimetric azo-
casein assay as described in the general methods section (Chapter 2.0, section 2.9.1). 
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6.4.4 Design, conduct and analysis of storage media for evaluation of protein yield 
and protease activity over time 
Fresh material from one faecal sample was collected and divided into 8 subsamples (1 
g). 1 sample for each buffer and each sample would be used for total protein extraction 
(i.e. with bead beating) and for extracellular protein only analysis (no bead beating) each 
containing 1 g faecal material. Each sample was allocated to a buffer (1,2,3 or 4) and 
this buffer was added to the faecal sample to prepare a 10% w/v faecal slurry which was 
conducted by mixing on a Vortex Genie 2™ until no clumps remained. To prepare the 
crude total protein extract the faecal slurry was divided into 2 mL RNAse and DNase 
free lysing matrix tubes (MP Biomedicals) containing 1.4 mm ceramic spheres, 0.1 mm 
silica spheres and one 4 mm glass sphere. Samples were kept on ice throughout. The 
samples were subject to bead beating using a FastPrep-24 bead beater (MP Biomedical) 
at a speed of (6.0 m/s) for 30s with a period of 5 min on ice between each beating. To 
determine optimal number of bead beating steps this process was repeated up to 6 times. 
The bead beating step was repeated a further 2 times for optimal recovery of 
intracellular protein. Samples were subject to centrifugation at 20,000 x g for 30 min at 
4 °C and the supernatant from this step was filtered through a 100K Amicon Ultra 
centrifugal filter tubes (Millipore, Darmstadt, Germany) according to the manufacturer’s 
instructions. For the extracellular only samples, this centrifugation step was conducted 
immediately instead of the bead beating step. Supernatant after filtration was transferred 
to new sterile tubes and taken as the crude protein extract. NaN3 was added aseptically 
to each sample to a final concentration of 0.05% w/v neat samples,10-fold and 100-fold 
dilution were used to estimate protein concentration using the bicinchononic acid assay 
(BCA) method according to the manufacturer’s instructions (PIERCE, Rockford, IL, 
USA) and samples were normalised to 1 mg/mL protein using the appropriate buffer as 
a diluent to conduct subsequent protease activity estimates. Azo-casein assay were 
performed as described in General Methods (Chapter 2.0 section 2.9.1). Samples were 
kept in the freezer at -20 °C. The protein concentration measurements and protease 
activity estimates were performed on the same samples after 24 hours, 1 week, 1 month, 
3 months, 6 months and 1 year. 
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6.4.5 Design, conduct and analysis of the effects of storage of whole faecal samples 
at -20 and -80 °C:  
To assess whether long term storage of faecal samples provides impacts on the 
reproducibility on measurements of protein concentration and protease activity, faecal 
samples from 3 healthy volunteers were collected. Each sample was thoroughly mixed 
in a sterile environment and 13 lots of 1 g specimens were separated into sterile 
containers. 1 sample from each individual was processed immediately, and 6 samples 
from each individual were stored at -20 ˚C and the remaining 6 were stored at -80 ˚C. 
The fresh sample was subject to crude protein extraction, protein measurements and 
protease assay as previously described. The frozen samples were analysed in exactly the 
same way after 6 storage time points; 24 hours, 1 week, 1 month, 3 months, 6 months 
and 1 year. 
6.4.6 Statistical Analysis 
Differences between the buffers and differences between the storage of faecal samples at 
sub-zero temperatures in reproducibility of mean protein concentration was determined 
by correlation analysis using the spearman method and the pairwise comparison using 
the students t-test using a holm adjustment for familywise error after the samples had 
been demonstrated to follow a normal distribution. The same statistical analysis was 
implemented to compare the mean protease activity over time. 
 
To determine optimal bead beating steps mean enzyme activities were compared with 
pairwise comparisons using the Wilcoxon signed rank test with a Holm adjustment 
method. Similarly to determine the effect of NaN3 mean enzyme activity was compared 
using the Wilcoxon signed rank test. All statistical analysis was conducted in R 
software. 
 192 
 
6.5 REFERENCES 
 
 
1. Gill, S.R., Pop, M., DeBoy, R.T., Eckburg, P.B., Turnbaugh, P.J., Samuel, B.S., 
Gordon, J.I., Relman, D.A., Fraser-Liggett, C.M., and Nelson, K.E. (2006). 
Metagenomic Analysis of the Human Distal Gut Microbiome. Science 312, 
1355-1359. 
2. Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K.S., Manichanh, C., Nielsen, 
T., Pons, N., Levenez, F., Yamada, T., et al. (2010). A human gut microbial gene 
catalogue established by metagenomic sequencing. Nature 464, 59-65. 
3. Gloux, K., Berteau, O., El Oumami, H., Beguet, F., Leclerc, M., and Doré, J. 
(2011). A metagenomic beta-glucuronidase uncovers a core adaptive function of 
the human intestinal microbiome. Proceedings of the Nationall Academy of 
Science U S A 108 Suppl 1, 4539-4546. 
4. Jones, B.V., Begley, M.i., Hill, C., Gahan, C.G.M., and Marchesi, J.R. (2008). 
Functional and comparative metagenomic analysis of bile salt hydrolase activity 
in the human gut microbiome. Proceedings of the National Academy of Sciences 
105, 13580-13585. 
5. Flores, R., Shi, J., Gail, M.H., Ravel, J., and Goedert, J.J. (2012). Assessment of 
the human faecal microbiota: I. Measurement and reproducibility of selected 
enzymatic activities. European Journal of Clinical Investigation. 2012 
Aug;42(8):848-854. doi: 10.1111/j.1365-2362.2012.02660.x. Epub 2012 Mar 13. 
6. Eckburg, P.B., Bik, E.M., Bernstein, C.N., Purdom, E., Dethlefsen, L., Sargent, 
M., Gill, S.R., Nelson, K.E., and Relman, D.A. (2005). Diversity of the human 
intestinal microbial flora. Science. 2005 Jun 10;308(5728):1635-8. Epub 2005 
Apr 14. 
7. Peterson, D.A., Frank, D.N., Pace, N.R., and Gordon, J.I. (2008). Metagenomic 
Approaches for Defining the Pathogenesis of Inflammatory Bowel Diseases. Cell 
Host & Microbe 3, 417-427. 
8. Ekkers, D.M., Cretoiu, M.S., Kielak, A.M., and Elsas, J.D. (2012). The great 
screen anomaly--a new frontier in product discovery through functional 
metagenomics. Applied Microbiology and Biotechnology 93, 1005-1020. 
9. Cowan, D., Meyer, Q., Stafford, W., Muyanga, S., Cameron, R., and Wittwer, P. 
(2005). Metagenomic gene discovery: past, present and future. Trends in 
Biotechnology 23, 321-329. 
10. Bertrand, H.l.n., Poly, F., Van, V.T., Lombard, N., Nalin, R., Vogel, T.M., and 
Simonet, P. (2005). High molecular weight DNA recovery from soils 
prerequisite for biotechnological metagenomic library construction. Journal of 
Microbiological Methods 62, 1-11. 
11. Salonen, A., Nikkilä, J., Jalanka-Tuovinen, J., Immonen, O., Rajilić-Stojanović, 
M., Kekkonen, R.A., Palva, A., and de Vos, W.M. (2010). Comparative analysis 
of fecal DNA extraction methods with phylogenetic microarray: Effective 
recovery of bacterial and archaeal DNA using mechanical cell lysis. Journal of 
Microbiological Methods 81, 127-134. 
12. Purohit, M.K., and Singh, S.P. (2009). Assessment of various methods for 
extraction of metagenomic DNA from saline habitats of coastal Gujarat (India) 
to explore molecular diversity. Letters in Applied Microbiology 49, 338-344. 
13. Yuan, S., Cohen, D.B., Ravel, J., Abdo, Z., and Forney, L.J. (2012). Evaluation 
of methods for the extraction and purification of DNA from the human 
microbiome. PLoS One 7. 
 193 
 
14. McOrist, A.L., Jackson, M., and Bird, A.R. (2002). A comparison of five 
methods for extraction of bacterial DNA from human faecal samples. Journal of 
Microbiological Methods 50, 131-139. 
15. Salonen, A., Nikkila, J., Jalanka-Tuovinen, J., Immonen, O., Rajilic-Stojanovic, 
M., Kekkonen, R.A., Palva, A., and de Vos, W.M.(2010). Comparative analysis 
of fecal DNA extraction methods with phylogenetic microarray: effective 
recovery of bacterial and archaeal DNA using mechanical cell lysis. Journal of 
Microbiological Methods 81, 127-134. 
16. Lauber, C.L., Zhou, N., Gordon, J.I., Knight, R., and Fierer, N. (2010). Effect of 
storage conditions on the assessment of bacterial community structure in soil and 
human-associated samples. FEMS Microbiology Letters 307, 80-86. 
17. Carroll, I.M., Ringel-Kulka, T., Siddle, J.P., Klaenhammer, T.R., and Ringel, Y. 
(2012). Characterization of the fecal microbiota using high-throughput 
sequencing reveals a stable microbial community during storage. PLoS One 7, 
e46953. 
18. Macfarlane, G.T., Cummings, J.H., and Allison, C. (1986). Protein Degradation 
by Human Intestinal Bacteria. J Gen Microbiol 132, 1647-1656. 
19. Lacerda, C.M.R., and Reardon, K.F. (2009). Environmental proteomics: 
applications of proteome profiling in environmental microbiology and 
biotechnology. Briefings in Functional Genomics & Proteomics 8, 75-87. 
20. Kolmeder, C.A., de Been, M., Nikkilä, J., Ritamo, I., Mättö, J., Valmu, L., 
Salojärvi, J., Palva, A., Salonen, A., and de Vos, W.M. (2012). Comparative 
Metaproteomics and Diversity Analysis of Human Intestinal Microbiota Testifies 
for Its Temporal Stability and Expression of Core Functions. PLoS ONE 7, 
e29913. 
21. Wilmes, P., and Bond, P.L. (2006). Metaproteomics: studying functional gene 
expression in microbial ecosystems. Trends in Microbiology 14, 92-97. 
22. Costa, F., Mumolo, M.G., Ceccarelli, L., Bellini, M., Romano, M.R., Sterpi, C., 
Ricchiuti, A., Marchi, S., and Bottai, M. (2005). Calprotectin is a stronger 
predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut 54, 
364-368. 
23. Chassaing, B., Srinivasan, G., Delgado, M.A., Young, A.N., Gewirtz, A.T., and 
Vijay-Kumar, M. (2012). Fecal lipocalin 2, a sensitive and broadly dynamic non-
invasive biomarker for intestinal inflammation. PLoS One 7, e44328. 
24. Möstl, E., and Palme, R. (2002). Hormones as indicators of stress. Domestic 
Animal Endocrinology 23, 67-74. 
25. Freeman, H.J. (1986). Effects of Differing Purified Cellulose, Pectin, and 
Hemicellulose Fiber Diets on Fecal Enzymes in 1,2-Dimethylhydrazine-induced 
Rat Colon Carcinogenesis. Cancer Research 46, 5529-5532. 
26. Gibson, S.A., McFarlan, C., Hay, S., and MacFarlane, G.T. (1989). Significance 
of microflora in proteolysis in the colon. Appl Environ Microbiol 55, 679-683. 
27. Macfarlane, G.T., and Macfarlane, S. (2012). Bacteria, colonic fermentation, and 
gastrointestinal health. Journal of AOAC International 95, 50-60. 
28. Steck, N., Mueller, K., Schemann, M., and Haller, D. (2013). Bacterial proteases 
in IBD and IBS. Gut. 
29. Hughes, R., Magee, E.A., and Bingham, S. (2000). Protein degradation in the 
large intestine: relevance to colorectal cancer. Current Issues in Intestigative 
Microbiology 1, 51-58. 
30. Flintoft, L. (2003). A bad influence. Nature Reviews Cancer 3, 890-890. 
 194 
 
31. Ulger Toprak, N., Yagci, A., Gulluoglu, B.M., Akin, M.L., Demirkalem, P., 
Celenk, T., and Soyletir, G. (2006). A possible role of Bacteroides fragilis 
enterotoxin in the aetiology of colorectal cancer. Clinical Microbiology and 
Infection 12, 782-786. 
32. Shen, H.-B., and Chou, K.-C. (2009). Identification of proteases and their types. 
Analytical Biochemistry 385, 153-160. 
33. Rawlings, N.D., Barrett, A.J., and Bateman, A. (2014). MEROPS: the database 
of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Research 
40, D343-D350. 
34. Steck, N., Hoffmann, M., Sava, I.G., Kim, S.C., Hahne, H., Tonkonogy, S.L., 
Mair, K., Krueger, D., Pruteanu, M., Shanahan, F., et al. (2011). Enterococcus 
faecalis metalloprotease compromises epithelial barrier and contributes to 
intestinal inflammation. Gastroenterology 141, 959-971. 
35. Wu, S., Rhee, K.-J., Zhang, M., Franco, A., and Sears, C.L. (2007). Bacteroides 
fragilis toxin stimulates intestinal epithelial cell shedding and gamma-secretase-
dependent E-cadherin cleavage. Journal of Cell Science 120, 1944-1952. 
36. Wu, S., Lim, K.-C., Huang, J., Saidi, R.F., and Sears, C.L. (1998). Bacteroides 
fragilis enterotoxin cleaves the zonula adherens protein, E-cadherin. Proceedings 
of the National Academy of Sciences 95, 14979-14984. 
37. Lozupone, C.A., Stombaugh, J.I., Gordon, J.I., Jansson, J.K., and Knight, R. 
(2012). Diversity, stability and resilience of the human gut microbiota. Nature 
489, 220-230. 
38. Flores, R., Shi, J., Gail, M.H., Gajer, P., Ravel, J., and Goedert, J.J. (2012). 
Association of Fecal Microbial Diversity and Taxonomy with Selected 
Enzymatic Functions. PLoS ONE 7, e39745. 
39. Smith, P.K., Krohn, R.I., Hermanson, G.T., Mallia, A.K., Gartner, F.H., 
Provenzano, M.D., Fujimoto, E.K., Goeke, N.M., Olson, B.J., and Klenk, D.C. 
(1985). Measurement of protein using bicinchoninic acid. Analytical 
Biochemistry 150, 76-85. 
40. Privalov, P,L(1990). Cold Denaturation of Protein. Critical Reviews in 
Biochemistry and Molecular Biology 25, 281-306. 
41. Khan, M.Z., Altmann, J., Isani, S.S., and Yu, J. (2002). A matter of time: 
evaluating the storage of fecal samples for steroid analysis. General and 
Comparative Endocrinology 128, 57-64. 
 
  
 195 
 
SUPPLEMENTARY MATERIALS
 
 
0
500
1000
1500
2000
2500
3000
3500
4000
4500
0
10
20
30
40
50
60
70
0 1 7 30 90 182 365
0
1000
2000
3000
4000
5000
6000
0
5
10
15
20
25
30
35
40
45
50
0 1 7 30 90 182 365
0
1000
2000
3000
4000
5000
6000
7000
8000
0
10
20
30
40
50
60
70
0 1 7 30 90 182 365
Time (Days)
[P
ro
te
in
] µ
g
/ m
L
%
 R
e
la
ti
v
e
 a
c
ti
v
it
y
 196 
 
from previous page  
Supplementary materials figure 6 3. Protein concentration estimates and protease 
activity assay results over time for 3 individuals. 
The line graph shows the relative protease activity over time (primary y axis) and the bar 
graph represents protein concentration (secondary y axis) over time for each individual. 
Red data indicate total protein extraction stored in buffer 1, blue data indicate 
extracellular protein stored in buffer 1, green data indicate total protein extracts stored in 
buffer 2 and purple data indicate extracellular protein stored in buffer 2. Samples are 
plotted as the average of triplicate measurements for both protein concentration 
estimates and protease activity assay and the error bars represent the standard deviation. 
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7.0 A COMPREHENSIVE COMPARISON OF THE HEALTHY AND 
IBD FEACAL DEGRADOME 
7.1 INTRODUCTION 
Inflammatory bowel disorders (IBD) encompass a spectrum of diseases of which the 
two main pathologies are; Ulcerative colitis (UC) and Crohn’s disease (CD). They are 
debilitating and chronically recurring disorders of the human gastrointestinal tract 
characterised by chronic inflammation of the intestinal mucosa [1-3] and an inability to 
control an inflammatory response to an unknown stimulus [3]. The onset of the disease 
occurs predominantly in individuals between the ages of 15-30 years [1] mainly in 
inhabitants of the developed world.  
Symptoms of IBD include severe abdominal pain and discomfort, bloating, periods of 
constipation, periods of diarrhoea, a highly disturbed bowel pattern, gastrointestinal 
bleeding and weight loss [3, 4]. Research has also suggested a correlation between IBD 
and psychiatric disorders such as anxiety and depression.[5] Evidently, the disease has a 
profound impact on people’s lives especially their quality of life, its occurrence is also 
increasing and as a result, further consideration must be given to the increasing burden 
on the healthcare system [6] and other socioeconomic indices. 
 
Symptoms of CD and UC differ in that UC is characterised pathologically by ulceration 
of the mucosa and is limited to the rectum and the colon. Patients suffering often have 
mucus-like and bloody diarrhoea while CD can affect any region of the gastrointestinal 
tract and is characterised by diarrhoea, anorexia, weight loss and involves transmural 
rather than mucosal inflammation. Therapeutics are administered to ameliorate the 
symptoms of the disease and treatments often include the prescription of 
immunosuppressive drugs such as Azathiaprine, steroids; commonly prednisolone and 
anti-inflammatory drugs such as Pentasa and Asacol, and in more severe cases, surgical 
removal of affected regions of the gut including abscesses and fistulas may be required 
to alleviate pain. However, IBD remains irremediable and is chronically relapsing. 
Removal of fistulas and abscesses by surgical intervention do not cure the disease, they 
are a means of alleviating pain in an attempt to improve the patients quality of life [7]. 
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The cause of IBD is complex and remains idiopathic as it has been shown that there are 
a number of factors, interacting with one another that lead to the onset of the disease. 
The disease can be widely attributed to; genetics factors, mucosal immunity and 
interactions of the gut microbiota, and is often attributed to the initiation of an 
inflammatory response by the host’s impaired immune system to commensal gut 
bacteria. Figure 7.1 highlights the main factors contributing to IBD for which the factors 
that have received the most established and more convincing evidence for involvement 
in IBD will be discussed. 
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Figure 7.11. Contributory 
factors to IBD and their 
interactions. The pathogenesis 
of IBD cannot be attributed to 
a solitary factor; in fact it is 
currently thought that the 
disease is a consequence of 
multiple factors including 
interplay between an impaired 
immune system, the gut 
microbiota and environmental 
factors with an underlying 
genetic predisposition for 
disease development. 
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IBD is generally considered a disease of the developed world and consequently, 
environmental stimuli have also been implicated with IBD, namely smoking, diet, stress, 
and the use of certain drugs [8].  
 
The relationship between IBD and smoking is complex and studies have shown a 
contrasting correlation between the two main disease pathologies. Smoking has been 
found to be a significant risk factor in CD but UC is more associated with ex-smokers or 
non-smokers and has even been considered to be a beneficial environmental factor in 
preventing disease progression [9]. The mechanisms by which smoking is hypothesised 
to influence IBD include; modulating cellular immunity[10], altering gut permeability 
and motility [11], varying mucosal blood flow, altering mucus production and 
stimulating the release of glucocorticoids [12, 13]. It is conjectured that nicotine is the 
metabolite responsible for the observed effects of smoking in IBD as nicotinic 
acetylcholine receptors (nAChRs) are present in cells of the colonic epithelium [14] and 
T-cells have been found to express nAChRs suggesting that nicotine may be able to 
modulate T-cell activity [15]. However there remains no clear evidence for this to date 
and the results of clinical trials remain modest [12].    
    
The relationship between diet and IBD is similarly complex and has been the subject of 
much research given that IBD is most prevalent in the western world. Studying the 
effect of diet on disease progression presents a challenge as in human subject studies it 
difficult to determine the component of each diet that may be influencing the gut 
mucosa and the compliance of an individual to accurately describe their diets is another 
limiting factor that must be considered. In a Japanese cohort study, it was found that the 
consumption of sugars, sweeteners, fats and oils were positively associated with IBD 
[16] similar findings regarding sugar intake have been observed in other population 
based studies in the USA, Canada [17] and Europe [18-20]. Conversely, a diet high in 
fibre, fruit and vegetables has been shown to be negatively correlated with IBD [20, 21]. 
However, many studies on the dietary impact on IBD have reported inconclusive 
findings and there are significant challenges to effectively study the role of diet [8]. 
 
Stress has also been implicated in the pathogenesis of IBD largely due to the effect it 
can have on the immune system function [22]. However the specific pathways by which 
psychological stress may be involved in IBD are again, unknown. Animal models have 
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provided some insight into how chronic stress exacerbates a colitis phenotype by 
impairing the immune system, increase intestinal permeability, impairing mucosal 
epithelia barrier integrity and defence against bacteria [23, 24].   
 
There are two main drug groups that have received attention for their association with 
IBD and they are the oral contraceptive pills (OCP) and non-steroidal anti-inflammatory 
drugs (NSAIDs). A meta-analysis of a putative role of the OCP in IBD deduced a 
modest positive relationship in women who took the oral contraceptive and development 
of IBD (both UC and CD) compared to controls, however the associations found were 
weak and limited to small data sets [25].  The basis for OCP contribution to IBD 
aetiology stems from the effects of oestrogen [26] and its association with multifocal, 
gastrointestinal infarcation and putative thrombogenic effects [27].  
 
NSAIDs are the other leading class of drugs that have received significant attention for 
implication in IBD and there is far less ambiguity surrounding the involvement of these 
drugs. Studies have shown that usage of NSAIDs is positively correlated  with the 
development or exacerbation of IBD [28] The mechanism of action proposed for how 
they are implicated in IBD differs to that of OCP. NSAIDs have been shown to cause 
significant damage to the upper gastrointestinal tract, the small intestine and the colon 
[29] [28] by enhancing epithelial permeability, inhibiting cyclooxygenase 2 (COX2) and 
enterohepatic recirculation [29]. More specifically to IBD are NSAIDs role in inhibiting 
COX2, a  regulatory enzyme in the biosynthetic pathway of prostaglandins (PG) [30] 
which, as well as having many other critical cellular functions, also function in 
mediating intestinal epithelial inflammation [31] particularly by initiating anti-
inflammatory cytokines namely interleukin (Il)-10. Studies on Il-10 deficient mouse 
models have shown that colitis develops faster, and with increased severity and 
consequently it has been found that functioning PG are integral in the inhibition of 
chronic inflammation [8, 30]. Coupling this information with other studies showing that 
NSAIDs are correlated with the exacerbation or remission of IBD [28] it has become 
widely accepted that usage of NSAIDs in IBD patients should be avoided if possible. 
 
There is mounting evidence to suggest a role for certain environmental stimuli as risk 
factors in the development or exacerbation of IBD, and in some cases, in the protection 
against the disease. However, current data is still very limited and there is a level of 
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ambiguity surrounding some of the findings. In order to determine which environmental 
factors are integral to the onset of the disease more studies are required to deduce the 
molecular basis of their interaction with the gut and how they might be affecting 
mucosal immunity and gut function and consequently causing inflammation.   
 
Population studies investigating the occurrence of IBD amongst relatives have suggested 
that genetically determined factors may be contributing to the disease. It has been found 
that there is up to a 10-fold greater risk of individuals within families of developing IBD 
[32]. Further evidence for the heritability of the disease has been generated by the 
studies of monozygotic twins compared to dizygotic twins whereby the rates of 
monozygotic twins developing the disease are much higher than in dizygotic twins(10-
15%) [33]. It is now widely accepted that genetics factors are associated with IBD. The 
implementation of genome wide association studies (GWAS) and deep-sequencing 
analyses have enabled the identification of a number of susceptibility loci for IBD. It has 
become clear that IBD cannot be attributed to one gene alteration but is rather a 
heterogeneous polygenic disease [1] and variations at a number of different loci render 
susceptibility to IBD rather than definite onset of the disease as a result. Over 100 
susceptibility loci have been identified in large cohorts of patients with IBD [34-50]. 
 
Gene identification and their encoded proteins enable the analysis of the molecular 
mechanism and function of these genes and how gene variants might be a contributory 
factor in IBD. The majority of the well-characterised loci have been found to be genes 
that encode proteins involved in both the innate and adaptive immune system, the 
autophagy pathway and in maintaining epithelial barrier integrity and function. Despite 
CD and UC conferring different clinical features, GWAS studies have shown 
concordance in the susceptibility loci between the two suggesting that each disease 
phenotype shares common pathways [51]. 
One of the first well characterised loci to be discovered and implicated in IBD is that of 
the pericentometric region of chromosome 16 called IBD-1.Within this region is a gene 
called NOD2 (nucleotide-binding oligomerization domain containing 2 or sometimes 
known as CARD15) of which a cytosine insertion mutation in this gene is associated 
with Crohn’s disease [38]. NOD2 is a pattern recognition receptor protein and the wild 
type protein activates nuclear factor kappa B (NF-κB) which regulate the expression of a 
number of genes involved in both innate and adaptive immunity in response to bacterial 
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lipopolysaccharides. NF-kβ regulates the expression of a number of genes in both innate 
and adaptive immunity including interleukins (IL) 1,2,6,8,9,10,11,12,13,15, tumour 
necrosis factor (TNF) α and β, interferons (IFN) β and y [52]. Mutations in NOD2 
therefore render the host less able to respond to a bacterial stimulus. 
 
Other identified risk loci that form part of the adaptive immune system and their 
regulation of interleukin receptor pathways include regions containing the genes; 
STAT3, JAK3, and TYK2, IL-23R and IL12B. Signal transducer and activator of 
transcription 3 (STAT3), janus kinase 2(JAK2), a tyrosine kinase and tyrosine kinase 2 
(TYK2) are involved in a fundamental cellular signalling process and coordinate the 
transcription of immunregulatory components. Mutations in this pathway again mean 
the host is deficient in forming an appropriate response to a particular stimulus.  Genetic 
variants of the genes encoding interluekins 12, 17 and 23 have also been identified as 
risk factors for CD and UC and their expression has been found to be induced in active 
forms of IBD [53] suggesting their role as proinflammatory mediators if dysregulated. 
Some alternative variants of IL-23 receptor genes have also been found to confer 
protection against IBD [54]. 
 
Another common pathway associated with genetic susceptibility in IBD is related to that 
of autophagy. Some of the genes identified via GWAS studies involved in autophagy 
include ATG16L1, IRGM and LRRK2. Autophagy is an integral cell homeostasis 
mechanism involved in the degradation and recycling of intracellular components and 
organelles and the targeted degradation of intracellular pathogens. ATG16L1 
(Autophagy related protein 16-1) as its name suggests, is an essential protein for the 
autophagy process. Variants of this gene that lead to loss in function e.g. the single 
nucleotide polymorphisms (SNPs) rs2241880 and polymorphism Thr300Ala have been 
strongly associated with increased risk for CD [55]. SNPs in the immunity-related 
GTPase family M gene (IRGM) leading to loss of its wildtype function of the interferon 
induced autophagy pathways targeting intracellular pathogens and has been strongly 
related to both CD and UC [56]. Similarly, the Leucine-rich repeat kinase 2 (LRRK2) 
enzyme is also involved in the intracellular degradation of pathogens and mutations lead 
to a deficiency in this process and an exacerbated colitis has been observed in LRRKS2 
deficient mouse models [57]. 
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The final pathway discussed here that’s heavily implicated in both forms of IBD involve 
genes involved the structure and function of the gut epithelia. Aside from its 
fundamental role in nutrient absorption, the gut epithelia acts as both a physical and 
biochemical barrier protecting the underlying tissue from not only pathogenic bacteria 
but also preventing the helpful commensal bacteria from infiltrating the underlying 
tissue. It plays an active role in sensing and responding to microbial stimuli to illicit an 
appropriate immune response to maintain gut homeostasis. Dysregualtion of epithelial 
barrier integrity can have severe consequences for host health due to an enhanced 
probability of bacteria and bacterial molecules translocating and is therefore implicated 
with the development of IBD. Some of the better characterised genes involved in the 
causation of a dysregulated epithelia barrier include CDH1, GNA12, PTPN2, HNF4A, 
LAMB1, OCTN2 and ECM1. For example, CDH1 encodes epithelial E-cadherin, a 
transmembreane glycoprotein involved in epithelial cellular adhesion. Truncated forms 
of this protein and a consequent increase in permeability have been associated with CD 
[58] as have a number of the other genes mentioned that encode proteins that are 
involved in cellular junction integrity and protection against epithelial permeability [59, 
60]. 
 
Unsurprisingly given the vast number of antigenic stimuli in the gut from bacteria, food 
and drink etc. and because of their intrinsic involvement in cytokine secretion and 
regulation of the inflammatory process, dysregulation of various cells of the gut-
associated lymphoid tissue (GALT) such as T and B cells have also been implicated in 
the pathogenesis of IBD. For example T-cells, which secrete cytokines as part of the 
inflammatory process in response to antigens processed by antigen presenting cells 
(APCs) have been demonstrated to have an abnormal response to ‘normal’ antigens i.e. 
resident commensal bacteria [61]. Abnormal levels of circulating CD4(+) (cytokine 
secreting) and CD8(+) T cells (cytotoxic) have also been found in IBD patients when 
compared with healthy volunteers suggesting a role for over-activation of T-cells in the 
progression of IBD [62]. 
  
Studies of the pathogenesis of IBD have been hugely advanced with the use of 
experimental animal models, namely murine models with altered epithelial barrier 
function and innate or adaptive immune responses [63]. The selective disruption of 
genes such as those mentioned above are commonly implemented to study IBD for 
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example disruption of STAT3 in macrophages results in Il-10 deficient mice and has 
been used to demonstrate Il-10 deficient mice significantly increase inflammatory 
cytokine production including TNFα, Il-1, IFNy and IL-6 [64]. Other models directly 
target the epithelial barrier e.g. Toll-like receptor 4 (TLR4) and myeloid differentiation 
primary response gene (MyD88) deficient mice subsequently treated with Dextran 
sulphate sodium (DSS), which cause acute colitis by disrupting the mucosal barrier have 
shown TLR4 to be involved in prevention of bacterial translocation following epithelial 
injury [65]. Increasingly sophisticated animal models are now being utilised to study 
specific questions regarding the aetiology of IBD and have highlighted that functional 
defects in the epithelial barrier, roles of numerous cytokines, T-cells and many other 
cells and proteins of both the innate and adaptive immune response are contributing to 
IBD however, perhaps one of the most significant findings has been that despite a clear, 
yet complex interplay between numerous genetic loci, the actual development of colitis 
is dependent upon the presence of the gut microbiota [63].   
 
The fundamental question of which bacteria are involved and more specifically what 
molecular mechanisms of these bacteria are contributing to the progression of colitis are 
yet to be solved and remain a significant factor in determining the pathophysiology of 
this complex disease.  
 
Recent deep-sequencing approaches and the implementation of powerful bioinformatics 
tools [66, 67] have enabled us to recognise the genetic diversity and potential of the gut 
microbiota and have allowed us to elucidate that dysbiosis of the gut microbiota is 
associated with IBD [68]. One of the most frequently observed general dysbiosis is the 
marked reduction in the Firmictues phylum and an increase in members of the 
Actinobacteria. It has been considered that the changes in composition and diversity of 
the gut microbiota can lead to enrichment of pathogenic bacteria which are contributing 
to initiation of the disease and parallel to this, a decrease in ‘protective’ commensals and 
their products may also be a contributory factor. Other evidence for a role of bacteria in 
IBD include; the loss of epithelial barrier integrity and increased bacterial translocation, 
an insufficient or overactive response to bacterial stimuli, dysbiosis leads to commensal 
with altered metabolic activities which may be harmful to the host or lastly, the presence 
of a specific pathogen.   
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Research on the community of gut microbiota in IBD are generally commensurate in 
that the disease can be characterised by a dysbiosis of the gut microbiota, however the 
question remains whether this dysbiosis is a cause or an effect of the disease.  
Patients with IBD often have extraintestinal complications, increased risk of developing 
CRC. However, regardless of whether dysbiosis is cause or effect, the fact remains that 
the microbiota is altered. It is vital that the key players and the differences in molecular, 
metabolic and enzymatic activities as a result of dysbiosis are determined for a number 
of reasons; a) this may be a putative cause of the disease, b) to deduce the potential long 
term effects of dysbiosis and c) if dysbiosis is a consequence, understanding the 
dominant organisms and their metabolic capacity may help us determine the driving 
force behind these alterations. 
Substantial research has been conducted into determining the presence of a specific 
pathogen as a solitary causative agent of IBD. Mycobacterium avium subspecies 
paratuberculosis (MAP), adherent-invasive E. coli (AIEC) Helicobacter spp. and 
Campylobacter spp. have received the most attention for their putative role in the 
disease. MAP first received attention for implications with IBD due to its similarity with 
the bovine condition Johne’s disease in which MAP is also the causative agent. It is also 
commonly isolated from meat, dairy and sometimes water so there are numerous sources 
of infection [69]. MAP has been shown to induce intestinal inflammation and severe 
mucosal damage via goblet cell invasion [69]. However while in some cases MAP has 
been isolated from a significant majority of IBD patients [70] other studies have failed 
to isolate the bacteria in cohorts of IBD patients [71] and so the involvement of MAP in 
IBD remains controversial.    
 
AIEC has been frequently isolated from CD patients and has been shown to adhere and 
invade intestinal epithelial cells by binding to adhesion receptor carcinoembryonic 
antigen-related cell adhesion molecule 6 (CEACAM6) with type one pili and flagella 
[72] and recruiting actin microfilaments and microtubules. They can pass the mucosal 
barrier by way of a long polar fimbriae interacting with the Peyer’s Patches of the 
epithelial lining [73] and from here, can survive and replicate in macrophages without 
inducing cell death. Numerous studies have also shown that AIEC can induce colitis in 
genetically susceptible animal models [74]. AIEC has been significantly associated with 
ileal crohns lesion tissue and there is increasingly strong evidence for its involvement in 
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the disease (36.4% compared to 6.2% in controls) however, it is rarely isolated from UC 
patients [74]. 
 
Helicobacter and Campylobacter sp. were originally suggested to be implicated with 
IBD due to their previously concluded causation of gastric ulcers and gastroenteritis 
respectively. Interestingly, Helicobacter pylori prevalence has commonly been found to 
be significantly lower in IBD patients than in healthy [75, 76]. Other Helicobacter 
species including H. hepaticus, H. bilis, H. trogontum, H. rodentium and H. typhlonius 
however, have shown the ability to induce colitis in experimental animal models [77, 
78] and have been positively associated with UC [79]. The case is similar for non-jejuni 
Camplyobacter species too. Species implicated in IBD, namely CD include C. concisus, 
C. hominis, C. ureolyticus and C. gracilis [80]. C. concisus has perhaps received the 
most attention and has been found to be significantly more prevalent in children with 
CD compared to healthy controls [81]. C concisus has been shown to attach to epithelial 
cells and disrupt epithelial junction proteins causing a loss in barrier integrity and a 
consequent increase in epithelial permeability [82].   
Clearly there is much supporting evidence for the theory of a specific pathogen, 
however rarely are they found in all sufferers of CD or UC and even more rarely do they 
appear in both forms of the disease nor do any of the mentioned pathogens meet all four 
criteria of Koch’s postulates.  One feature that becomes apparent when studying 
pathogens and indeed commensals is that many of them have the ability to become 
invasive and have stimuli that induce a pro-inflammatory response. The primary 
molecules responsible for this are virulence factors [83]. 
 
Efforts are continuously being made to identify the molecular structures and 
mechanisms of pathogenic or commensal bacteria that may be acting as virulence 
factors and are responsible for their contribution to the pathogenesis of IBD. Virulence 
factors that have received particular attention with regards to their role in IBD include 
adhesins, bioilm formation, [84] motility, type-specific secretion systems and exotoxins 
[85].  
Aside from these factors, many of the molecular features of IBD such as alteration in 
innate immune defence, chronic inflammation, impaired intestinal epithelial barrier 
function can be associated with a well-established virulence factor of microorganisms 
and that is; protease activity and the term ‘degradome’ is used to encompass the entire 
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proteolytic repertoire of single microorganisms or the metagenome from a particular 
environment (which the case of this research will be the human gut). 
 
Microbial proteases have been proven to be responsible in part or even entirely for the 
virulence of certain microorganisms and the onset of many diseases and there is 
increasing evidence implicating them in the pathology of diseases of the human gut (see 
Table 7.1). Host proteases have also been implicated in IBD; a large scale study 
incorporating a number of European studies analysing the ancestry of IBD were used by 
the IBDase consortium (an FP7 project now completed) to screen for protease and 
protease inhibitor genes in critical regions inferring susceptibility to IBD. This study 
identified 75 protease genes and 7 protease inhibitor genes in CD and 14 protease and 4 
protease inhibitor genes in UC [86] as well as matrix metalloproteases (MMP) that had 
previously been implicated in IBD. 
 
Table 7.1. A Description of proteases produced by pathogens and opportunistic 
pathogens of the human gastrointestinal tract (inclusive of the oral microbiota) and their  
host target.  
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MMPs are zinc-dependent endopeptidases the activity of which has been associated with 
IBD via the uncontrolled degradation of extracellular matrix (ECM), a major feature of 
IBD, and subsequent tissue damage. MMP activity has been shown to be significantly 
Species Classification Protease Host target Ref 
Bacteroides fragilis 
 
Opportunistic 
pathogen 
Metalloprotease; 
fragylisin 
 
Degradation of E-
cadherin via induction of 
γ-secretase  dependent 
shedding and subsequent 
loss of epithelial barreire 
function 
[87] 
Enterohaemorrhagic 
Escherichia coli 
 
Pathogen 
Metalloproteinase 
StcE 
 
Cleavage of mucin 7 and 
glycoprotein 340, 
facilitation of adherence 
to epithelial cells 
 
[88] 
Enterococcus faecalis 
Opportunistic 
pathogen 
Metalloprotease; 
Gelatinase E (GelE) 
 
Degradation of 
extracellular domain of 
E-cadherin and 
subsequent loss of 
epithelial barrier 
function 
[89] 
Helicobacter pylori Pathogen 
Serine protease high 
temperature 
requirement A 
(HpHtrA) 
 
Facilitates the 
degradation of E-
cadherin 
[90] 
Campylobacter jejuni Pathogen HtrA homologue 
Aids with adherence and 
invasion in a INT407 
cell line 
[91] 
Shigella flexneri Pathogen Pic serine protease 
Facilitates bacterial 
adherence and invasion 
by degradation of 
mucin. Also has 
haemagglutinin activity 
[92] 
Clostridium difficile Pathogen 
Cwp84 cysteine 
protease 
Degradation of ECM [93] 
Porphyromonas 
gingivalis 
Pathogen 
Cysteine protease 
Gingipain 
Degradation of IL-1β, Il-
6 and TNFα and can 
truncate IL-8 resulting in 
enhanced neutrophil 
recruitment 
[94] 
Listeria 
monocytogenes 
Pathogen ClpC Serine protease 
Promotes escape from 
the phagosmome of 
macrophages and aids 
with adherence and 
invasion 
[95] 
Vibrio cholerae Pathogen 
Metalloprotease; 
vibriolysin/HA 
protease 
Morphological changes 
in filamentous actin and 
Zonula occludens-
associated protein (ZO-
1); alters epithelial 
barrier function. 
[96] 
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elevated in the inflamed mucosa compared to non-inflamed with a particular increase in 
MMP-9 [97] . Other MMPs such as MMP 1 (a collagenase) and MMP-3 (stromelysin-1) 
have been found to be unregulated in patients with IBD, while their endogenous 
inhibitors; Tissue inhibitor of metalloproteases (TIMPs) have been found to be in 
insufficient quantities to control the level of MMP in inflamed areas of the gut [98].  As 
a result of such findings, studies have focused on the effects of metalloprotease 
inhibitors on colitis. Through the use of animal models, many studies have concluded 
that administration of MMP inhibitors such as Marismastat [99], Batimastat[100] and 
Phenantroline [101] in animal models of colitis have significantly reduced the effects of 
inflammation.  
Elafin, an elastase specific natural serine protease inhibitor has also been found to be 
reduced in IBD patients [102] and is associated with an increase in elastolytic activity. It 
has also been demonstrated that the delivery of elafin to the colon, via elafin producing 
strains of lactic acid bacteria, confers protection against colitis, restoration of epithelial 
homeostasis as well as a decrease in elastolytic activity in the colon [102]. 
Evidently, protease activity represents a good therapeutic target for IBD, and this clearly 
demonstrates that they are involved in disease aetiology. Though since MMPs, and 
indeed, proteases belonging to other families are often parts of integral biological and 
physiological processes, and the inhibitors are often have a broad inhibitory spectrum, 
much more research is needed to understand the specific functions and mechanisms of 
proteases as well as the effect of the addition of both endogenous and synthetic inhibitor 
as a potential therapeutic to target proteases and treat IBD. Additionally, recent research 
as part of the IPODD consortium (Intestinal Proteases: Opportunities and Drug 
Discovery) have found that the origin of MMP activity in the gut could actually be 
attributed to bacteria and also that specific metalloproteases such as Fragilysin from 
Bacteroides fragilis, an organisms generally considered a commensal of the gut 
microbiota but can also be opportunistically pathogenic, can exhibit similar MMP 
activity as the host and can  significantly contribute to chronic inflammation [103, 104] .   
 
It is not just pathogenic proteases that can be implicated in disorders of the gut. 
Proteases are also produced by the commensal gut microbiota and there are theories and 
evidence from studies of pure cultures of gut commensals that suggest they can 
contribute to damage to the gut [105, 106]. An increased repertoire of proteases provides 
bacteria with a metabolic advantage which, although it remains to be proven whether 
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microbial dysbiosis is a cause or effect in IBD, may provide further explanation for how 
dysbiosis occurs; diet, lifestyle, host genetics etc. may select for bacteria with an 
enhanced proteolytic repertoire thus are able to out-compete members of the ‘normal’ 
gut microbiota that are unable to utilise both exogenous (dietary) and endogenous 
protein as successfully. Endogenous protein is provided in the form of extracellular 
matrix protein, mucin, keratin [107], collagen, immune system proteins including 
immunoglobulins, defensins, cellular adhesion molecules (e.g. E-cadherin) and 
transmembrane proteins (occludins, claudins, zonula occludins) and protease activated 
receptors (PARs) [105, 106].  
 
Compromised host epithelial barrier function is a proposed mechanism for aetiology of 
IBD which has been mentioned previously. The main proteins involved in epithelial cell 
structure and function that are putative targets of microbial proteases include E-
cadherin; a transmembrane adherence protein that joins epithelial cells together, and 
other protein complexes involved in tight junctions including the transmembrane protein 
mentioned earlier.    
Steck and colleagues have demonstrated that the extracellular metalloprotease secreted 
by Enterococcus faecalis; GelatinaseE (gelE) can impair intestinal barrier function in Il-
10 deficient mice (Il-10
-/-
). It was also found that gelE was capable of degrading 
recombinant mouse E-cadherin suggesting a defined mechanism for E. faecalis 
involvement in deleteriously altering epithelial barrier function [89]. Other bacteria have 
also been shown to compromise epithelial barrier function by utilising proteases some of 
which are shown in Table 1.  Therefore there is clear evidence to implicate proteolytic 
activity in compromising epithelial barrier function which may have implications for 
IBD and perhaps other gastrointestinal disorders [106]. Also, an area of research that 
remains relatively overlooked is the level of microbial translocation and associated pro-
inflammatory products due to intestinal permeability and contribution to systemic 
infections in people with disorders of the gastrointestinal tract. Microbial proteolytic 
activity may be a direct contributor to increased susceptibility to microbial translocation 
from the gut. 
 
Bacterial proteases may also exert activity on human host cells by way of protease 
activated receptors (PARs). PARs come in four isoforms (PAR1-4) and are a family of 
G protein-coupled receptors that are expressed on enterocytes (as well as numerous 
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other cells including immune cells, neurons and endothelial cells). They are activated 
(normally) by endogenous serine proteases, in response to a particular stimuli, including 
inflammation [105] and can contribute to the pro-inflammatory response. Many bacterial 
species have been shown to be capable of activating host PARs with detrimental effects 
[108]. The cysteine protease of the oral pathogen Porphyromonas ginigvalis; Gingipain 
has been demonstrated to cleave and activate PAR-1 leading to an up-regulation of pro-
inflammatory cytokines[94] and can also activate PAR2 on human neutrophils [106]. 
PAR2 is overexpressed in mast cells in ulcerative colitis [109] and organisms such as 
Pseudomonas aeruginosa and Serratia marcescens secrete proteases (exoprotease LepA 
and serralysin respectively) that can cleave PAR-1,-2 and -4 and consequently activate 
NF-κB [107, 110]. Clearly there is a role for dysregulated PAR cleavage and activation 
in IBD, however it has been demonstrated that host serine proteases are also increased in 
IBD [111] so more work is to be done to determine the extent of microbial involvement 
in PAR activation compared to endogenous proteolytic activation. 
 
Microbial proteases have been shown to modulate immune system proteins including 
immunoglubulins (Ig) (namely secretory IgA, the most abundant Ig in the human gut), 
cytokines and Toll-like receptors (TLRs) the effects of which have been shown to either 
enhance the immune response or inhibit it, the consequence of which for both are 
significant in causing a pro-inflammatory response or enabling bacterial establishment 
respectively. 
The ability to degrade IgA has been demonstrated by numerous bacteria including 
Pseudomonas aeruginosa [112] and Proteus mirabilis [113] suggesting a mechanism for 
evasion of this protective protein. The ability of gut commensals or pathogens to do this 
would significantly improve their ability to colonise the gut and/or establish an 
infection. 
Evidence from studies of other bacteria that are not considered normal commensals of 
the gut microbiota suggests a role for disruption of cytokine signalling [105]. For 
example the trypsin-like cysteine proteases; Gingipans, produced by Porphyromonas 
ginigvalis have been shown to degrade Il-1β, Il-6 and TNFα and can also truncate Il-8 
resulting in enhanced neutrophil recruitment exerting a strong pro-inflammatory 
response at sites of periodontis without elimination of the bacterial infection [114]. 
Another cysteine protease produced by Streptococcus pyogenes (SPE B) can cleave Il-
1β in its inactive form to produce active Il-1β in a way analogous to that of endogenous 
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human cysteine protease consequently increasing Il-10 levels and the inflammatory 
response [115]. Table 1 includes other bacterial species that target cytokine and other 
immune system proteins via proteolytic degradation. Clearly there is much evidence that 
bacteria can utilise their proteases to modulate the host immune response to both 
enhance or inhibit it, both of which have a deleterious effect on the host and can be 
implicated in the pathogenesis of IBD.  
 
Mucins, highly glycosylated large proteins that line the gut epithelia may also be 
considered a protein involved in immunity due to their protective role as a physical 
barrier in the gut. In IBD, the mucus layer is thinner and has an increased abundance of 
luminal bacteria associated with it [116]. Consequently, it has been hypothesised that the 
diminished mucus layer is as a result of degradation by the gut microbiota of which the 
ability to do so, enabled by both proteases and glycosidases, is also associated with 
enhanced adherence and disruption of epithelial barrier tight junctions [106, 116]. It is 
yet to be determined whether the diminished mucus barrier is due to bacterial 
degradation, or as a result of the disease thus allowing more bacteria to colonise. Further 
research is in need, but this is still a proposed mechanism for how bacteria with 
enhanced proteolytic capacity may gain access to the gut epithelium in the first instance 
and may go on to disrupt barrier function.  
 
The metabolism of exogenous protein in the form of dietary protein can also be 
implicated in disorders of the gut particularly IBD and colon cancer by the release of 
toxic metabolic products such as ammonia, amines, sulphur metabolites and phenolic 
compounds [117]. It has been hypothesised that the products of metabolism of dietary 
protein by host but more so by microbial proteases, is contributing to an increased pool 
of these harmful metabolites which thus far have been limited to their implication in 
colon cancer [117]. While associations between diet and IBD have been studied, the 
molecular consequences of dietary protein metabolism and its effect on the pool of 
harmful metabolites have not been studied with regards to IBD. 
 
Previous research has shown that there is elevated microbial serine proteolytic activity 
in the gut of those suffering from IBS with diarrhoea, but most activity was of host 
origin [111] [118] and matrix metalloprotease activity is also increased [97] but again it 
has not been determined whether or not this is host or bacterial in origin. The European 
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research consortium IBDase has investigated the role of proteases and protease 
inhibitors in IBD [86] mainly of human origin, but researchers belonging to the 
‘IPODD’ Consortium have found that the activity of many of the proteases, particularly 
metalloproteases can be attributed to gut bacteria (http://www.efcca.org/index.php/our-
activities/latest-news/33-targeting-the-demolition-squad) . 
While proteases produced by pathogens are well documented, the extent and capacity of 
proteolytic activity of commensals, particularly of the gut microbiota has not been 
comprehensively researched. It is therefore important that the proteolytic capacity of the 
gut microbiota be determined if we are to examine the impact proteolytic activity is 
having on the host. 
 
  
 215 
 
AIMS 
 
The aim of this research is to expand our understanding of proteolytic function within 
the gut microbiota by comparing  proteolytic capacity in faecal samples as a 
representative of the gut microbiota in healthy individuals with that of IBD sufferers and 
also characterise the gut proteolytic microbiota in IBD in a relatively large cohort-based 
study.  It is hypothesised that the gut microbiota of IBD sufferers harbours an altered 
and aggressive commensal bacteria with an increased repertoire of proteases with an 
increased substrate range. This research will help determine whether proteolysis carried 
out by the gut microbiota may be a virulence factor contributing to inflammatory 
disorders of the gut.[119].Additionally, this research will also implement novel tools for 
an extensive assessment of protease activity in faecal protein extracts which, to the 
authors knowledge, has not been done before on mixed faecal protein samples nor in an 
IBD cohort. With the conclusions generated from the research undertaken for Chapter 
6.0, the optimal procedure for processing and storing the faecal samples with the 
overriding purpose of analysing protease activity could also be implemented for this 
research. Faecal samples could also be stored for extended periods of time at sub-zero 
temperatures  
 
 
The main aims of this research are: - 
 
1. To conduct a comprehensive comparison of faecal protease (FP) activities 
between a cohort of patients with IBD versus healthy controls, and in doing so 
incorporating exploration of novel tools for assessing total protease activity in 
faecal samples. 
 
2. To determine which types of proteases are most abundant in each cohort and 
establish any differences and the origin of FP activity. 
 
 
3. To begin to unravel the potential that FP activity may be implicated as a 
virulence factor in IBD by analysis of their effect on human cell lines. 
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4. To conduct a comparison of gut microbial communities between each cohort 
using 16S rRNA gene sequencing analysis and to determine any correlations 
between certain bacterial taxonomies with elevated or low FP activity. 
7.2 RESULTS 
 
7.2.1 Protein concentration in healthy and IBD protein extracts 
There was no significant difference found between the total average of protein 
concentrations of all the healthy samples and all the IBD samples (Figure 7.2.1).  
 
 
Figure 7.2.1 Average protein concentrations after extraction of the total cohort of 
healthy compared with the IBD patients. Center lines show the medians; box limits 
indicate the 25th and 75th percentiles as determined by R software; whiskers extend 1.5 
times the interquartile range from the 25th and 75th percentiles, outliers are represented 
by dots; width of the boxes is proportional to the square root of the sample size. 
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Healthy(n) = 24, IBD(n)= 26 sample points which include total protein and extracellular 
protein samples.  
 
7.2.2 Feacal Protease activity in Patients with IBD compared to Healthy controls  
General protease activity was assayed colourimetrically using azo-dye impregnated 
casein as the substrate. The IBD samples showed significantly higher caseinolytic 
activity (Figure 7.2.2). Keratin azure (azure dye-impregnated sheep’s wool keratin) was 
used to determine keratinolytic activity. The IDB samples showed significantly higher 
keratinolytic activity when compared to the healthy samples. 
 
Figure 7.2.2. A=Azo-casein assay. B= Azo-coll assay, C= Keratin azure assay. Results 
represent the mean of triplicate data per sample and then the mean of the entire cohort of 
healthy samples (green boxplot on the left of each plot) compared with the entire cohort 
of IBD samples (red boxplot on the right of each plot). Statistical significance between 
FP activities in Healthy compared to IBD was determined using the Mann-whitney U 
test in R software. 
P = 1.405e-4 P = 0.08213 P = 1.929e-5
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7.2.3 Temperature and Ph profiles of FP activity 
FP activity was significantly higher at 37 °C for each cohort (figure 7.2.3 A & B) 
compared to the activity at all other temperatures apart from activity at 40 °C which was 
also signifcantly higher than activity at all other temperatures.Optimum FP activity was 
observed at pH 8.0 (at a temperature of 37 °C) for both cohorts (Figures 7.2.3 C & D). 
 
 
 
P= 0.00086P= 0.01471
P= 0.00119
P= 0.01366
P= 5.7e- 10 P= 2.3e-14
4 8 11
3
0
4
0
5
0
6
0
P= 0.00022 P= 8.4e-05
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from previous page 
Figure 7.2.3. Temperature (A & B) assays and pH (C & D) assays to determine the 
optimum temperature and pH respectively for FP activity Results represent the mean of 
triplicate data per sample and then the mean of the entire cohort of healthy samples 
(green boxplot on the right of each figure) compared with the entire cohort of IBD 
samples (red boxplot on the left of each figure). Statistical significance between FP 
activities at the various temperatures and pH were determined using ANOVA and 
continuous pairwise comparisons in R software.  
7.2.3 Protease Inhibitor assays 
ProteaseARREST™ (G-Biosciences) species specific inhibitor cocktails were used to 
test the samples for presence of bacterial, mammalian, fungal and plant proteases by 
assessing relative activity after incubation with the inhibitor. A lower activity was 
representation of a greater level of inhibition indicating greater levels of proteases 
belonging to that species. All samples (healthy and IBD) showed greatest inhibition of 
activity upon addition of the bacterial protease inhibition cocktail (figure 7.2.4) and in 
the presence of mammalian proteases inhibitors, activity was also diminished in all 
samples (figure 7.2.4). In the presence of fungal protease inhibitors, the healthy samples 
maintained high levels of activity however they had a negative effect (less than 50%) on 
over half of both the IBD types (table 7.1). None of the samples were negatively 
affected by the presence of the plant specific protease inhibitor cocktail (figure 7.2.5 and 
table 7.1). 
 
As it appeared that bacterial proteases were responsible for a significant level of FP 
activity from this assay, to determine the contribution on intracellular bacterial proteases 
to the observed activities an Optiprep™ density gradient medium was used to isolate 
bacterial cells and then determine FP activity before and after cellular disruption by bead 
beating.   It was found that following cellular disruption significantly higher % relative 
activity was observed (figure 7.2.4B, P<0.05) suggesting that intracellular bacterial 
proteases were contributing to the FP levels observed from previous assays but disrupted 
bacterial cells exhibited significantly lower FP activity compared to total protein extract 
and extracellular protein extract (P<0.05) indicating that secreted proteases are 
responsibly for a significant level of the activity observed. Total protein and 
 220 
 
extracellular protein were not significantly different suggesting that after normalisation 
of protein, the samples were composed of a similar abundance of proteases.  
  
To determine which proteases families were most abundant in each sample and whether 
there were differences between healthy and IBD, a series of protease inhibitors were 
used to assess activity after incubation with the following inhibitors; AEBSF, ALLN, 
Antipain-dihydrocholride, Aproptinin, Bestatin, Chymostatin, E-64, EDTA, Leupeptin, 
Pepstatin, Phosphoramidon and PMSF. Each of these inhibitors are specific for a 
particular family of proteases for example PMSF is a serine protease inhibitor and 
phosphoramidon inhibits metalloproteases. The serine protease inhibitors AEBSF, 
Aprotinin, chymotrypsin inhibitor, PMSF and the metal ion chelator EDTA-Na caused 
significant inhibition of activity compared to FP activity when no inhibitor was present 
in the healthy cohort (Figure 7.2.5). Similarly, these inhibitors were also responsible for 
a significant reduction in FP activity in the IBD cohort too, apart from in the presence of 
chymotrypsin-like inhibitor (figure 7.2.5) however, in addition to these, the trypsin-like 
serine protease and cysteine protease inhibitor Antipain dihydrochloride, and the 
metalloprotease inhibitor phosphoramidon, also caused significant reduction to FP 
activity. In the presence of phosphoramidon, IBD FP activity was significantly different 
when compared to the healthy cohort (P=0.0097) suggesting a greater level of inhibition 
of FP activity due to phosphoramidon in the IBD cohort compared to the healthy 
controls. 
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Figure 7.2.4A: ProteaseARREST™ assays for Bacterial, mammalian fungal and plant 
specific protease inhibition (from left to right). Results represent the mean of triplicate 
data per sample and then the mean of the entire cohort of healthy samples (green 
boxplots) compared with the entire cohort of IBD samples (red boxplots. Centre lines 
show the medians; box limits indicate the 25th and 75th percentiles as determined by R 
software; whiskers extend 1.5 times the interquartile range from the 25th and 75th 
percentiles, outliers are represented by dots.N = 11, 13, 11, 13, 11, 13, 11, 13 sample 
points. High activity is indicative of less inhibition due to the presence of the protease 
inhibitor cocktail; conversely, low activity is indicative of inhibition by the inhibitor and 
indicates the presences of that type of protease in the sample. Statistical significance 
between FP activities in Healthy compared to IBD was determined using the Mann-
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whitney U test in R software. Differences between activity within each cohort in the 
presence of the different inhibitors was assessed by ANOVA and pairwise comparisons.  
B: Relative proteolytic activity (%) following isolation of bacterial cells using an 
Optiprep™ density gradient method with and without cellular disruption. Relative 
proteolytic activity was compared with that of total protein protease activity and 
extracellular protein protease activity without bacterial cell isolation. Bacterial specific 
protease activity was significantly higher after cellular disruption (P<0.05).  However, 
protease activity was significantly higher in the total protein and extracellular protein 
extracts (P<0.05). 
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From previous page  
Figure 7.2.5. FP activity from the healthy cohort (green boxplots) and the IBD cohort 
(red boxplots) after incubation with different protease inhibitors (at 37°C and a neutral 
pH). Centre lines show the medians; box limits indicate the 25th and 75th percentiles as 
determined by R software; whiskers extend 1.5 times the interquartile range from the 
25th and 75th percentiles, outliers are represented by dots. n = 11, 13, 11, 13, 11, 13, 11, 
13, 11, 13, 11, 13, 11, 13, 11, 13, 11, 13, 11, 13, 11, 13, 11, 13 sample points. 
% Relative activity was calculated compared to the no inhibitor present controls. Lower 
points are indicative of low activity and therefore higher levels of inhibition meaning 
that there are proteases from the family of proteases targeted by that inhibitor in that 
particular sample. Asterisk (*) indicates FP activity that is significantly different from 
no inhibitor controls: Healthy:- AEBSF; P = 0.00102, Aprotinin; P = 0.00041, 
Chymotrypsin inhibitor; P = 0.01509, EDTA-Na; P = 0.03015 and PMSF; P = 0.01509. 
IBD:- AEBSF; P = 0.00344, Aprotinin; P = 7.7e-05, Antipain dihydrochloride; P = 
0.04532, EDTA-Na; P = 0.00291, Phosphoramidon; P = 0.00174 and PMSF; P = 
0.00174. 
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7.2.4 Specific protease activity profiles 
To futher assess the substrate specificity of each cohort, a set of three fluorometric 
substrate were chosen following results from the inhibitor study. Mca-Lys-Pro-Leu-Gly-
Leu-Dpa-Ala-Arg-NH2 (MMP) was used as a substrate for matrix metalloprotease 
activity and showed significantly elevated activity in the IBD cohort (figure 7.2.6 A). 
MeOSuc-AAPV-AMC (MEO) is a substrate for neutrophil elastase activity for which 
was signficnatly greater in the IBD cohort once again (figure 7.2.6 B). Suc-Ala-Ala-Pro-
Phe-AMC was used as a synthetic substrate specific for chymotrypsin activity. No 
differences were observed between the two cohorts (figure 7.2.6 C). 
 
Figure 7.2.6. Relative Fluorescent Units (RFU) released as a result of FP activity from 
the healthy cohort (green boxplots) and the IBD cohort (red boxplots) after incubation 
with fluorescent labelled substrates A; MMP, B; MEO and C; Chymotrypsin. Center 
lines show the medians; box limits indicate the 25th and 75th percentiles as determined 
by R software; whiskers extend 1.5 times the interquartile range from the 25th and 75th 
percentiles, outliers are represented by dots. n = 11, 13 sample points. Significant 
differences between the activity of the two cohorts are shown (MMP; P = 0.03962 and 
MEO; P = 0.0341). P values with no statistical significant difference are not shown.  
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7.2.5 Degradation of mucin 
In order to determine the ability of the samples to degrade mucin, firstly mucin was 
labelled using  biotin through the protein moiety as described in materials and methods. 
Samples were run through a Sephadex G25 column following biotinylation and a slot 
blot assay with Periodic acid Sschiff’s stain was perforemd to test the collected fractions 
for  mucin and labelling was checked by adhering the mucin to a 96-well plate and 
streptavidin labelling. Using samples that were successfully biotin labelled, a mucinase 
assay was performed using the protein extracts from each sample in the two cohorts. No 
statistically signficnat difference was observed in mucinase acitivity between the two 
cohorts. 
 
Figure 7.2.7. Relative activity of mucinase in the healthy cohort compared with the IBD 
cohort to trypsin control. Centre lines show the medians; box limits indicate the 25th 
and 75th percentiles as determined by R software; whiskers extend 1.5 times the 
interquartile range from the 25th and 75th percentiles, n = 11, 13 sample points. There 
was no significant difference between the relative activities of each cohort.  
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7.2.6 Bacterial Community in the Healthy cohort and IBD patient cohort 
A total of 1426461 high-quality sequences were produced in this study using Illumina 
Miseq™ DNA sequencing technology with an average of 59436 sequences per sample. 
The Shannon diversity index and community richness Chao index were calculated for 
each cohort and are shown in table 7.2. Analysis of the Shannon index for diversity 
revealed a higher diversity in healthy faecal samples compared to IBD faecal samples, 
however, this was not statistically significant. When separated into their respective 
disease phenotypes (CD or UC) samples showed a similar diversity indices and species 
richness. 
 
The microbial structure of the two cohorts and the IBD cohort separated in respective 
disease type (CD or UC) to the phylum level are shown in figure 7.2.7A. The dominant 
phyla in the healthy groups were Firmicutes, Bacteroidetes and more prominent in the 
IBD sample groups were Proteobacteria and Actinobacteria were also dominant in the 
IBD sample group. However no statistically significant differences were observed at the 
phylum level. There were significant differences between healthy and IBD faecal 
samples at different bacterial taxonomic ranks namely class and family rank (table 7.3). 
The microbial structure of the two different IBD types (CD and UC) used in this study 
are shown in figure 7.2.7B. The dominant phyla in both groups were Proteobacteria, 
Firmicutes, Bacteroidetes and Actinobacteria. Bacteroidetes appeared reduced in the 
CD group compared to the UC group and conversely, Actinobacteria were increased in 
the CD group and decreased in the UC group.  
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Table 7.3. 16S r DNA sequencing data summary comparing the IBD patients faecal 
microbial diversity with the healthy participant faecal microbial diversity. Shannon 
index form diversity was calculated for each group and was found to be statistically 
significantly different ( P= 0.00?). The Chao index was used to determine the richness of 
OTUs in the dataset.  
 Healthy (n = 
11) 
IBD (n = 13) CD ( n = 7 ) UC (n = 6) 
# Sequences 50794±3069 66747±51124 78459±18194 53084±36585 
# Filtered 
OTUs 
475±75 464±98 410±152 397±164 
Chao 524±205 395±241 404±174 384±230 
Shannon 2.627±2.755 2.295426±3.01 2.275±2.766 2.319±2.567 
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 From previous page 
Figure 7.2.8. A; % Relative abundance of the main bacterial phyla after analysis of 16S 
Ribosomal DNA gene sequences from faecal samples of healthy participants and 
patients with IBD. The IBD cohort is characterised by a reduction in Bacteroidetes and 
an expansion of Proteobacteria and Actinobacteria. B; % Relative abundance of the 
main bacterial phyla after analysis of 16S Ribosomal DNA gene sequences from faecal 
samples from the IBD cohort separated into their respective disease types (CD and UC). 
Firmicutes, Proteobacteria, Actinobacteria and Bacteroidetes are again, the dominant 
phyla. % Proportion on Actinobacteria is higher in CD than UC, similarly are 
Proteobacteria. C; Family level comparison of Firmicutes in the two cohorts. 
Clostridiales encompasses Clostridiales insertae sedis XI,XII and XIII, Clostridiaceae 
encompasses Clostridiaceae 1,2 and 4 and the group ‘other’ encompasses 
Aerococcaceae, Carnobacteriacaea, Erysipelotrichaceae, Enterococcaceae, 
Eubacteriaceae, Gracilibacteriaceae, Heliobacteriaceae and Peptostreptococcaceae. 
Samples that were found to be significantly different between the groups within the 
Firmicutes Phylum are indicated by an ‘*’. The Clostridiaceae, Clostridiales and 
Streptococcaceae are shown in the smaller insert graph with a different scale for 
proportion of sequences. 
 
Table 7.3 Bacterial groups that are significantly different between the two cohorts     
as determined using an adjusted P-value as determined by two groups comparisons 
using white’s non-parametric t-test and Benjamin-Hochberg false discovery rate to 
account for multiple comparisons 
 
Taxonomy Rank p value Adjusted p 
value 
%IBD % Healthy 
Alphaproteobacteria Class 9.99e-4 8.99e-3 0.100712 2.58415 
Bacilli Class 9.99e-4 0.018 0.592636 0.064676 
Gammaproteobacteria Class 6.99e-3 0.042 12.5288 0.0345518 
Actinobacteria Class 9.99e-3 0.045 11.6796 0.95237 
Enterobacteriaceae Family 2.39e-4 0.011 12.4971 0.00611988 
  
 232 
 
7.2.7 Association of Faecal Microbial Diversity and Taxonomy with protease 
activity 
 In order attempt to determine any microbial taxonomic associations with high and low 
levels of faecal protease activity, the data obtained from general protease activity assays 
was used to divide the samples from the entire study group into quartiles for high (n = 6) 
and low activity (n = 6). 
 
The distance matrix that had previously been calculated in Mothur [120] was analysed 
by nonmetric multidimensional scaling (NMDS) to enable a qualitative visualisation of 
the similarity between community structure in high FP activity compared to low FP 
activity. Analysis of the NMDS showed separation in high vs low FP activity when the 
cohort of high FP was compared to the cohort of low FP activity (figure 7.2.11 A). 
When the IBD and healthy samples were analysed they too revealed a separation 
between samples with high FP and low FP activities (figure 7.2.11 B and C) notably in 
the healthy cohort, the high FP samples were much more similar than the high FP 
samples that showed much more variation. 
Comparison of the microbial communities of the samples with high and low activities 
was conducted in STAMP [121] and R software [122]. Shannon index for diversity was 
calculated for each group and was found to be statistically significantly reduced in the 
high FP group compared to the low FP activity group ( P<0.05, figure 7.2.10). 
 
STAMP software was used to determine if there were any compositional differences in 
the faecal microbiota of the high activity compared to low activity sample groups. 
Compositional differences of associations with high or low FP activity were observed at 
the Phylum level (figure 7.2.12). 
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Figure 7.2.9. FP activity in faecal protein extracts from all study participants (not 
separated into disease type or healthy). The bottom quartile represents sample with low 
FP activity (n = 6) as determined by R software and the top quartile represents the 
samples with high FP activity (n = 6). Samples not in either quartile were deemed 
insignificantly representative of high or low FP activity and so were not included in 
further analysis. 
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Figure 7.2.10 Microbial diversity of sample with high and low FP. 
Shannon index of diversity was calculated for each group and was found to be 
statistically significantly different (P= 0.00866) between high and low FP groups.  
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Figure 7.2.11 NMDS map showing the separation of samples that exhibit high FP activity from the samples that exhibit low FP activity. 
A; the entire cohort (both healthy and IBD after statistical speartion into cohorts of high and low FP activity). B; the IBD cohort separated into 
high and low FP activity and C; the healthy cohort separated into high and low FP activity. 
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Figure 7.2.12. % Relative abundance of the main bacterial phyla after analysis of 
16S Ribosomal DNA gene sequences from faecal samples of healthy participants and 
patients with IBD separated into quartiles of high and low FP activity. The high FP 
activity cohort is characterised by a reduction in Bacteroidetes and an overall reduction 
in diversity and an expansion of Proteobacteria. The low FP activity cohort can be 
characterised by the presence of members from other Phyla, and dominance by 
Bacteroidetes and an increase in Verrucomicrobia. Phyla found to be significantly 
different in abundance between the two groups are marked with an ‘*’. 
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7.2.8 Effect of protease activity on TER  
To begin to unravel the role of the gut microbiota and their proteases as virulence 
factors, the effect of faecal protease extract from both the cohorts on the epithelial 
barrier integrity of two human gut epithelial cell lines (HT-29 and HCT116) was 
investigated by measuring the TEER and the translocation of fluorescent labelled 
sodium fluorescein molecular markers after 24hours of incubation. Concentrated E. 
faecalis crude protein extract was used as a positive control as this has been previously 
shown to decrease TER [89]. Protein extract buffer and a sample with of cell culture 
alone were also used as negative controls. Samples were first compared to determine 
which showed a statistically significant decrease in TER with the control, these samples 
were further compared before and after 24hours of incubation to determine if this 
change was significant. Healthy sample 5 and IBD samples 6, 11 and 12 showed a 
significant decrease in TER after incubation (P = 0.02856, 0.04898, 0.02815 
respectively) as did the concentrated E. faecalis supernatant (P = 0.0002566). IBD 
samples, 6, 11 and 12 also showed a higher translocation of a sodium fluorescein 
molecular marker from the apical side to the basolateral side of the cell monolayer when 
no inhibitor was present compared to when the inhibitor was present (figure 7.2.13; P= 
0.0369, 0.00063 and 0.0463 respectively) To confirm whether the decrease in TER was 
protease mediated, in parallel the Transwell cultures were also incubated with protein 
extract from each sample and a protease inhibitor cocktail. These samples were subject 
to the same statistical test to determine if TER was significantly altered after the 
incubation period. None of the samples showed a significant decrease in activity (figure 
7.2.13 B) thus indicating that the cell monolayer was being effected by protease activity 
and not some other factor. A significant (P <0.001, rho = -0.763) negative correlation 
between FP activity and the % of original TER after incubation with protease extract for 
24 hours (figure 7.2.13 C). 
 
Healthy sample 5 did show translocation of the fluorescent marker but the sample with 
and without inhibitor were not statistically significantly different (figure 7.2.14) 
furthering the possibility that an alternative enzymatic activity was also responsible for 
the decrease in TER and epithelial permeability. Healthy sample 6 and IBD sample 9 
however, also showed significant translocation with no inhibitor compared to when the 
inhibitor was present.  
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Figure 7.2.13 Effect of FP activities from protein extracts on TER of Ht-29 cell line 
without (A) an inhibitor present and with (B) inhibitor after 24 hours of incubation. TER 
measurements were made at time ‘0’ and after 24 hours incubation and the % change in 
TER was plotted. Centre lines show the medians; box limits indicate the 25th and 75th 
percentiles as determined by R software; whiskers extend 1.5 times the interquartile 
range from the 25th and 75th percentiles, n = 11(healthy, which are represented by the 
green circles), 13(IBD, which are represented by the red circles) sample points. 
Samples that had a significant change in TER after incubation compared to their original 
reading are indicated with an ‘*’. 
As no samples showed a significant decrease in TER in the presence of a potent protease 
inhibitor, samples were subject to correlation and regression analysis to determine 
whether FP activity and decrease in TER were associated with one another (C). A 
significant negative correlation was observed (rho = -0.763, P = 3.541e-05). 
C 
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Figure 7.2.14. Permeability assay showing the translocation of sodium fluorescein 
molecular marker across a monolayer of HCT116 after 24 hours of incubation with 
protein extract from each sample from both cohorts. Concentrated supernatant of E. 
feacalis was used as a positive control and cells incubated with the protein buffer were 
used as the negative control and to ensure the buffer was having no effect on cell layer 
permeability. Samples with ‘*’ represent samples that had a significantly different 
concentration of sodium fluorescein translocate across the apical layer to the basolateral 
layer upon addition of a protease inhibitor cocktail. 
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7.3 DISCUSSION 
 
The aim of this research was to conduct a novel, comprehensive analysis of the gut 
degradome, hypothesised to be a virulence factor in patients with IBD; a debilitating, 
chronically recurring disease of the gastrointestinal tract of prominence in the developed 
world and associated with early onset (ages 15-30) [1]. Recent years have seen many 
advances in understanding the aetiology of this disease with regards to genetics, 
environmental factors, such as diet and smoking and importantly, alterations in and 
actions of the gut microbiota and the implementation of germ-free or gnotobiotic animal 
models, however the pathogenesis of the disease remains far from fully being 
understood. Genome wide association studies have identified susceptibility loci and 
certain genes that contribute to an individual’s predisposition to develop the disease. In 
broad terms, identified loci comprise genes that have been demonstrated to be of 
importance in; immune response to bacterial stimuli, autophagy pathways and epithelial 
barrier function [63]. One of the first genes to be identified in such studies was a 
frameshift mutation in the NOD2 gene, a gene involved in immune regulatory pathways 
such as the activation of nuclear factor (NF)-κB [1, 38]. Since then, many more 
susceptibility loci and genes have been identified including JAK2, STAT3, ATG16L1, 
and ECM1[63]. The implementation of animal models with modified or deleted genes 
identified to be implicated in IBD susceptibility have helped provide evidence for the 
implications of dysfunctional genes [123] [124] but one of the key findings from animal 
models is that, in the absence of a gut microbiota, IBD does not occur. However, what 
remains unclear is the level of bacterial involvement in the disease; is there a singular 
infectious microbial agent? (a pathogen) Is colitis a result of an overreaction of the 
immune system (defective pro-inflammatory response) to commensal bacteria? (e.g. 
defects in NOD2, JAK2/STAT3) or an ‘under reaction’ of the immune system to a 
legitimate microbial stimuli? (e.g. a defect in the autophagy pathway; ATG16L1, IRGM, 
LRRK) or, is the altered gut microbiota, a phenomena increasingly observed in patients 
suffering with IBD, responsible for the onset of the disease? If so, what molecular 
mechanisms are they implementing in order to do so? 
 
The hypothesis of IBD as almost an autoimmune disease suggests that IBD would occur 
regardless of the balance of the gut microbiota, as long as it was present. Evidence for 
this stems from research that has shown that the gut microbiota is largely influenced by 
 242 
 
the host’s immune phenotype [125, 126] and that colitis has been induced when germ-
free animal models of colitis are reconstituted with a ‘healthy’ microbiota [127]. 
Additional evidence for this theory come from the effect of that antibiotics administered 
topically that have been shown to reduce colitis [128]. However, these studies did not 
utilise next generation sequencing to determine which bacteria were most affected by 
the antibiotics and for the former argument (colitis developing after introduction of a 
normal microbiota) it was not determined whether the established gut microbiota was 
similar to the microbiota that was initially administered and it is widely known that the 
gut microbiota is integral to development of innate immunity [129]. Consequently, 
germ-free animals are likely unable to appropriately respond to commensal bacteria 
regardless of colitis susceptibility genotype and are therefore, not an appropriate model 
for assessing the impact on the normal gut microbiota on colitis and were not used in 
this research.  
Research into the role of a defective immune response to microbial stimuli, the role of a 
lone pathogen as mentioned previously and dysbiosis of the gut microbiota in IBD 
certainly suggest a more direct and specific role for gut microorganisms in the 
pathogenesis of the disease.  
 
It has been widely observed that dysbiosis of the gut microbiota is associated with IBD 
as well as many other diseases [63, 130]. 16S rRNA gene analysis and comparison of 
the two cohorts in this study also revealed significant difference in the gut microbiota of 
IBD patients compared with healthy volunteers. However it remains to be determined 
whether this is a cause or an effect of the disease. Although there is mounting evidence 
to suggest that one of the main causative factors of IBD might be due to a ‘shift’ in the 
ratio between probiotic or neutral commensals to more prominent ‘aggressive’ 
commensals in IBD [131] which have the capacity to interact with the gut and 
ultimately; adhere to the mucosal lining, disrupt epithelial barrier integrity, evade the 
immune response and alter visceral sensitivity and bowel habits [106] The fact that IBD 
is observed to have a positive correlation with a ‘Western’ lifestyle which is associated 
with a general diet, extensive use of antibiotics, a level of hygiene and improved living 
conditions etc. suggest that this lifestyle may be an initial driving force behind shaping 
the gut microbiota and consequently, driving an aggressive gut microbiota capable of 
instigating IBD in those susceptible.  Determining the differences between specific 
functions of the gut microbiota in healthy individuals compared to the functions of the 
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gut microbiota in IBD may help ascertain how they might be contributing to disease or 
is integral in determining what the potential long term affects dysbiosis may be having 
on the guts of individuals suffering with the disease (regardless of whether dysbiosis is 
cause or effect). It is apt to say that bacteria are integral to the development of IBD but 
to understand exactly how, the actual molecular mechanisms, occurring in the gut at the 
epithelial barrier interface rather than just microbial diversity alone need to be studied 
more definitively.  
 
In this study, a coupling of 16S rRNA gene analysis and a function-driven approach 
were implemented to begin to unravel the implications of the gut microbiota in IBD. 
This function-driven approach was focussed on the gut microbial degradome aka the 
entire proteolytic repertoire of the gut microbiota.    
 
The action of proteolytic activity is only recently becoming recognised as a significant 
microbial function relating to human disease and therefore much work is still to be done 
if we are to understand the impact the microbial degradome is having on us as their 
human hosts [118]. Proteases are utilised by both pathogenic and commensal 
microorganisms and have even been implicated in the onset of diseases such as IBD. 
There is mounting evidence to support the theory that microbial proteases are integral to 
microbial involved in IBD since protease activity appears to be increased in IBD 
patients compared with healthy samples [132] though most studies have been limited to 
studying ulcerative colitis alone. 
 
Research by Steck et al., has demonstrated how microbial proteases may contribute to 
IBD. Their researched showed how gelE is capable of degrading the transmembrane 
glycoprotein E-cadherin, a protein involved in epithelial barrier function. Degradation of 
this protein results in a loss of barrier function, increased translocation and intestinal 
inflammation and may be a trigger for onset of IBD [133]. However in practice, since 
the gut harbours around 10 to 100 trillion bacteria [134] the analysis of only one 
microorganism may not be so relevant and similarly the degradome of a particular 
environment should be seen as a system rather than individual proteases since we cannot 
discount relationships and interactions between them. Therefore in this study, it was 
attempted to capture the entire faecal degradome as a representation of the distal gut 
microbiota degradome to pursue the understanding of the role of proteases as they are in 
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the gut and to compare proteolytic activity between healthy individuals in our cohort 
(n=11) and individuals with IBD (n=13). The IBD samples had statistically significantly 
elevated caseinolytic (P = 1.405e-4) and keratinase activity (P = 1.929e-5, figure 7.2.2 A 
and C) as determined by azo-casein assay and keratin azure assay respectively. 
Significantly higher caseinolytic activity has been observed in patients with UC and 
diarrhoeic IBS before [132, 135, 136] suggesting that the microbiota of those suffering 
with gastrointestinal disorders is enriched with proteolytic bacteria and perhaps a wider 
substrate specificity since keratin azure was also significantly higher. Keratin azure is a 
dye-impregnated keratin from sheep’s wool often used to determine the keratinolytic 
capacity of bacteria and fungi. This substrate was chosen as keratin is a major 
constituent of intestinal epithelial cells and absence or removal of certain keratin types 
has been associated with the development of colitis and diarrhoea [137] and dye-
impregnated feathers, hair or wool have been demonstrated to be useful substrates for 
assessing keratinase production [138, 139]. These data also suggests that with the high 
levels of proteolytic bacteria also have an extended functional repertoire i.e. the high 
level of protease activity may correspond with high levels of different types of proteases 
present, hence the enhanced ability to degrade keratin. 
 
Collagenase activity is often considered a virulence factor of microorganisms [140]. 
Although it initially appeared that azo-coll degradation (collagenase activity) was more 
prevalent in the IBD cohort, the data were not significantly affected by disease state 
(figure 7.2.2B) and collagenase activity is a feature of a healthy gut microbiota too. This 
is concurrent with previous research by Pruteanu and colleagues who studied microbial 
collagenase activity in a culture-dependent study comparing the activity in faecal 
samples from healthy controls versus patients with IBD and found that activity was 
found in 25% of samples regardless of disease [141].  
 
It was decided that since the environment of the distal gut has been found to be altered 
in those suffering with IBD, the effects of different temperature and pH were to be 
elucidated to determine if the temperature and pH could be having an effect on the 
bacteria inhabiting the distal gut and therefore, the proteolytic activity. Optimal 
temperature for FP activity was 37 °C for both cohorts (figure 7.2.3) which was 
unsurprising since 37 °C is the optimum temperature for growth in the human gut. The 
pH assay was conducted as previous studies have shown a drop in intestinal luminal pH 
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in sufferers of IBD [142] and so it could be hypothesised the IBD cohort FP activity 
would indicate a low pH tolerance. However both cohorts showed significantly higher 
FP activity at a pH of 8.0 compared to activity at a more acidic or alkaline pH (figure 
7.2.3). Host-derived proteases that have been isolated faecal samples such as trypsin and 
chymotrypsin have been shown to have an optimal pH of around 8.0 similarly; protease 
positive bacteria isolated from culture-dependent studies commonly have enzymes that 
operate optimally at pH 8.0. Clearly acid tolerance observed in proteases of the stomach 
is not replicated in the small and large intestine as exemplified by FP activity observed 
here.  
 
The use of protease inhibition assays (ProteSEEKER™) revealed which families of 
proteases were most abundant in each of the samples. This inhibitor set comprises 12 
inhibitors that individually target the different families of proteases reversibly or 
irreversibly. Both cohorts showed significantly reduced activity in the presence of 
AEBSF, Aprotinin, chymotrypsin inhibitor, EDTA-Na and PMSF and additionally, 
Antipain dihydrochloride also showed significant inhibition in the IBD cohort but not in 
the healthy cohort (figure 7.2.5). AEBSF (or 4-(2-Aminoethyl) benzenesulfonyl fluoride 
hydrochloride) Aprotinin, chymotrypsin and PMSF (or phenylmethanesulfonylfluoride 
or phenylmethylsulfonyl fluoride) are all serine protease inhibitors with slightly 
different mechanisms of action.  
The significant levels of inhibition of FP activity upon addition of these various serine 
inhibitors in both cohorts signifies that there are significant quantities of serine proteases 
in the human distal gut and also may suggest that some of the FP activity observed can 
be attributed to host serine proteases such as trypsin and chymotrypsin which are 
secreted in the duodenum from the pancreas. Previous research has investigated the 
levels of the gastrointestinal trypsin inhibitor; pancreatic secretory trypsin inhibitor 
(PSTI) in the guts of healthy controls compared with IBD and found significantly 
reduced levels in affected areas of the colon in patients with both UC and CD [143] and 
other studies have found significantly higher tryptic faecal protease activity in patients 
with CD and UC [111, 135, 144]. A particular study by Midtvedt and colleagues 
observed an inverse correlation between faecal tryptic activity (FTA) and Bacteroidetes 
suggesting that bacteria in this phyla are normally large contributors to controlling the 
trypsin-like protease pool by further proteolytic breakdown of trypsin [144]. Evidences 
for microbial breakdown of trypsin also comes from studies in germ-free and 
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conventional rats whereby germ-free rats have FTA but conventional rats do not [145] 
and Bacteroides species have been shown to degrade trypsin in vitro and in vivo [144, 
146]. Ultimately this demonstrated ability of species of the gut microbiota that are able 
to degrade trypsin suggests that the healthy gut microbiota has a role in controlling 
levels of trypsin and related pancreatic proteases in the gut and dysbiosis of the gut 
microbiota in disorders cause an abundance of bacteria that do not affect trypsin levels 
and this may have implications in the pathogenesis of IBD. 16S rRNA gene analysis 
conducted in this research did show a reduction in the Bacteroidetes Phylum in the IBD 
cohort compared to the healthy cohort (figure 7.2.8A) and similarly in the low FP 
sample group compared to the high FP group (figure 7.2.12) . While this was not a 
statistically significant, there does appear to be a trend in the correlation between 
Bacteroidetes and low protease activity and perhaps to further explore the relationship 
between Bacteroidetes and protease activity with regards to IBD, a similar study could 
be conducted encompassing a larger IBD population. Also, serine protease activity was 
prevalent in the healthy cohort (figure 7.2.5) so serine FP activity cannot be solely 
attributed to IBD. The theory that elevated trypsin-like serine protease activity is 
potentially involved in the pathogenesis of IBD also suggests that it is host proteases 
that are problematic. Host factors have been heavily implicated in the pathogenesis of 
IBD including trypsin and matrix metalloproteases and studies in other gastrointestinal 
disorders such as Irritable Bowel Syndrome with diarrhoea have identified trypsin and 
chymotrypsin-like proteases as a source of elevated FP activity observed in this disorder 
[111] However, there are bacterial homologs of trypsin [147, 148]. To attempt to 
differentiate between host and bacterial, as well as other types of proteases (fungi, plant) 
two approaches were taken. Firstly a ProteaseARREST™ inhibition assay was used 
with inhibitor cocktails that were specific for bacterial, mammalian, fungal and plant 
proteases (referred to now as BPI, MPI, FPI and PPI respectively). Secondly, an 
OptiPrep™ Density gradient column was used to isolate bacterial cells and compare the 
protease activity after cellular disruption with that of total protein extract and 
extracellular protein extract. 
 
Bacterial-specific and mammalian specific proteases were the most abundant types of 
proteases found in both cohorts (figure 7.2.4) which is unsurprising since it is known 
that bacterial protease activity occurs in faecal samples of both healthy and unhealthy 
individuals [119] and also host-derived proteases are evident in faecal extracts in healthy 
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individuals and IBD individuals [118], but bacterial FP activity was significantly more 
inhibited than mammalian FP activity in the IBD cohort suggesting more bacterial 
proteases present in the faecal samples of the IBD sufferers. While the plant protease 
inhibitor cocktail had no effect, the fungal protease inhibitor cocktail significant reduced 
FP activity in the IBD cohort (figure 7.2.4). When fungal culture was attempted from 
remaining faecal samples of each individual (which had been stored at -20 °C) using 
potato dextrose agar and malt agar supplemented with chloramphenicol (40 μg ml−1) and 
kanamycin (50 μg ml−1) no fungal colonies were observed (data not shown) and no 
positive bands were observed following an attempt at 18srRNA amplification by PCR 
(data not shown). This may be indicative of the faecal samples being frozen for too long 
and the fungi were no longer viable or at levels too low to detect by molecular methods 
as has been shown before [149]. 
 
These data suggest FP activity can be partly attributed to fungal or yeast proteases in the 
IBD cohort. There is also increasing evidence to implicate fungi IBD [150] and that 
there is an increase in diversity and composition of fungi in those with IBD [151]. 
However, there are limitations of this assay as while the contents and concentrations of 
the inhibitors in each ProteaseARRTEST™ cocktail are not and will not be disclosed by 
the company, although each inhibitor contains inhibits specific for the organism is 
question, it could also be assumed that there is overlap between the types of protease 
inhibitor presents. Most protease inhibitor cocktails deemed specific for bacterial 
proteases are comprised of; AEBSF, Aprotinin, Bestatin, E-64, Leupeptin, Pepstatin, 
PMSF and EDTA. Mammalian protease inhibitor and Fungal protease inhibitor 
cocktails also often include AEBSF, Aprotinin, Bestatin, E-64, Leupeptin, Pepstatin but 
rarely PMSF; and inhibitor that caused significantly diminished FP activity in both the 
healthy and IBD cohort (figure 7.2.5). FPI often include 1,10 Phenanthroline 
monohydrate; a metalloprotease inhibitor of which the mechanism of action is as a 
chelator of iron, zinc and other divalent metals so perhaps, since the IBD cohort FP 
activity was significantly affected in the presence of another metalloprotease inhibitor; 
Phosphoramidon (figure 7.2.5) the loss in activity in the presence of the FPI cocktail 
maybe as a result of a significant abundance of metalloproteases in the IBD cohort as 
opposed to an abundance of fungal proteases. PPI cocktails commonly include E-64, 
pepstain, bestatin and leupeptin; none of which caused significant loss in activity of 
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either cohort (figure 7.2.5). It is also important to note that the concentrations of each 
inhibitor are also likely to be different in each cocktail. 
 
An Optiprep™ density gradient was used for isolation bacterial cells and then FP 
activity was determined before and after cellular disruption by bead beating. It was 
found that following cellular disruption, significantly higher relative activity (%) was 
observed (figure 7.2.4B, P<0.05) suggesting that intracellular bacterial proteases were 
contributing to the FP levels observed from previous assays but disrupted bacterial cells 
exhibited significantly lower FP activity compared to total protein extract and 
extracellular protein extract (P<0.05) and after normalisation of protein, extracellular 
protein and total protein extract displayed a similar level of activity indicating that 
secreted proteases are contributing to a significant amount of proteolysis in the gut 
lumen. What remains to be determined here however, is how much bacterial proteases 
are contributing to this extracellular proteolysis and how much can be attributed to the 
host. Also, which other cells in the faecal samples are being disrupted to release protein 
contributing to total protein FP activity. As previously mentioned Tooth and colleagues 
studied faecal protease activity in patients with irritable bowel syndrome with diarrhoea 
and determined that a significant amount of serine FP activity was of host origin [111]. 
In Tooth’s study however, faecal samples were subject to affinity chromatography 
through a benzamidine-sepharose resin for the specific purification of serine proteases. 
Thus, while this research of Tooth and colleagues suggests faecal serine proteases are 
mainly of host origin but this does not infer information reading to the origin of other 
types of protease which have been found to be present in faeces in this research although 
the use of affinity chromatography would definitely be a useful direction for future 
progression of this study and will be discussed in more detail later on. 
 
The results of both protease inhibition assays (figure 7.2.4 and figure 7.2.5)  were 
concurrent with the findings of the general protease activity assays in that a significant 
proportion of FP activity could be attributed to metallo-, as well as serine proteases 
(which have previously been discussed) which are the families of proteases that most 
bacterial keratinases belong to [152], and similarly, the significant difference in FP 
activity as a result of the addition of the metalloprotease inhibitor; phosphoramidon was 
observed in the IBD cohort but not in the healthy cohort (figure 7.2.5). To further 
investigate metalloprotease activity and specific serine protease activity a set of three 
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fluorogenic substrates were chosen based on the ability to degrade also being associated 
with virulence (figure 7.2.6) . The substrates were; a synthetic matrix metalloprotease 
substrate, a neutrophil elastase and a chymotrypsin specific substrate. Matrix 
metalloproteases have been implicated in IBD [118, 153] and have been assumed to be 
of host origin. In this study, MMP activity was elevated in the IBD cohort (figure 7.2.5). 
Thus this data, coupled with the inhibition assay strongly suggest a role for 
metalloprotease activity in IBD. Studies as part of the IPODD consortium have similarly 
determined a role for bacterial degradation of extracellular matrix in IBD [141]. 
Research has also shown metalloproteases previously thought to be of host origin to 
actually be bacteria-derived [104, 154]. Also, many proteases that are potential virulence 
factors in the human gut are metalloproteases for example GelE from E. faecalis and 
fragilysin from Bacteroides fragilis. Serine proteases are also required for pathogenicity 
in many bacteria [155]. Their presence in the healthy samples indicates that they are not 
acting as virulence factors in IBD. However neutrophil elastase activity was elevated in 
the IBD cohort (figure 7.2.4 B) though this is perhaps unsurprising since this enzyme is 
secreted during inflammation [156]and it is likely that these enzymes are of host origin 
although very little is known about bacterial neutrophil elastase homologs.  
 
This research has highlighted that commensal FP activity is likely having different 
implications in the healthy gut compared to the IBD gut. Or the fact that there is 
elevated metalloprotease activity in the IBD gut is indicative of the presence of 
metalloprotease producing bacteria in IBD guts which are absent or reduced in the 
healthy gut. However it still remains to be conclusively determined whether these 
proteases are of host origin or bacterial. Developing methods to both isolate functionally 
active proteases and then to determine their origin remains a vital future consideration 
for this research. 
 
A key molecular feature of IBD is the loss of function of the epithelial barrier and an 
increase in permeability. To further investigate the role of FP as putative virulence 
factors in the disease, the ability of the faecal protein extracts from each cohort to alter 
TER and consequently the functional state of paracellular barrier and also the 
permeability of a human intestinal cell line were determined. A resultant decrease in 
TER is indicative of disruption of the tight junctions and deregulated paracellular 
diffusion [157]. It was found that three of the IBD samples caused a significant decrease 
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in TER but interestingly, so did one sample from the healthy cohort. Upon the addition 
of protease inhibitors, no samples showed any reduction in TER indicating that the 
activity of proteases in these samples were contributing to the drop in TER and that in 
situ, proteases from these samples could be affecting epithelial barrier integrity. 
Interestingly, the healthy sample that caused a decrease in TER did not cause an increase 
in permeability of the fluorescein molecular marker. This is likely because the 
fluorescent marker if a relatively large molecule and TER offers a much more sensitive 
measurement of barrier integrity as TER measures the ion permeability of cell 
monolayers and so it is likely that only partial disruption of the junctions may have 
occurred [157]. IBD samples that caused a significant decrease in TER measurements 
also caused a significant increase in permeability as did the concentrated supernatant of 
the E. faecalis isolate thus indicating that tight junctions were disrupted to such an 
extent that large molecules could pass through the cellular monolayer. Surprisingly, one 
IBD sample that had not caused a decrease in TER appeared to cause an increase in 
cellular permeability. At this point it can only be speculated that this may be due to the 
involvement of an intracellular pathway causing endocytosis and exocytosis of the 
fluorescent marker, but the reasons for this are unclear. These data definitely indicate 
that FP of some samples are contributing to an altered functional state of the epithelial 
barrier but as some, but not all samples were capable of this drop in TER and increase in 
cellular permeability it was hypothesised that this may be again due to elevated levels of 
protease activity as indeed, the IBD samples that reduced TER fell into the high protease 
activity bracket of protease activity within the entire cohort. To further validate this, 
statistical analysis approach was implemented and it was determined that TER was 
negatively correlated with FP activity i.e. the higher the FP activity, the lower the TER 
after incubation. This indicates that faecal proteases are a possible contributor to a 
compromised epithelial barrier and may be a particular problem in IBD. 
 
Illumna Miseq sequencing technology was utilised to compare the bacterial community 
composition of the distal gut microbiota of patients with IBD with those of the healthy 
controls and between the two disease pathologies in this study; UC and CD. All samples 
were dominated by Firmicutes, Bacteroidetes and Proteobacteria but upon initial 
analysis of relative proportions of bacterial phyla present in each sample, there were 
noticeable differences between the healthy and IBD cohort with a marked reduction in 
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Bacteroidetes and an expansion of Actinobacteria and Proteobacteria in the IBD cohort 
(figure 7.2.8A).  
Analysis of the lower taxonomic divisions revealed significant differences at the Class, 
Family and Genus level. While the Alphaproteobacteria were significantly increased in 
the healthy cohort (P = 8.99e-3), the Gammaproetobacteria were markedly increased in 
the IBD cohort (P = 0.025). The Enterobacteriaceae family, which belongs to the 
Gammaproteobacteria Class were also significantly increased in the IBD cohort 
compared to the healthy (P = 0.011 and P = 0.049 respectively). The Proteobacteria are 
increasingly suggested to be implicated in IBD largely due to that fact that this phyla 
includes the genera Camplyobacter, Helicobacter, Klebsiella and the species; E. coli 
which have been associated with IBD [158] and most studies are concurrent with this 
study in finding an abundance of Gammaproteobacteria in IBD groups [159]. However 
the implications of this have only gone so far as to describe lone pathogens that belong 
to this class which includes Klebsiella and E. coli for which their roles in IBD have been 
discussed previously, but the Gammaproteobacteria is a large class that encompasses 
the second greatest number of genera of all bacteria phyla second only to Firmicutes 
[160]. Members of the Gammaproteobacteria are morphologically, biochemically and 
physiologically diverse also making it difficult to speculate a putative role for their 
expansion and its association with IBD. Looking more closely at the lower taxonomic 
divisions that were found to be significantly altered in IBD such as the 
Enterobacteriaceae family may help shed some light upon the role of proteobacteria in 
IBD.   Winter and colleagues have provided evidence that members of the 
Enterobacteriaceae family such as E. coli have the genetic capacity to utilise certain by-
products of intestinal inflammation such as nitrate, and thus are selected for by the 
environment created by the inflamed gut. This in turn causes harmful bacteria with this 
genetic capacity to utilise these products to outcompete those that can’t and ultimately 
this can exacerbate the severity of inflammation [161]. Therefore, perhaps it is fair to 
suggest that the Enterobacteriaceae family have a genetic repertoire that allows them to 
thrive in a damaged gut and ultimately cause more damage [162]. 
 
This study is thus far concurrent with a number of other molecular based studies 
observing compositional alterations in the gut microbiota in IBD. Frank and colleagues 
implemented a rRNA sequence analysis approach on gastrointestinal tissue samples to 
study the diversity of the gut microbiota in IBD and found their data to be dominated by 
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the four phyla; Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria but with 
marked reductions in the Bacteroidetes in the IBD cohort and substantial increases in 
Actinobacteria and Proteobacteria [163]. Similarly, Manichanh and colleagues 
observed the same dominant phyla as did Mangin and colleagues who also observed a 
similar distinctive increase in the Enterobacteria [164]. It is a noteworthy that these 
studies also found a distinguishing reduction in Firmicutes. When the Firmicutes phyla 
alone were subject to closer scrutiny, there were noticeable differences in the Family 
taxonomic division between the two cohorts (figure 7.2.8 C). One of the most noticeable 
differences was in the Rumminococcaceae Family (P = 0.029) and the Clostridiaceae 
family (P = 0.048). Both families include metabolically important species with regards 
to the gut, two genera have received a lot of attention for their putative protective role 
against IBD. Many studies have observed a correlation in a decrease in abundance of 
both the Faecalibacterium genera [165] and Butyricicoccus [166]  in IBD. 
Butyricicoccus pullicaecorum has recently emerged as a potential beneficial commensal 
significantly reduced in IBD cohorts and has been shown to exert anti-inflammatory 
effects in rat models of IBD [166]. Faecalibacterium prausnitzii is the only species 
within the Faecalibacterium genus and this organism in particular has demonstrated 
anti-inflammatory properties [167] indicating a significant role in gut homeostasis and 
anti-inflammatory balance in a healthy state conducted by this organism.  The anti-
inflammatory effects of such organisms can be partly attributed to their ability to 
produce short chain fatty acids (SCFAs). In the pinnacle work of Marchesi and 
colleagues [168] investigating the metabonome in IBD, SCFAs were found to be 
significantly depleted in IBD which coincided with a depletion of SCFA producing 
microorganisms. Their work strongly suggests a correlation between levels of SCFAs 
and dysbiosis of the gut microbiota in IBD as well as providing another non-invasive 
means of characterising IBD. 
 
While most studies analysing the gut microbiota in IBD have confirmed a reduction  in 
F. prausnitizii abundance in IBD [66, 163-165] a recent study by Hansen and colleagues 
challenged this notion as they confirmed an significant increase in F. prausnitzii in 
paediatric CD patients [169] thus furthering the complexity of an already pathogenically  
multifarious disease. While animal models of IBD have provided generous amounts of 
information regarding an anti-inflammatory role for this organism, perhaps the use of F. 
prausnitzii as well as other microorganisms as a putative probiotic in human studies 
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would be more useful in determining whether they are integral to controlling 
inflammation or simply innocent bystanders. Particularly, R. Balfour Sartor, an MD and 
leading researcher in the field of the gut microbiota and IBD has stated an area of 
research that needs to be developed further is in the coupled use of probiotics and 
immunosuppressive agents  [170].  
 
While this study, as well as copious others have demonstrated a dysbiosis and reduction 
in diversity within the gut microbiota in IBD, it is important to remember that IBD 
encompasses numerous disease types, the most commonly occurring being UC and CD. 
In this study the gut microbiota composition of the UC (n = 6) and CD (n = 7) were also 
compared.  Initial observation of the different dominant Phyla abundance showed some 
differences, but not as apparent as the entire IBD cohort compared to the healthy cohort 
(figure 7.2.8 A and B). The UC group were dominated by Firmicutes and Bacteroidetes, 
and to a lesser extent; Actinobacteria and Proteobacteria while the CD group had an 
abundance of Proteobacteria and fewer Firmicutes and Bacteroidetes, however no 
significant differences were observed between the two cohorts.  Larger scale studies 
have also found no significant difference in richness and diversity between the two 
disease types, but also that the pattern of microbial shift is more prevalent in CD than in 
UC [171].  They have found significant differences in Proteobacteria between the two 
disease types, particularly the Gammaproteobacteria [172]. 
While it is fairly apparent that dysbiosis of the gut microbiota is indeed a factor in IBD, 
with the increasing number of studies that aim to decipher the implications of dysbiosis 
of the gut microbiota in IBD , comes an increase in conflicting, as well as supportive 
data. There are an unprecedented number of variables that affect the pathogenesis of 
IBD such as diet, lifestyle, host genotype, host immunity and the fact that many 
participants recruited in studies have different levels of disease severity which all 
contribute to making the gut microbiota in IBD incredibly difficult to study. This 
highlights the necessity of implementing functional analysis and ‘omic’ approaches to 
assess how activity of the gut microbiota might be contributing to IBD. 
 
Since it is hypothesised that shifts in microbial composition in IBD have marked 
implications on the function of the gut microbiota, particularly with regard to their 
metabolic capability, 
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it is fair to perceive that this could be coupled with the increased FP activity in the IBD 
cohort observed in this study. FP activity was shown to separate depending on high or 
low FP as revealed by nMDS analysis of the entire cohort, the IBD samples only and the 
healthy samples (figure 7.2.11) indicating that high FP activity is associated with an 
alteration in the diversity of the gut microbiota. High FP activity was also associated 
with a decrease in bacterial diversity (table 7.2.3) a phenomena observed in IBS patients 
before [173]. 
To determine any bacterial composition associations with FP activity in IBD, the data 
were split into quartiles of high and low protease activity and the bacterial communities 
of each sample group were assessed. Unfortunately, this resulted in a relatively small 
data set (high FP activity n= 6 and low FP activity n = 6) but it did provide some 
important preliminary information for future, more large scale studies of gut microbial 
protease activity and implications in IBD.  Initial trends observed were a noticeable 
reduction in Proteobacteria and Bacteroidetes in the low FP group (figure 7.2.12) and 
an increase in Verrucomicrobia.  
After applying a stringent compositional analysis related to FP activity it was found that 
the Verrucomicrobia were positively associated with low FP activity (P = 0.042). 
Verrucomicrobia is a relatively small phylum with variable molecular and metabolic 
characteristics but one of the most noteworthy species with regards to the human gut 
microbiota is Akkermania muciniphila. A muciniphila was first isolated as a novel 
mucin-degrading bacteria from human faeces in the guts of healthy individuals [174] 
there is also evidence to suggest the species has an intimate relationship with the human 
mucosal barrier and may exert beneficial functions with regards to gut barrier function 
and maintenance of gut homeostasis. The organisms can also produce short chain fatty 
acids as a by-product of mucin degradation [174, 175]. It has also been negatively 
associated with IBD [176].   
Research by both Pullan et al., and Fyderek et al., have observed a significantly 
diminished mucus layer in patients with IBD compared with healthy controls [177, 178]. 
While A. muciniphila is reduced in IBD, a preponderance of other mucosa-associated 
bacterial species often considered harmful, have been found to dominate the gut mucosa, 
including Streptococcus spp. [178] and the mucolytic bacterial species; Ruminococcus 
gnavus and R. torques [176]. It is yet to be determined whether the loss in species such 
as A. muciniphila and dominance of R. gnavus and R. torques directly contributes to a 
diminished mucus layer or whether the converse is true, i.e. a diminished mucus layer 
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leads to a loss in A. muciniphila. A. muciniphila has an extended mucinolytic, as well as 
proteolytic repertoire and indeed this trait appears to be shared by most of the 
Verrucomicrobia [179]  as determined by analyses of their genomes [179]. Aside from 
mucinolytic capacity, the role of these enzymes remains relatively unexplored. 
Additionally, it is important to note that no difference between mucinase activities 
between the two cohorts was observed in this study. The decrease in this highly 
proteolytic phylum in the low FP cohort  does lend itself to the hypothesis that this 
phylum may have a level of control over other proteolytic microorganism and upon its 
diminution, other highly proteolytic genera are able to dominate, and perhaps this is 
exerting a deleterious effect on the host.  Verrucomicrobia are widely considered a 
beneficial phylum in the gut and have been negatively associated with FP activity here, 
this, coupled with other evidence from this study that protease activity is elevated in the 
inflamed gut, it is clear that there is mounting evidence to implicate a role of degradative 
enzymes of bacteria in the pathogenesis of IBD. Though it remains unclear whether the 
marked reductions in Verrucomicrobia is as a consequence of an inflamed gut or is a 
possible cause and if it were a cause, what are the driving forces behind loss of 
Verrucomicrobia? Further work needs to be conducted to determine what, if any, the 
role of species belonging to the Verrucomicrobia in inflammation might be, for example 
it would be very interesting to determine any anti-inflammatory, probiotic or mucosa-
thickening effects, of members of the Verrucomicrobia as well as their interaction with 
other bacteria, particularly (opportunistic/putative) pathogens in IBD, in vitro and in 
vivo as it is believed currently that this is an avenue yet to be explored. 
 
To conclude, this is the first study to the author’s knowledge that has involved a 
relatively large cohort to conduct a comprehensive analysis coupling function-based 
characterisation as well as 16S rRNA bacterial community characterisation to explore 
the faecal degradome in the IBD gut. Distinctions in the microbiota of the healthy cohort 
compared to the IBD cohort were observed and results were generally concurrent with 
previous studies conducting 16S rRNA gene profiling of bacterial communities in IBD. 
Distinctions of the bacterial communities of high FP activity versus low FP activity 
were additionally observed with high FP activity also characterised by a reduction in 
microbial diversity. Perhaps the most significant observation was a marked decrease in 
the Verrucomicrobia, the implications of which remain to be explored in future studies.  
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It has been determined that increased protease activity can be attributed to patients with 
IBD, in particular, this elevated activity appears to be mainly ascribed to metallo-type 
proteases. This increase in FP activity may also have consequences for gut physiology 
and homeostasis in terms of the ability to cause disruption of the gut epithelial barrier as 
demonstrated here whereby protein extracts were capable of decreasing TER and 
increasing paracellular permeability. This was an occurrence more characteristic of the 
IBD cohort. This study therefore indicates that elevated FP activity is likely to be acting 
as a detrimental factor in IBD and that metalloproteases are the most probable source of 
the deleterious effects of FP activity as other types of proteases present were also high in 
the healthy cohort. While the fundamental question of whether protease activity is 
involved in the progression of IBD or whether it’s a consequence of dysbiosis which is 
in itself, is a consequence, not cause, of the disease, it is certainly clear from results of 
this study that the gut degradome has the potential to act as a significant virulence 
factor.   
 
This study has also highlighted that perhaps more efforts should be made to elucidate 
the origin of FP activity (i.e. host, bacterial, fungal) to determine whether proteases 
previously thought to be of host origin are actually bacterial which may then offer 
alternative possibility for therapeutic intervention. Exploration into techniques for 
isolating proteases from faecal samples in order to functionally characterise them and 
deduce the sequence would be a priority in progressing this research. One interesting 
methodology that has potential for protease isolation from faecal samples would be the 
implementation of affinity chromatography columns incorporated with an immobilised 
ligand specific for different types of proteases. This methodology has been implemented 
for isolation of proteases from bacterial cell culture [180] and faecal samples [111]. 
However, the aims here are to access the entire degradome this research has indicated 
that the isolation, identification and characterisation of metalloproteases would be more 
pressing in terms of IBD. Future research could entail the development of a 
chromatography column with a matrix of metalloprotease specific ligands which will 
reversibly bind to metalloproteases which could subsequently be eluted and 
characterised functionally as well as have its amino acid sequence determined in order to 
hopefully elucidate its origin.  
This research has validated that proteolytic activity is a significant factor in the onset of 
IBD. This lends to the idea that the implementation of protease inhibitors would be a 
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useful strategy for therapeutic intervention. As described earlier, other research projects 
have begun to unravel the potential of inhibitors in treating the disease [99-102] with 
mant studies providing promising results particularly the use of endogenous serine 
protease inhibitor; elafin [102] . However many of the inhibitors used are very broad 
acting, such as the use of inhibitors that act as metal ion chelators to halt protease 
activity [101] and this could have deleterious repercussions for other cellular processes. 
Also, our research here suggests that elevated protease acitivity may be largely 
attributed to the gut microbiota and alterations in it’s composition lead to increase and 
decrease in activity. Therefore more research could focus on deciphering protease 
inhibitors that could be used to target microbial proteases. These protease inhibitors may 
also be microbial-derived and therefore it would be very useful to begin to unravel the 
anti-degradome as well as the degradome of the gut microbiota via functional as well as 
sequence analysis.   
Findings of this study provide the basis for much future research particularly in the area 
of metagenomics. Metagenomics will provide a means of uncovering proteases and their 
function and to some extent, their origin. However, there is still a lot of novelty in the 
gut microbiota and many proteases remain uncharacterised. This highlights the 
importance of the development of novel function-based assay techniques for protease 
characterisation.  
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7.4 MATERIALS AND METHODS  
 
7.4.1 Characterisation of faecal proteases within the healthy cohort and the IBD 
patients cohort 
Characterisation of FP activity in each cohort was conducted using a work flow outlined 
in figure 7.4.1. Faecal samples were collected from volunteers and divided into 1 g 
samples in sterile tubes and frozen at -20 °C. Protein extraction was conducted as 
described in Chapter 2.0 and protein concentration was estimated using the BCA assay 
and normalised to 1 mg/mL for subsequent general protease activity assays using the 
colorimetric substrates; azo-casein, azo-coll and keratin azure. Procedures were 
conducted as described in Chapter 2.0. DNA was also extracted from faecal samples 
following the methods outlined in Chapter 2.0. 
 
Figure 7.4.1 Brief outline of the methods used and the workflow of this study 
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7.4.2 Protease inhibitor assays 
Protease inhibitor assays to determine the origin of FP activity was conducted using 
Bacterial, Mammalian, Plant and Yeast ProteaseArrest™ (G-Biosciences, St. Louis, 
USA) inhibitor cocktails. Assays were carried out according to the manufacturer’s 
instructions on protein extracts from each individual in the study after normalisation to 1 
mg/mL protein per sample.  
Functional characterisation of the types of proteases present in each sample was 
conducted using ProteSEEKER™ (G-Biosciences) according to the manufacturer’s 
instructions.  
7.4.3 Optiprep™ denisty gradient for isolation of bacterial cells 
A 10% w/v faecal suspension was prepared using fresh faeces from 3 samples of the 
entire cohort in sterile PBS. The suspension was centrifuged at 200 x g for 5 min at 4°C 
in order to remove faecal debris. The resulting supernatant was collected and subject to 
centrifugation at 5,500 x g for 20 min at 4°C. The bacterial pellet was resuspended in 4 
mL 22% w/v Optiprep™ (Simga-Alrich, Dorset, UK) in Phosphate Buffered Saline 
(PBS) (pH 7.0). An Optiprep™ density gradient was prepared as follows; 4 mL (0.6 ml) 
50% (w/v) OptiPrep™ in PBS was applied to the bottom of the gradient, 4 ml 22% 
(w/v) crude faecal suspension was very carefully applied over the top and this was over-
laid with 4 mL PBS. The gradient was subject to centrifugation at 10,000 x g for 1 hr at 
4°C. After such time, the bacterial cell layer, which could be distinctly found above the 
bottom layer was carefully removed. Any remaining OptiPrep™ solution was removed 
from the cells by diluting the suspension in PBS and centrifuging at 5,500 x g for 20 min 
at 4°C. This was carried out a further two times and the cell pellet was resuspended in 
PBS (pH 7.0). To determine the potential contribution of intracellular proteases to total 
FP activity, half of each sample was subject to 3 cycles of bead beating to disrupt 
bacterial cells and release intracellular protein. Protein concentration of each sample was 
estimated using the BCA assay and subject to protease assay using azo-casein as the 
substrate. 
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7.4.4 Protease assays using specific substrates; 
Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 was obtained from Enzo Life Sciences 
(Exeter, UK) and was used as a synthetic fluorogenic substrate for matrix 
metalloprotease activity. The assay was conducted as previously described [181]. 
Briefly, MMP substrate was reconstituted in molecular grade water for stock solution 
(20 mM). This stock solution was further diluted in fluorometric buffer (50 mM Tris, 
0.1 M NaCl, , 0.05% (w/v) Brij35, 0.1% (w/v) pH 7.5) to a final concentration of 5 µM. 
100 µl 1 mg/mL protein extracts were incubated with the substrate for 2 hours in a 96-
well plate. Fluorescence was measured (λex = 325 nm, λem = 395 nm) using the Tecan® 
Infinite M200 Pro Microplate reader (Tecan®, Zurich, Switzerland). Data was plotted as 
the mean of triplicate data as relative fluorescence units after subtraction of blank 
measurements.  
MeOSuc-AAPV-AMC was obtained from Enzo Life Sciences (Exeter, UK) as a 
synthetic, highly sensitive substrate for neutrophil elastase activity. The substrate stock 
solution was prepared in Dimethyl sulfoxide (DMSO) at a concentration of 10 mM. This 
was further diluted to 200 µM in fluorometric buffer (50 mM Tris, 0.1 M NaCl, 0.05% 
(W/v Brij-35, pH 7.5) and incubated for 2 hours in a 96-well plate with 100 µL protein 
extract from each sample in triplicate. Fluorescence was read  (λex = 380nm, λem = 460 
nm) using a Tecan® Infinite M200 Pro Microplate reader (Tecan®) and data was 
plotted as the mean of triplicate data after subtraction from blank measurements. 
Suc-Ala-Ala-Pro-Phe-AMC was used as a synthetic fluorogenic substrate for 
Chymotrypsin-like activity and was obtained from Merck Millipore (Darmstadt, 
Germany). The assay was conducted as previously described [182]. Briefly, Suc-Ala-
Ala-Pro-Phe-AMC was reconstituted in 50 mM Tris-HCl (pH 8.0) to a final 
concentration of 125 nmol/mL and incubated with 100 µL of 1mg/mL protein extracts 
for 2 hours at 37 °C. After incubation activity was measured fluorometrically (λex = 380 
nm, λem = 460nm) using a Tecan® Infinite M200 Pro Microplate reader (Tecan®).  
7.4.5 Biotinylation of mucin 
Biotin N-hydroxysuccinimide ester (BNHS) was dissolved in dimethylfomramide 
(DMF) to a final concentration of 20 mg/mL. 0.1 mL BNHS solution was added to 1 mg 
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porcine mucin (Sigma-Aldrich) dissolved in 0.9 mL PBS and incubated at 4 °C 
overnight. The biotin/mucin solution was applied to a Sephadex G25 column and run in 
PBS. Fractions were collected and subject to slot blot assays to ensure mucin was 
present. This was carried out by serially diluting fractions (10-fold dilution series) in 
PBS and adding 5 µL aliquots to a moist nitrocellulose membrane. After drying, the 
membranes were transferred to freshly prepared periodic acid, acetic acid solution (1% 
(v/v) and 3% (v/) respectively) and covered for 30 min at room temperature. Membranes 
were rinsed twice 2 min per wash) ikn freshly prepared 0.1% (w/v) sodium 
metabisulfate in 1 mM HCl and transferred to Schiff’s reagent (Sigma-aldrich) for 15 
min. Samples were washed a further 3 times with sodium metabisulfate solution and 
allowed to dry. Pink-red coloration was indicative of PAS-reactive glycoprotein i.e. 
mucin. 
 
Fractions containing mucin that had been successfully labelled with biotin were pooled 
and stored as 0.2 mL samples at 4 °C. Biotin labelled mucin (50 µL) was added to each 
well of a 96-well plate (Thermo Fisher Scientific, Rockford, IL) and incubated overnight 
to allow adherence to the plate. Plates were emptied taking care not to disturb the 
adhered mucin and washed with 10 mM Tris-HCl, pH 8.0 (50 µL) followed by 3 further 
washing steps (200 µL). Protein extracts were diluted (10-fold) in PBS and triplicate 
samples of 100 µL of each sample was added to wells of the 96 well plate. The plate 
was incubated at 37 ˚C for 2 hours. After such time the media was carefully removed 
and wells were washed 4 times with PBS (200 µL). To block non-specific binding, 
blocking buffer (1 % Bovine serum albumin in PBS supplemented with 0.2 % (v/v) 
Tween-20) (200 µL) was added to each well and the microplate was incubated overnight 
at 4 ˚C. The plates were carefully emptied and washed with PBS (200 µL) twice and 
incubated with streptavidin-horse radish peroxidase solution (Vector Laboratories, Ltd, 
Peterborough) (75 µL) for 1 hour at room temperature. The plates were washed 3 times 
with PBS (200 µL) and incubated in the dark with OPD solution (1,2-phenylenediamine 
dihydrochloride-Dako UK Ltd, Cambridgeshire, UK) (100 µL) for 1 hour. The reaction 
was terminated by the addition of 0.5 M sulphuric acid and the resulting absorbance was 
measured at 490 nm. 
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7.4.6 MiSeq™ Illumina seqeuncing of 16S rRNA genes 
Bacterial community composition of each sample to compare between the two cohorts 
was characterised by sequencing of the 16S rRNA genes using MiSeq™ Illumina 
sequencing technology by amplification of the V3 (forward primer = 
5’TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCA
G) and the V4 (reverse primer 
=5’GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATC
TAATCC) regions of the 16S rRNA genes by polymerase chain reaction (PCR). These 
primers were chosen as they had been demonstrated in a previous study to be the most 
promising primer pair for coverage and phylum spectrum [183]. 
 
7.4.7 Analysis of 16S rRNA gene sequences using the Mothur Pipeline 
16S rRNA gene data generated by the MiSeq Illumina sequencing platform was 
processed by the bioinformatics pipeline of mothur [120].  Briefly, reads that were 
shorter than 200 nucleotides in length, contianed ambiguous bases, chimeric sequences 
and reads without recognisable primer (forward and reverse) were eliminated. Primers 
were trimmed from the left over sequences using Mothur. Sequences were aligned to the 
Silva 16S rRNA sequence reference database [184]. Multiples of the same uniques 
sequence were removed from to reduce computational power. Sequences were clustered 
into operational taxonomic units (OTUs) at a level of 97% similarity uisng the SILVA 
ribosomal RNA gene database [184] and further classified using the Ribosomal database 
project [185]. Shannon diversity indicies and the chao species richness estimator were 
conducted using Mothur. STAMP software [121] was used to assess difference between 
various taxonomic bacterial levels of the two cohorts and also to compare samples with 
high versus low FP activity using a two-sided Welch’s t-test with a Benjamini-Hochberg 
precedure for mutliple test correction. Heatmaps, Non-metric multi-dimensional scaling 
(nMDS) anlaysis and significance of diveristy indicies were performed using R software 
[122] as were all further statistical analyses. The scripts utilised the vegan [186], gplot 
[187], RcolorBrewer [188] and ggplot 2 [189] packages. 
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7.4.8 Transepithelial resistance measurments 
Pre-warmed culture medium (0.9 mL) was added to each well of a 24-well tissue culture 
plate (Corning Life Sciences, Lowell, MA). Ascetically, cell culture inserts, 6.5 mm 
diameter, 0.4 µm pore polyester membrane (Corning Life Sciences) were added to each 
well and were equilibrated at 37 ⁰C for 20 min. Cells were seeded at 10 5 cells per sq. 
cm (0.3 mL volume) onto each insert and cultured under routine conditions (as outlined 
in Chapter 2X) for 48 hrs by which time a monolayer had developed. After such time, 
the media from the apical and basolateral compartments was replenished, 100 µL fresh 
protein extract from each sample (healthy n =11, IBD n = 13) was added to three inserts 
taking care not to disturb the cell monolayer. The supernatant from a laboratory isolate 
of E. faecalis was added to three inserts as a positive control, PBS was added to a further 
three inserts and three inserts were left without additional components to act as negative 
controls. To determine the involvements of proteases on change in TER replica 24-well 
plates were prepared with the addition of an EDTA-free Halt protease inhibitor cocktail 
(Thermo Fisher Scientific) supplemented with Phosphoramidon (G-Biosciences).   
 
Trans epithelial resistance measurements (TER) using a voltmeter EVOM
2 
(World 
Precision Instruments, Sarasota, Fl)
 
were taken immediately upon addition of sample 
and after 24 hrs of incubation. Significance in the change in TER for each sample was 
determined using the Mann Whitney U test in R software. 
7.4.9 Permeability Assay 
Cell culture inserts were removed to a new 24-well plate containing fresh culture 
medium (0.9 mL). To measure translocation, media in the apical compartment was 
carefully removed and discarded and replaced with Krebs solution (Sigma-Aldrich) 
containing 500 µg/mL sodium fluorescein (Sigma-Aldrich). The cells were incubated in 
routine conditions for 2 hrs. Following incubation, 3 X 100 µL aliquots from the outer 
chamber of each well were removed and transferred to a 96-well plate. Fluorescence 
was measured (λex = 460 nm, λem = 515nm) using a Tecan® Infinite M200 Pro 
Microplate reader (Tecan®). Significance was determined using the Mann Whitney U 
test in R comparing the fluorescence for each sample with and without inhibitor present.  
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8.0 GENERAL CONCLUSIONS AND DISCUSSION 
 
 
Comprehensive studies to investigate tools for functional metagenomic isolation of 
proteases as well as examining the role of microbial proteases in a diseased gut were 
undertaken. This research has both ameliorated and highlighted further some of the 
difficulties of FM particularly when screening for proteases. It has also validated that 
proteases are associated with diseases of the gut, specifically, IBD. 
 
In this chapter, the general conclusions of each main area of work will be reiterated with 
respect to the main aims and objectives that were explained in Chapter 1.0. In addition, 
the implications of this study will be discussed in a broader context particularly 
regarding proteases within the gut microbiota and functional metagenomics along with 
the future directions that each area of work should be striving towards. 
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8.1 CONCLUSIONS 
1) Aim: To develop a simple, yet robust agar to eliminate the occurrence of false 
positive in functional metagenomic library screening for proteases (Chapter 3.0). 
It was hypotheisised that the use of SMA to screen for protease activity may lead to 
false positives due to acid production as a result of galactosidase enzyme activity and as 
a consequence, an alternative simple agar screen was needed. The use of a lactose free 
skimmed milk agar was explored as this could potentially eliminate the problem of false 
positive due to galactosidase activity. Indeed, strains and FM isolates previously deemed 
positive for protease secretion and activity using SMA, but negative using other means 
were also negative using LFSMA ,but gave a positive protease phenotype when 
screening known protease producers such as B. subtilis MY2016. This Valio™ lactose-
free milk agar is therefore an effective and robust agar for correctly identifying proteases 
via FM as well as for assessing protease acitivity in pure cultures.  
2) Aim: To identify and functionally characterise the active protease gene(s) from a 
fosmid vector isolated using metagenomics from an diary waste treatment plant 
(Chapter 4.0). 
It had initially been hypothesised that activated sludge from a dairy waste treatment 
would be a bacterial ecosystem enriched for bacteria that have the ability to degrade the 
protein in diary waste stream and would therefore provide a good sampling site for DNA 
extraction for FM library construction and screening for bacterial protease activity. This 
hypothesis proved correct as one large insert (38 kb) fosmid clone was found to confer a 
proteolytic phenotype. Further analysis of the sequenced insert revealed two putative 
protease sequences both of which appeared to be able to be responsible for the protease 
phenotype observed by the fosmid clone. Upon sub-cloning of each putative sequence, 
however, only one sequence (designated M1-2) was able to recapitulate the proteolytic 
phenotype even though sequence analysis revealed little reason as to why the other 
sequence (designated M1-1) did not express a protease. Thus, this suggested that either 
this sequence did not encode a protease gene, highlighting the negative aspects of in 
silico data mining for bacterial enzymes based on sequence homologies. The lack of 
expression also suggested that perhaps E. coli was just unable to express the gene and 
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led us to believe that alternative hosts might be more appropriate for creating an FM 
library for proteases. This research also highlighted that our study also revealed that the 
genetic locus isolated that encoded M1-2 was also conserved with a well-characterised 
family of proteases and shared 56 % sequence identity to another metagenome-derived 
metalloprotease. Further analysis of other studies that had isolated proteases from 
diverse habitats using FM and claimed novelty uncovered that they too were closely 
related to already characterised families of proteases as defined by the MEROPS 
database [1] and the protein sequences shared greater than 50 % homology with their 
closest matches after BLASTp searches. Really, a new or novel gene and function needs 
to have no homologue in the database or it should define a cluster of genes annotated as 
unknown. Thus this prompted the query as to whether or not these proteases could really 
be called novel and whether or not FM was capable of isolating novel proteases. 
 
3) Aim: To conduct a culture-dependent analysis on protease producers within the 
gut microbiota (Chapter 5.0). 
 
In this research, one of the overriding objectives was to begin to uncover the role of 
bacterial proteases in the human gut. One of the first steps towards achieving this goal 
was to culture and identify gut bacteria that secreted proteases as although the cultivable 
microorganisms may not be numerically dominant, this may not necessarily imply that 
their proteases are insignificant. Aerobic protease producers was found to be dominated 
by the Enterococcus genus, particularly E. faecalis as well as a Lactobacillus casei a 
species widely considered to be a probiotic. Anaerobic protease producers were likely to 
belong to the Bacteroides and Bifidobacteria genera. To the authors knowledge, only 
one other study has conducted a culture-dependent study on protease producers in the 
human gut [2] in similar findings were reported except Clostridia, Staphylococci and 
Propionobacteria were also isolated although they were identified based on morphology 
and Gram testing. 16S rRNA gene sequencing is arguably a more accurate means of 
identifying bacteria and so perhaps it is fair to conclude that the study here is more 
useful and it is likely that Enterococcus, Lactobacillus, Bacteroides and Bifidobacteria 
are the most dominant genera of bacteria that produce proteases in the gut, that we are 
currently able to culture. 
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4) Aim: To develop novel metagenomic tools to obtain characterised proteases 
from (gut) bacteria and to implement these tools to screen the gut microbiota for 
protease activity (Chapter 5.0). 
 
It was hypothesised that the use of a novel shuttle vector system utilising a Gram 
negative as well as a Gram positive host that has a demonstrated capacity to express and 
secrete proteases effectively will be much more efficient in capturing protease genes 
from the gut metagenome. The Gram positive host; B. subtilis WB800N was capable of 
expressing and secreting two well-characterised proteases from other bacteria while the 
E. coli host could not. This data showed that when attempting a FM screen, host 
selection is very important and careful thought should be put into choosing a host that 
has the genetic machinery capable of expressing the target gene. It was also found that 
one protease gene could not be expressed by ether host and further literature analysis 
revealed this is because expression of the gene is reliant on a number of other genes too 
suggesting larger inserts are needed for the expression of some proteases. 
 
Unfortunately, when this host was implemented to screen the gut microbiota for 
proteases, the transformation procedure was time consuming, and successful 
transformation was unpredictable. The inadequate success of transformation of B. 
subtilis WB800N resulted in a limited library with regards to genetic coverage due to 
too few clones compared to the number of clones needed in most successful FM 
libraries. This research therefore, has highlighted the difficulties associated with 
screening for proteases using FM strategies. However, from these results, we are able to 
develop new hypotheses and techniques that will aid future projects and help us to add 
novelty to the current protease sequence space. Exploration of alternative hosts is one 
option, particularly with a well-characterised procedure for transformation to allow the 
generation of enough libraries for adequate coverage of the mgDNA from the 
environment in question. However, it seems more likely the main issues experienced 
here are due to the library preparation itself and more efforts should be implemented to 
ensure fragments of DNA that are >3 kb are used to generate the library to hopefully 
capture the protease gene as well as any regulatory genes that are also needed for 
expression [3]. Methodologies to enable this have been discussed in chapter 5.0. 
Additionally, the methods used in chapter 5.0 did not include recombinant plasmid 
selection which may have further reduced the efficiency of the library. In order to 
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generate an efficient FM library, it may be useful to use a screening means that only 
allows the growth of clones harbouring a protease gene. A similar methodology was 
used to isolate Akkermansia muciniphila [4] with mucin as a sole carbon source and so it 
may also be useful to utilise this approach with culture-dependent screens of the gut 
microbiota to isolate protease producers and potentially novel species.  Other carbon 
sources might include collagen, fibrinogen and Immunoglobulins. 
  
One outstanding factor that this research has generated in chapter 5.0, and chapter 7.0 in 
particular, stresses the importance of a more direct approach to studying microbial 
proteases as they are diverse in terms of their catalysis, substrate specificity and 
regulation. While the method of PCR-based discovery has its drawbacks due to the 
necessity to have a substantial a priori sequence knowledge, if we take a different point 
of view of aiming to isolate proteases with novel functions instead of striving towards 
isolating proteases with completely novel sequences, we may be more efficiently able to 
uncover proteases with clinical and industrial relevance. Purohit et al., [5] have 
demonstrated this process as discussed in chapter 5.0 and in an extensive review 
describing the process of PCR-based mining and genome walking techniques for 
isolation of novel bacterial genes by Kotik [6], several studies are highlighted in which 
genes expressing novel functions were isolated. For example, Hayashi and colleagues 
[7] utilised a PCR-mining method to isolate novel xylanase genes from the human gut. 
Uchiyama and Watanabe [8] also alleviated the problem of isolating low copy number 
genes in environmental DNA samples by developing an inverse PCR using biotin-
labelled degenerate primer, affinity purification of the PCR product followed by nested 
PCR and utilised this techniques to isolate putative chitinase genes, one of which shared 
less than 35 % nucleotide homology with any other database chitinases. 
 
This could be a useful future direction for studying gut microbial proteases, specifically 
those that may be significant in terms of disease, as degenerate primers can be designed 
based on alignments of proteases that are known the act as virulence factors.  
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5) Aim: To determine optimal conditions for faecal protease extraction and storage 
over time (Chapter 6.0).  
As more and more studies are utilising faecal samples as a means of accessing microbial 
DNA, metabolites, and protein as well as other molecules, it is becoming increasingly 
important to assess the parameters that affect the storage of such samples. As the area of 
interest in this research is predominantly microbial proteases, the effect of long term 
storage on protein extract protein concentration and protease activity was determined. 
From the findings of this chapter it can now be advised that for future research of gut 
microbial proteases, whole faecal samples stored at sub-zero temperatures provide the 
most robust and repeatable means for accessing microbial protease activity. 
 
6) Aim: To conduct a comprehensive comparison of protease activity in an IBD 
cohort and compare to a group of healthy volunteers (Chapter 7.0). 
 
One of the most significant findings of this research has been that gut-derived proteases 
are positively associated with IBD and that they appear to have either an expanded or a 
different repertoire of functions evidenced by their enhanced and altered substrate 
specificity. It was also found that different types of proteases were present between the 
two cohorts all of which was determined by protease inhibitor analysis and specific 
substrate activity analysis in chapter 7. 
Coupling degradomic studies such as in Chapter 7.0 with correct procedure described in 
chapter 6.0 has helped us to understand the types of proteases that are present in the gut 
microbiota and how they may be implicated in IBD. From here, projects can now be 
designed to specifically analyse the groups of proteases to unravel their role in IBD and 
other diseases. a useful direction for this study is the identification of specific proteases 
via proteomic analysis analogous to the methods described by Tooth et al., [9] which 
was used to identify serine proteases in IBS. As this research has discovered that 
metalloproteases are significantly elevated in an IBD cohort, utilisation of a metal-
ligand binding affinity chromatography system to isolate metalloproteases from faecal 
samples in a similarly designed cohort study would be a significantly useful direction 
for this research to now take. Specific isolation of types of proteases will facilitate more 
comprehensive characterisation as well as assisting in proteomic identification and from 
here, we can fully understand the implications of specific proteases with regards to IBD. 
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7) Aim: To conduct 16S rRNA community profiling analysis for each cohort 
(Chapter 7.0) 
 
This research has further validated that there is a dysbiosis of the gut microbiota in IBD 
and that compositional alterations of the gut microbiota are associated with high levels 
of protease activity. Specifically, the Verrucomicrobia phyla were significantly reduced 
in the high protease activity cohort and future studies with larger cohorts will help 
solidify these findings as well as potentially uncovering other significant correlations 
with other bacterial species such as the members of the Bacteroidetes phylum, of which 
a reduction in the IBD cohort, though not statistically significant, was also observed in 
this research. While the implications of alterations in the gut microbiota relating to 
protease activity remain unclear, new hypotheses for future research can be inferred 
regarding the role of Verrucomicrobia in gut health and disease, specifically 
inflammatory disorders.  Research into members of the Verrucomicrobia such as A. 
muciniphila and interactions with gut epithelial cells and other bacteria thought to 
dominate in the absence of A. muciniphila will be incredibly useful in unravelling these 
phenomena and furthering our understanding of the role of the gut microbiota in IBD. 
 
8) Aim: To further unravel the potential role of the gut degradome in the virulence 
of inflammation (Chapter 7.0) 
We have demonstrated that faecal proteases isolated from an IBD cohort are capable of 
disrupting epithelial barrier function. Repeating this investigation with a larger cohort 
and conducting experimentation into the specific mechanisms by which these faecal 
proteases are disrupting barrier inegrity , such as investigating degradation of E-cadherin 
and other transmembrane proteins and tight junction protein will futher validate this and 
lead to research into the use of protease inhibitors as for protection of the gut epitheila 
barrier can be executed.  Future research such as this, coupled with research by Motta 
and colleagues [10] may help futher develop protease inhibtiors as a therapeutic 
intervention tool for the incidence increasing, debilitating and chronically recurring 
disorder that is IBD. 
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8.2 CONCLUDING REMARKS 
 
This research has begun to unravel the molecular mechanisms behind the dysbiosis of 
the gut microbiota in IBD and this, coupled with future research highlighted in this 
chapter, could have great implications in the treatment of the disease. Chapter 7.0 
demonstrates the significance of microbial proteases with regards to gut health and 
disease. This emphasises the importance of the research conducted in chapters 3, 4 and 5 
in developing tools for isolating and characterising proteases from the gut degradome. 
This research, and the future research discussed in this chapter, must be pursued if we 
are to access the full degradome of the gut microbiota; an area of biological research that 
this thesis has shown is justifiable, valuable and worthwhile.  
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